








Sumoylation of Nuclear Transport Receptors  





for the award of the degree 
“Doctor rerum naturalium” 



















     


















Members of the Thesis Committee: 
 
1) Prof. Dr. Frauke Melchior (Reviewer) 
DKFZ-ZMBH Alliance, ZMBH, Heidelberg 
 
2) Prof. Dr. Nils Brose (Reviewer) 
Dept. of Molecular Neurobiology, Max Planck Institute for Experimental Medicine, 
Göttingen 
 
3) Prof. Dr. Gerhard Braus 
Dept. of Molecular Microbiology and Genetics, Institute for Microbiology and Genetics, 


























I hereby declare that this submission is my own work and that to my best knowledge and 
belief all extrinsic sources and aid are appropriately quoted. 
 
  
 Volkan Sakin 




     
















 LIST of PUBLICATIONS 
 5 
LIST of PUBLICATIONS 
 
Moutty, M.C., Sakin, V., and Melchior, F. (2011). Importin α/β mediates nuclear import of 
individual SUMO E1 subunits and of the holo-enzyme. Mol Biol Cell. 22(5): 652-60. 
Sakin V., Eskiocak U., Kars M.D., Iseri O.D., Gunduz U. (2008). hTERT gene expression 

























     









 TABLE of CONTENTS 
 7 
TABLE of CONTENTS 
List of Publications  5 
Acknowledgements 11 
Abstract 13   
List of Figures 15 
Introduction  17 
1. SUMO (Small Ubiquitin-like Modifier)  17 
1.1. SUMOylation and its machinery  18        
1.2. Functional outcomes of SUMOylation  21 
2. Nucleocytoplasmic transport  21 
2.1. The structure of nuclear pore complexes  22 
2.2 Nuclear transport receptors (NTRs)  22 
2.3. Ran 23 
2.3.1. Biochemical features of Ran  23 
2.3.2. Ran GTPase cycle  24   
2.3.3. Functions of Ran in nuclear transport and beyond 25 
2.4. Molecular mechanisms of nucleocytoplasmic transport  26 
3. Intriguing links between sumoylation and nucleocytoplasmic transport  28 
3.1. Multisubunit SUMO E3 ligase RanBP2 30 
4. Aims of this work  32 
Materials & Methods 33 
1. Materials  33 
1.1. Technical Equipment  33 
1.2. Software 34 
1.3. Consumables  35 
1.4. Chemicals, reagents, and enzymes  35 
1.5. Kits 37 
1.6. Buffers and Stock Solutions  37 
1.7. Media 39 
1.8. Cell lines  39 
1.9. Oligonucleotides, vectors, and plasmids 40 
1.10. Proteins 42 
1.11. Antibodies 44 
1.12. siRNAs  46 
2. Methods  47 
2.1. Molecular biology techniques  47  
2.1.1. Culturing and storage of bacteria   47 
2.1.2. Plasmid preparation  47 
      
 
 8 
2.1.3. Cloning  48  
2.1.4. Sequencing  50 
2.1.5. Site-directed mutagenesis  50  
2.1.6. Vectors and plasmids constructed in this work 51 
2.2. Biochemical techniques 52 
2.2.1. Measurement of protein concentration 52 
2.2.2. SDS-PAGE and protein detection methods 52 
2.2.3. Sample Preparation  54 
2.2.4. Immobilization of proteins to Cyanogenbromide (CNBr)-activated  55 
sepharose beads 
2.2.5. Generation of Crm1 antibodies 56 
2.2.6. Antibody purification 56 
2.2.7. Recombinant protein expression and purification 56 
2.2.8. Labeling of GST-Ubc9 with Alexa Fluor 488 62 
2.2.9. Pulldown assays with immobilized Rcc1 and NTF2 62 
2.2.10. Cultivation of hybridoma cells for SUMO1 and SUMO2/3 antibodies 63 
2.2.11. Crosslinking of SUMO antibodies to beads  63 
2.2.12. SUMO Immunoprecipitations (IPs) 63 
2.2.13. Permeabilization of HeLa suspension cells with digitonin  64 
2.2.14. In vitro sumoylation assays with recombinant proteins 64 
2.2.15. In vitro sumoylation of Ran with semi-permeabilized cells 65 
2.2.16. Mass spectrometry analysis of SUMOylation sites 65 
2.3. Cell biological techniques 65 
2.3.1. Cultivation and storage of mammalian cells 65 
2.3.2. Cell cycle arrest  66 
2.3.3. Transient transfection of mammalian cells 66 
2.3.4. Lysate preparation from adherent HeLa cells 67 
2.3.5. Fluorescence-based detection of intracellular proteins 67 
2.3.6. In vitro import assays 68 
Results  69 
Chapter I: RanBP2-dependent sumoylation in nuclear transport 69 
1. The nuclear transport receptors Crm1, Imp β, and Imp5 are endogenously  69 
sumoylated in HeLa cells 
2. A catalytic fragment of RanBP2 can stimulate transport receptor sumoylation  71 
in vitro 
3. RanBP2 complex poorly stimulates transport receptor sumoylation in vitro  73 
4. Recombinant Ran is sumoylated with YFP-SUMO1 in semi-permeabilized cells   73 
5. Analysis of Ran Sumoylation in vitro   76 
 TABLE of CONTENTS 
 9 
5.1. Ran sumoylation is inefficient with SUMO E1 and E2   76  
5.2. The RanBP2/ Ubc9/ RanGAP1-SUMO1 complex stimulates Ran  78  
sumoylation whereas PIAS proteins do not. 
5.3. Transport receptors prevent poly- or multi-mono-sumoylation of Ran 81 
but still allow mono- sumoylation 
6. Identification of Ran sumoylation sites 83 
7. Functional Analysis of Ran sumoylation 86 
7.1.Does sumoylation of Ran affect its nuclear localization? 86 
7.2. Does sumoylation of Ran play a role in regulation of nucleocytoplasmic 89 
transport? 
7.2.1. Ran triple mutant can bind to its interactors NTF2 and RCC1 with  89 
comparable affinities to Ran WT 
7.2.2. RanK130,132,134R behaves as RanWT in Impα/β-dependent import 90 
7.2.3. RanK130,132,134R stimulates the in vitro import of GST-Ubc9-Alexa488 92 
by Imp13 more efficiently compared to RanWT 
7.2.4. Ran WT  and the Ran triple mutant behaved differently in the presence  93 
of NTF2 in Imp13-dependent import 
Chapter II: The mechanisms of intranuclear localization of SUMO E1 activating 96  
enzyme, Aos1/Uba2 heterodimer 
1. Generation of tools for in vitro import assays 96 
2. Neither transportin nor Importin 13 support the import of Aos1 96 
3. Importin α/β binds to the Uba2 NLS of the SUMO E1 holo-enzyme 97  
Discussion 100 
1. Heat shock and transport receptor sumoylation 100 
2. Functional consequences of nuclear transport receptor sumoylation  101 
3. Mechanistic aspects of Ran sumoylation  105 
3.1. Where does Ran sumoylation occur? Is it dependent on the RanBP2 complex?  105 
3.2. Sumoylation sites in Ran: K130, 132, and 134  106 
4. Functional aspects of Ran sumoylation  106 
4.1. Ran sumoylation in mammals  106 
4.2. Ran sumoylation in A. nidulans  109 
5. Outlook 110 
References  111 
Abbreviations  126 

















































First of all, I would like to thank my supervisor, Prof. Dr. Frauke Melchior, without whom 
I would have got lost many times during my PhD. I am very grateful to her for being such 
an inspiring and passionate scientist and opening up the doors of the exciting scientific 
world to me. She has been a great teacher from whom I not only learned how to carry out 
high quality science but also how to be optimistic and motivated even under difficult 
circumstances.  
 
I also would like to thank my committee members Prof. Dr. Nils Brose and Prof. Dr. 
Gerhard Braus for the fruitful discussions we had during my PhD. 
 
I am also grateful to Prof. Dr. Ralph Kehlenbach for the plasmids and protocols that he 
kindly shared. 
 
I would like to thank Dr. He-Hsuan Hsiao and Prof. Dr. Henning Urlaub for the mass 
spectrometry analysis. 
 
I am also thankful to our current and former members of molecular biology coordination 
office, Dr. Steffen Burkhardt, Kerstin Grüniger, and Ivana Jurik (Bacakova), not only for 
helping me have a cosy landing at Germany but also for taking care of many scientific and 
non-scientific issues. 
 
Special thanks go to Dr. Andreas Werner for all the recombinant proteins he has 
provided, for helping me with any problem I faced ranging from protein purification to 
German tax declaration, and for critically reading my PhD thesis. He has always been so 
kind and willing to help. Without him, all those complicated german forms would be left 
empty. I owe him a lot for all of that. Thanks Adreas, your helps are just unforgettable.  
 
I am also indebted to Dr. Annette Flotho for the countless advice and inspiring scientific 
discussions we had. I learned a lot from her concerning how to be precise, how to see the 
details, how one can always do better, and many more. Thanks Annette, it was indeed so 
much fun working with you. 
 
I would like to thank Tobias Winter for making our everyday life much more lively and 
„noisy“. I am especially thankful to him for „Das Wort des Tages“.  
 
     
 ACKNOWLEDGEMENTS                     
 
 12 
I am deeply grateful to Heidi Ehret not only for the technical helps she provided but also 
for her efforts and patience to teach me german. She brings so much energy and laughter 
to the lab, and it was such a privilage for me to be working next to her everyday even 
though my pipettes or ethanol solutions went for a walk from time to time. Du bist der 
beste Heidi. Vielen Dank für alles. 
 
I also want to thank all former and current Melchior lab members for providing such a 
friendly working atmosphere as well as for all the fun times we had not only in the lab 
but also outside. 
 
Special thanks from my heart go to my friend Dönem Avcı, for sharing the tea, lunch or 
ice-cream breaks as well as for the countless activities we have done together including 
getting our German driving licences, buying our first cars, and having road trips. Thanks 
for all the joy you brought to my life. 
 
I am also grateful to my friend Christian, who has been a great listener many times. I owe 
him a lot for helping me cope with many stressful days during my Phd and also for the 
wise piece of advice and the support he has given. 
 
I also would like to thank to my friend Miro for the countless unaccessible papers he has 
provided me with during the course of my PhD as well as his friendship. 
 
I would also like to thank to my brother Caglar Sakin, for his support and friendship. He 
is always very understanding and motivating, and it has always been a pleasure to 
include each other in our dreams. Now, time to make them real! 
 
Last but not least, I am truely thankful to my family. Knowing that you are there for me 
whenever I need is such a comforting feeling. Without your support and love, this work 
could not be achieved.  
Son olarak sevgili aileme, ve özellikle de beni kosulsuz seven ve destekleyen canim 
anneme, tesekkür etmek istiyorum. Sizin desteginizi, sevginizi hissetmeden bu işi asla 





Sumoylation has been linked to nucleocytoplasmic transport since the discovery of SUMO 
as a modifier of vertebrate RanGAP1, which is targeted to the nuclear pore complex 
(NPC) after sumoylation. The link between sumoylation and nucleocytoplasmic transport 
has been strengthened even more with the discovery that the major component of NPC 
cytoplasmic filaments, RanBP2, acts as a SUMO E3 ligase. RanBP2 is in stable complex 
with Ubc9 and sumoylated RanGAP1, and it was recently discovered that it is the RanBP2 
complex which acts as a multisubunit E3 ligase in cells. One fascinating feature of the 
RanBP2 complex is the very close proximity of the E3 ligase region and the binding site 
for sumoylated RanGAP1, both of which are embedded between binding sites for nuclear 
transport receptors and RanGTP. Consequently, nuclear transport receptors and the small 
GTPase Ran are candidates for RanBP2 dependent sumoylation. In line with this idea, in 
recent mass spectrometry based screens several nuclear transport receptors and Ran were 
found to be potential candidates for sumoylation. In this work, I aimed to test whether 
nuclear transport receptors and/or Ran are subjected to RanBP2-dependent sumoylation 
and to further investigate the mechanistics and the functional consequences of this 
modification. Indeed, upon enrichment of endogenously sumoylated proteins from HeLa 
cells by IP/peptide elution, in vivo sumoylation of Crm1, Impβ, and Imp5 could be 
confirmed. Although Ran sumoylation could not be detected by IPs, I could demonstrate 
that it is sumoylated in the context of semi-permeabilized cells. Subsequent in vitro 
sumoylation experiments revealed that an 80kDa RanBP2 fragment as well as the 
reconstituted RanBP2/Ubc9/RanGAP1-SUMO1 complex could stimulate the sumoylation 
of Ran, whereas PIAS E3 ligases could not. Large scale in vitro sumoylation of Ran by 
RanBP2 fragment followed by mass spectrometric analysis identified K130, 132, and 134 
as SUMO acceptor sites. Mutation of these three lysines into arginines allowed to 
investigate functional consequences. While Ran triple mutant was predominantly nuclear 
and behaved identical to wild type in the canonical Imp α/β-dependent import, it showed 
a striking stimulation in Imp13-dependent import. Intriguingly, the sumoylation deficient 
Ran mutant lost dependency on its import receptor NTF2, suggesting that it may enrich in 
the nucleus by other means. In a side project, I could show that the import of the SUMO 
E1 enzyme subunit, Aos1, is not supported by transportin or Imp13 and demonstrate that 
Imp α/β interacts with the E1 heterodimer mainly via the Uba2 NLS. These findings 
complemented the study published as “Imp α/β mediates nuclear import of individual 
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The abundance or the function of proteins in cells can be regulated at DNA, mRNA, or 
protein level. Regulations at protein level are mediated by posttranslational modifications 
(PTMs) that allow a fast and reversible way of changing the biochemical features of 
proteins. For many years, PTMs were regarded as covalent attachment of small chemical 
moieties (phosphate, acetyl, methyl, etc.) to the proteins. However, this deep-rooted 
perception changed with the discovery that proteins themselves can also be used as 
modifiers. The first example of such a protein modifier was ubiquitin (Ub), which is a 
very small protein with only 76 amino acids. The canonical function of this peptidic 
modifier turned out to be targeting proteins for proteasomal degradation, although many 
other regulatory functions have been reported since its discovery (reviewed in Hershko 
and Ciechanover, 1998; Hicke and Dunn, 2003; Welchman et al., 2005; Komander and 
Rape, 2012). The idea that proteins can be used as modifiers led to the discovery of 
plethora of other peptidic modifiers such as ISG15, Urm1, Nedd8, SUMO, etc., which are 
currently categorized as Ubiquitin-like modifiers (Ubls). Most Ubls are covalently 
attached to proteins via lysine residues, and the mechanism for conjugation is similar. 
They use an enzymatic cascade specific for the modifier.  
 
1. SUMO (Small Ubiquitin-like Modifier) 
The best investigated Ubl beside ubiquitin is SUMO, which is a small protein (~11kDa). 
Although SUMO and ubiquitin share only ~18% sequence homology, the structures of the 
two proteins look very similar to each other (Bayer et al., 1998) SUMO proteins are highly 
conserved among eukaryotes. While S.cerevisiae, D.melanogaster, and C.elegans have only a 
single SUMO gene, plants and vertebrates have more than one. Human genome, for 
instance, encodes for four SUMO proteins: SUMO2 and SUMO3 are almost identical, 
differing only in 3 amino acids. These paralogs are commonly referred to as SUMO2/3 
since there is currently no evidence that the two proteins have distinct targets. SUMO1 
and SUMO2/3, on the other hand, share only ~50% sequence identity. The functionality 
of SUMO4 in vivo is currently enigmatic (Bohren et al., 2004; Owerbach et al., 2005) since 
it is unclear whether  SUMO4 can be processed or conjugated in cells.  
 
The SUMO pathway is essential in almost all eukaryotic organisms, exceptions being 
S.pombe and A.nidulans. In fission yeast when the only SUMO protein, PMT3, is deleted, 
cells are still viable but they develop severe growth problems (Tanaka et al., 1999). 
Similarly in filamentous fungi A.nidulans, the deletion of the SUMO-encoding gene sumO 
does not affect the viability. However, the mutant strain exhibits impaired growth and 
reduced conidiation (Wong et al., 2008). In budding yeast, on the other hand, the only 
SUMO protein, SMT3, is indispensable for cell viability (Johnson et al., 1997; Giaever et 
                    INTRODUCTION    
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al., 2002). In higher organisms, sumoylation is also required, which was shown by 
deleting the only SUMO conjugating enzyme, Ubc9. Ubc9 knockdown in chicken DT40 
lymphocyte cell line, for instance, resulted in mitotic abnormalities followed by cell death 
(Hayashi et al., 2002). Similarly, Ubc9-knockout mice died during early embryogenesis 
due to mitotic abnormalities (Nacerddine et al., 2005). Whereas the requirement for 
sumoylation in eukaryotic cells is well-accepted in the field, the necessity for SUMO1 is 
currently controversial. In one study, the authors produced homozygous and 
heterozygous mice for SUMO1. All of the homozygous mice died during embryogenesis 
whereas surviving heterozygous mice developed cleft lip and palate (Alkuraya et al., 
2006). In another study, it was shown that both homozygous and heterozygous knock-out 
mice for SUMO1 developed congenital heart defects, and the reexpression of SUMO1 in 
cardiac tisse rescued the phenotype (Wang et al., 2011). On the other hand, in two papers, 
SUMO1-knockout mice were reported to be alive without obvious phenotype 
(Evdokimov et al., 2008; Zhang et al., 2008a), which suggested that the absence of SUMO1 
can be compensated by SUMO2/3. 
 
1.1. SUMOylation and its machinery 
The covalent attachment of SUMO proteins to the targets is called sumoylation, which 
comes in different forms such as monosumoylation, multiple monosumoylation, or 
polysumoylation (Ulrich, 2008). In humans, polysumoylation occurs with SUMO2/3 
proteins due to the presence of SUMO-acceptor sites in their N-terminal regions. 
Although SUMO1 is known to form chains in vitro, in vivo data is currently missing. 
Sumoylation requires an enzymatic cascade comprising an E1 activating enzyme, E2 
conjugating enzyme, and in most cases E3 ligases (summarized in Fig. 1). In the first step 
of conjugation, mature SUMO is recognized by the E1 activating enzyme, the heterodimer 
of SAE1/SAE2 in mammals, which activates SUMO in an ATP-dependent reaction (Gong 
et al., 1997; Desterro et al., 1999). Activation leads to a SUMO-adenylate intermediate, 
which is followed by the formation of a thioester bond between the carboxy terminus of 
SUMO and the catalytic cysteine of the SAE2 subunit of the heterodimer. The SUMO~E1 
thioester bond is recognized by the only E2 conjugating enzyme, Ubc9, and SUMO is 
transferred to the catalytic cysteine of Ubc9 by thioester bond formation (Lee et al., 1998; 
Saitoh et al., 1998; Schwarz et al., 1998). In some cases, Ubc9, by itself, can catalyze the 
formation of an isopeptide bond between the carboxy terminus of SUMO and the ε-amino 
group of the target lysine residue. This is due to a consensus sumoylation motif in target 
proteins, which canbe directly recognized by Ubc9 (Sampson et al., 2001; Bernier-Villamor 




















Fig. 1: Schematic overview of SUMO conjugation and deconjugation. The newly synthesized 
SUMO protein is first processed by isopeptidases to form the mature SUMO having the di-glycine 
(GG) motif at its C-terminus. Mature SUMO is then covalently linked to the SAE2 subunit of the E1 
heterodimer via a thioester bond (~) in an ATP-dependent reaction. Next, SUMO is transferred 
from E1 enzyme to the E2 conjugating enzyme, Ubc9, through thioester bond formation. In the 
final step, SUMO is covalently linked to lysine residues of target proteins, in most cases with the 
help of E3 ligases. The final outcome of sumoylation might be either a single SUMO moiety or 
SUMO chains attached to the target proteins. The modification is reversed by the actions of several 
isopeptidases in cells. 
 
of ψKxE (ψ: bulky hydrophobic amino acid, x: any amino acid) (Desterro et al., 1998; 
Rodriguez et al., 1999). In most cases, however, Ubc9 recognition by itself is not sufficient, 
and SUMO E3 ligases are required for efficient target sumoylation. Although the list of 
identified SUMO substrates is rapidly growing, the knowledge about E3 ligases is still 
rather limited. 
 
There are two types of well-studied SUMO E3 ligases: The first and the largest group is 
characterized by the presence of a SP-RING domain, which is structurally similar to the 
RING domains of Ub E3 ligases. The members of this group recognize the target and Ubc9 
directly. PIAS (Protein inhibitors of activated STATs) family of proteins (Johnson and 
Gupta, 2001; Schmidt and Muller, 2002), hMms21 (Potts and Yu, 2005), and Zip3 (Cheng 
et al., 2006) comprise the SP-RING domain SUMO E3 ligases. The PIAS family of proteins 
has two members in yeast: Siz1 (Takahashi et al., 2001) and Siz2 (Johnson and Gupta, 
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PIAS4 (reviewed in Rytinki et al., 2009). The second group is comprised of only one 
unique member, RanBP2 protein, which is discussed in great detail in the following 
chapter (Introduction/Section 3.1.). Besides these two groups, many other proteins have 
been reported to show SUMO E3 ligase activity. A few examples are Pc2 (Kagey et al., 
2003) (Kagey et al., 2003), HDAC4 (Grégoire and Yang, 2005; Lee et al., 2009), RHES 
(Subramaniam et al., 2009), TOPORS (Weger et al., 2005), MAPL (Braschi et al., 2009), TLS 
(Oh et al., 2010), and TRAF7 (Morita et al., 2005). However, the mechanisms underlying 
how these proteins function need to be further investigated. 
 
Sumoylation is a very dynamic modification which is reversed by SUMO-specific 
isopeptidases. Most of these enzymes are equipped with two distinct enzymatic activities: 
Hydrolase activity, which is responsible for the processing of the C-terminus of SUMO to 
expose a di-glycine motif (Gly-Gly) required for conjugation and the isopeptidase activity, 
which cleaves SUMO from either target proteins or chains. In yeast, there are only two 
SUMO isopeptidases, which are Ulp1 (Ubiquitin like protease 1) and Ulp2, whereas in 
mammals the number is still increasing although the SENP (SUMO/Sentrin specific 
proteases) family of proteases is well-defined with currently seven members: SENP1, 2, 3, 
5, 6, 7, and 8. Although classified in this family, SENP8 is not specific for SUMO but for 
Nedd8 (Gan-Erdene et al., 2003; Mendoza et al., 2003; Wu et al., 2003). All the other 
members are specific for SUMO, some showing paralog specificity for SUMO2/3. Very 
recently, the first examples of SUMO-isopeptidases which do not belong to the SENP 
family of proteases has been described, and the enzymes are named as DeSI1 
(DeSumoylating Isopeptidase 1) (Shin et al., 2012) and Uspl-1 (Ubiquitin-specific protease-
like 1) (Schulz et al., 2012). 
 
Noncovalent interactions with SUMO proteins contribute both to modification and to 
downstream events. At the moment, a single, yet prominent SUMO interaction motif 
(SIM) is known. SIMs are short stretches of hydrophobic amino acids, V/I-X-V/I-V/I, 
which are often flanked by negative charges, which can either be provided by acidic 
amino acids or phosphorylated serine residues (Song et al., 2004; Hannich et al., 2005; 
Hecker et al., 2006; Stehmeier and Muller, 2009). They are also found in SP-RING E3 
ligases. Functionally, they might be involved in the stimulation of target sumoylation 
(Meulmeester et al., 2008) as well as the assembly of many PML proteins into PML 







1.2. Functional outcomes of SUMOylation 
There are hundreds of proteins, mostly being nuclear, modified with SUMO (Golebiowski 
et al., 2009). Therefore, a wide range of cellular processes such as transcription, DNA 
repair, DNA replication, nucleocytoplasmic transport, signalling, and cell cycle are 
regulated by sumoylation. The functional consequences of sumoylation are very diverse 
and hard to predict. Yet, most of them can be explained at molecular level by three major 
changes in protein-protein interactions: First, sumoylation can promote protein-protein 
interactions since additional surfaces are introduced with SUMO. The prototypical 
example for such change is the sumoylation of RanGAP1, which targets the protein to the 
cytoplasmic filaments of nuclear pore complexes (Matunis et al., 1996; Mahajan et al., 
1997) by promoting its interaction with RanBP2. Another well-known example is the 
sumoylation of PML, which is required for the formation of PML nuclear bodies (Zhong 
et al., 2000). Secondly, it can disrupt the already existing protein-protein interactions as in 
the case of E2-25K and Usp25 sumoylation. Sumoylation of E2-25K inhibits the interaction 
of the enzyme with the ubiquitin E1 enzyme, thereby decreasing its ubiquitination 
activity (Pichler et al., 2005). Similarly, USP25 can no longer interact with ubiquitin chains 
upon sumoylation, which results in decrease in deubiquitinating activity (Meulmeester et 
al., 2008). Lastly, sumoylation can change the conformation of the protein as observed for 
the DNA repair enzyme, thymine DNA glycosylase. Upon sumoylation, the enzyme 
changes its conformation, which facilitates the release from DNA (Hardeland et al., 2002; 
Baba et al., 2005). Overall, different types of molecular changes due to sumoylation might 
change the subcellular/subnuclear localization, the activity, or the stability of proteins 
(reviewed in Geiss-Friedlander and Melchior, 2007).  
 
2. Nucleocytoplasmic transport  
In eukaryotes, the genetic material is physically separated from the rest of the cell in the 
nucleus. The eukaryotic nucleus is surrounded by the nuclear envelope which is 
composed of two membranes separated by the ER lumen. The outer nuclear membrane is 
continuous with the endoplasmic reticulum membrane. Compartmentalization of genetic 
material allows cells to perform different cellular processes at differing subcellular 
environments. As a result of that DNA replication and transcription are nuclear processes, 
whereas protein translation occurs in the cytoplasm. Such organization of cells, on one 
hand, provide the cells with additional ways of regulating the flow of information, but on 
the other hand, requires that proteins and RNAs are continuously shuttled between 
cytoplasm and nucleus. Such transport is accommodated by nuclear pore complexes 
(NPCs), which are the sole openings between the two compartments. 
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2.1. The structure of nuclear pore complexes  
NPCs have been extensively studied since their discovery in the 1950s (reviewed in Hoelz 
et al., 2011). They are proteinaceous structures formed at the regions where outer and 
inner nuclear membranes are fused and allow passive diffusion of small molecules such 
as ions, metabolites, or small proteins with a diameter less than 9nm (Paine et al., 1975; 
Bonner et al., 1978). Proteins bigger than ~40kDa, however, require transport signals 
which are recognized by nuclear transport receptors (NTRs) that facilitate the passage 
through the pores (Kiseleva et al., 1998). With the help of NTRs, transport of proteins up 
to 39nm in diameter could be achieved (Panté and Kann, 2002), which is approximately 
four times bigger than diffusion can accommodate. 
 
NPCs are composed of approximately 30 different proteins, collectively called 
nucleoporins (nups), which are present in multiples of eight copies. Due to this eight-fold 
symmetrical architecture of the pore complexes through the central axis of the pore, there 
are approximately 500-1000 protein molecules in a given NPC (Hoelz et al., 2011), which 
makes NPCs huge protein assemblies. In Dictyostelium discoideum, the outer diameter and 
the length of the pores were determined as ~125nm and ~150nm, respectively (Beck et al., 
2004; 2007), although NPCs are different in size in different organism. For instance, in 
budding yeast they have a mass of ~66MDa (Rout and Blobel, 1993) whereas in higher 
eukaryotes they are ~125Mda (Reichelt et al., 1990). Although individual proteins show 
little sequence homology among yeast and vertebrates (Adam, 2001), the overall structure 
of NPCs seem to be evolutionarily conserved (Yang et al., 1998). The number of NPCs, on 
the other hand, usually varies depending on the size and the transport needs of the cell. A 
typical proliferating human cell contains ~3000-5000 NPCs (Görlich and Kutay, 1999) 
whereas yeast cells have only ~190 (Rout and Blobel, 1993). 
 
2.2 Nuclear transport receptors (NTRs) 
NTRs are soluble components of the nucleocytoplasmic transport machinery that can 
carry cargo proteins and RNAs through the NPC. The best studied family of NTRs is the 
importin β (Imp β) superfamily of receptors, which has at least 21 members in humans 
and 14 members in budding yeast (reviewed in Görlich and Kutay, 1999). The name of the 
family comes from the founding member, Imp β, which was the first transport receptor 
identified (Enenkel et al., 1995; Görlich et al., 1995). Imp β-like transport receptors share 
some common features, although the sequence homology among them is relatively low 
(~15-20%) (Cook et al., 2007). They are made up of tandemly repeated HEAT motifs, 
which are ~50 aa long occuring in a wide range of eukaryotic proteins (Andrade et al., 
2001). They all have a similar size (~100kDa) and isoelectric point (average ~5.1) 
(Fornerod et al., 1997; Görlich et al., 1997). Imp β-like transport receptors are intrinsically 
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flexible, which is believed to help them recognize a wide range of different cargos (Conti 
et al., 2006). They can interact with FG repeats of nucleoporins (Ohno et al., 1998; Damelin 
and Silver, 2000), which allows them to go through the complex milieu of the central 
channel of nuclear pores. Finally, they all bind to the small GTPase Ran (discussed in 
great detail below in Section 2.3.) via their N-terminal regions. 
 
Depending on the direction they carry their respective cargo, Imp-β superfamily of 
transport receptors are divided into two groups: importins and exportins. Importins 
interact with their respective cargos in the cytoplasm and carry them to the nuclear 
compartment, whereas exportins function the other way around (reviewed in Macara, 
2001). Importins and exportins recognize signal sequences on their respective cargos 
either directly or indirectly via adaptor proteins such as Importin α (Impα) and 
snurportin. These sequences are called nuclear localization sequences (NLSs) and nuclear 
export sequences (NESs) for import and export, respectively. There exists different types 
of NLSs but the best characterized one is the classical NLS (cNLS). It is comprised of basic 
amino acids and can be either mono- or bipartite. In case of bipartite cNLSs, the second 
cluster of basic amino acids is usually separated from the first cluster with a linker of 
varying size (~10-12 aa) (reviewed in Lange et al., 2007). Nuclear export sequences, on the 
other hand, are usually comprised of hydrophobic amino acids. The best characterized 
NES so far is the leucine-rich NES originally discovered in the HIV-1-Rev protein (Fischer 
et al., 1995) and PKI (Wen et al., 1995). The leu-rich NES is specifically recognized by the 
well-studied exportin, Crm1 (chromosome region maintenance 1), although it is known 
that Crm1 can also recognize some of its cargos independent of a leu-rich NES. Such an 
interaction occurs, e.g., between Crm1 and snurportin (Paraskeva et al., 1999).  
 
2.3. Ran 
2.3.1. Biochemical features of Ran 
Ran (Ras-related nuclear protein) is a small GTPase (~25kDa) which belongs to the 
superfamily of Ras proteins. It shares homology to Ras in its guanine nucleotide binding 
domain (G-domain). Unlike many other G-proteins, Ran is predominantly nuclear, and a 
small pool of it can also be found in cytoplasm. In contrast to other members of the Ras 
superfamily, which are modified by fatty acids or isoprenoids that usually target the 
proteins to membranes, Ran is not modified and hence soluble. All eukaryotic cells 
contain Ran, and it has been highly conserved throughout evolution (Rush et al, 1996). It 
is an extremely abundant protein (~107 copies/cell) and makes up of ~0.4% of the total 
cellular protein (Bischoff and Ponstingl, 1991). As a small GTPase, Ran has intrinsic 
GTPase activity, which is however very slow, and it requires the help of a GTPase 
activating protein for full catalytic activity. Therefore, Ran is considered to be an 
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incomplete enzyme. Ran has a strong affinity towards guanine nucleotide, which is Mg2+-
dependent (pM-nM range), and the dissociation of the nucleotide from the protein is very 
slow. 
 
2.3.2. Ran GTPase cycle 
Like all other G-proteins, Ran cycles between GDP- and GTP-bound conformations. The 
conformational change between these two different states is striking and occurs in three 
different regions of Ran named as switch I (aa 37-45), switch II (aa 69-85), and the C-
terminal acidic tail (Scheffzek et al., 1995). Due to its biochemical properties discussed 
above, Ran requires two accessory proteins in order to switch between the two 
conformations: In mammals, these are RanGAP1 (Ran GTPase activating protein 1) and 
RCC1 (Regulator of chromosome condensation 1) (Fig. 2). RanGAP1 increases the intrinsic 
GTPase activity of Ran by a factor of 105 in vitro (Bischoff et al., 1994), thereby converting 
RanGTP to RanGDP. RCC1, on the other hand, stimulates the nucleotide exchange on Ran 
by up to five orders of magnitude (Bischoff and Ponstingl, 1991), allowing Ran to bind 
GTP since free GTP concentrations in cells are 10-fold higher than GDP (Bourne et al., 
1991). Interestingly, RanGAP1 and RCC1 are localized to different compartments in cells. 
RanGAP1 is localized to the cytoplasm and the cytoplasmic filaments of nuclear pore 
complexes, the latter being mediated via sumoylation of RanGAP1 as mentioned 
previously (Matunis et al., 1996; Mahajan et al., 1997). RCC1, on the other hand, is a 
chromatin-bound protein, which interacts with the core nucleosome components H2A 
and H2B (Ohtsubo et al., 1987; Nemergut et al., 2001). Differential localization of the two 
effectors of Ran results in a steep gradient of RanGTP to RanGDP in the direction of 
nucleus to cytoplasm, which is essential for the directionality of nucleocytoplasmic 
transport (Izaurralde et al., 1997). Attempts to measure this gradient by FRET-based 
experiments led to the estimation that the RanGTP concentration in the nucleus is 100-fold 
higher than in the cytoplasm (Kalab et al., 2002). 
 
Despite the continuous efflux of Ran (105 mol/sec per nucleus) from the nucleus (Smith et 
al., 2002; Görlich et al., 2003) due to shuttling importins and exportins, Ran is still 
predominantly nuclear (Moore and Blobel, 1994). This is mainly due to the active import 
of Ran to the nucleus by its import receptor, NTF2 (Nuclear transport factor 2) (Ribbeck et 
al., 1998; Smith et al., 1998). NTF2 is a homodimeric import receptor, which does not 
belong to the Imp β superfamily of transport receptors. NTF2 forms a complex with Ran 
in GDP-bound state and passes through the nuclear pores since it has the intrinsic ability 
to interact with  nucleoporins via their FG-repeats (Bayliss et al., 2002). On the  
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nucleoplasmic side, probably the nucleotide exchange reaction with RCC1 triggers the 
dissociation of Ran from NTF2 since it can not interact with Ran in GTP-bound 
conformation (Stewart et al., 1998).  
 
2.3.3. Functions of Ran in nuclear transport and beyond 
Ran is an essential protein with several important functions. Besides its well-established 
role to regulate the directionality of nucleocytoplasmic transport Ran is also involved in 
two other key cellular processes: Spindle formation and nuclear envelope reassembly. 
RanGTP in the nucleus interacts with importin-cargo complexes, releasing the cargos in 
the nucleus, and helping the importins recycle back to the cytoplasm. It also interacts with 
exportins, increasing their affinity towards their respective cargos, which results in 
trimeric export complex formation. Molecular details of such regulation is discussed in 
detail in Section 2.4. RanGTP also regulates the spindle assembly around the vicinity of 
chromatin by releasing spindle assembly factors such as TPX2 and NuMA from Imp α/β 
inhibition in a similar way how it releases the cargo proteins from Imp α/β in the nucleus 
(Nachury et al., 2001; Wiese et al., 2001; Gruss et al., 2002). The RanGTP gradient around 
the mitotic chromosomes (Kalab et al., 2002) spatially controls microtubule formation and 
stabilization. The role of Ran in nuclear envelope formation, on the other hand, is not yet 
fully understood but it is known that both nucleotide exchange and GTP hydrolysis are 
















Fig. 2: Schematic representation of the Ran cycle. Ran cycles between two different conformations 
with the help of two accessory proteins. The nucleotide exchange factor, RCC1, is responsible for 
the exchange of GDP with GTP in the nuclear compartment since it is a chromatin-bound enzyme. 
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2.4. Molecular mechanisms of nucleocytoplasmic transport  
Nucleocytoplasmic transport is a remarkably fast and complicated process, which enables 
~100-1000 cargos to go through a single pore complex every minute (Ribbeck and Görlich, 
2001). Most of the transport processes are mediated via the Imp β-superfamily of nuclear 
transport receptors although alternative transport mechanisms were described as well. 
Nucleocytoplasmic transport is a combination of biochemical reactions (refer to Fig. 3), 
which can be grouped into four distinct steps (reviewed in Stewart, 2007): In the first step, 
transport complexes are formed between transport receptors and cargo proteins. In case 
of import, importins recognize their respective cargo proteins in the cytoplasm directly or 
with the help of adaptor proteins such as Imp α and snurportin. In export, however, the 
interaction between exportins and cargo proteins is not strong enough and requires 
stabilization by RanGTP. Therefore, export complexes can only form in the nucleus, 
where high RanGTP concentrations are available. In the second step, transport complexes 
formed on either side of the nuclear envelope translocate through the nuclear pores. This 
step is energy-independent and non-directional (facilitated diffusion) (Schwoebel et al., 
1998; Englmeier et al., 1999; Ribbeck et al., 1999). Although several models such as 
„virtual gate model“ (Rout et al., 2003), „the spaghetti oil model“ (Macara, 2001), and 
„selective phase model“ (Ribbeck and Görlich, 2001) have been suggested to account for 
the movement of transport complexes through the pores, the exact underlying 
mechanisms remain still enigmatic. In the third step, the directionality of the cargo 
transport is established by compartment-specific dissociation of cargo proteins. For 
import, it is the high RanGTP concentrations in the nucleus that promote cargo 
dissociation. RanGTP interacts with all importins via their N-terminal region (Vetter et al., 
1999; Lee et al., 2005), which, in turn, leads to the release of respective cargo molecules in 
the nucleoplasm. For export, it is the RanGTP hydrolysis on the cytoplasmic filaments or 
in the cytoplasm, which leads to the dissociation of trimeric export complexes. The 
directionality of the translocation is not dependent on the composition of nuclear pores 
but on the dissociation of cargo-carrier complexes which was nicely documented by 
changing the direction of the transport by inverting the Ran gradient (Nachury and Weis, 
1999). In the final step, importins recycle back to the cytoplasm in complex with RanGTP. 
Hydrolysis of RanGTP by RanGAP1 sets them free for another round of import. This fast 
step is however complicated by the fact that transport receptors can block the hydrolysis 
of RanGTP by RanGAP1, which is exemplified in case of Imp β (Floer and Blobel, 1996). 
This inhibition is released by either cytoplasmic RanBP1 protein or the RanBP1-homology 
domains of RanBP2 at the cytoplasmic filaments. In case of RanGTP-Imp β complex, even 
the presence of RanBP1 or RanBP2 is not sufficient for GTP hydrolysis, and the reaction 
also requires the presence of Imp α and NLS-containing cargo (Yaseen and Blobel, 1999).  
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Fig. 3: Schematic representation of nucleocytoplasmic transport mechanisms. Different 
nucleocytoplasmic transport mechanisms are illustrated in the scheme. One is the canonical cargo 
transport via the Imp β superfamily of nuclear transport receptors and the other one is the import 
of Ran via NTF2, which does not belong to the Imp β superfamily. In case of importin- or exportin-
dependent transport, receptor-cargo complexes form either in the cytoplasm or nucleus, 
respectively. These complexes then translocate through the NPCs. In case of import, importins 
interact with the nuclear RanGTP, which, in turn, releases the bound cargo in the nucleoplasm. In 
case of export, trimeric export complexes disassemble on the cytoplasmic side of NPCs upon 
RanGTP hydrolysis by RanGAP1. Importins recycle in complex with RanGTP whereas exportins 
by themselves. To recycle Ran, dimeric NTF2 interacts with two RanGDP molecules in the 
cytoplasm. The tetrameric complex then translocates through the NPCs. In the nucleus, chromatin-
associated nucleotide exchange factor, RCC1, converts RanGDP into RanGTP, which possibly 
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Exportins, on the other hand recycle back to the nucleus in their free form by facilitated 
diffusion. 
 
3. Intriguing links between sumoylation and nucleocytoplasmic transport  
SUMO has been linked to nucleocytoplasmic transport ever since its discovery as a 
modifier of vertebrate RanGAP1, which is targeted to the nuclear pore complex (NPC) 
after sumoylation (Matunis et al., 1996; Mahajan et al., 1997; Lee et al., 1998; Mahajan et 
al., 1998). The interplay between sumoylation and nucleocytoplasmic transport has 
rapidly become evident with several papers describing either sumoylation or 
nucleocytoplasmic transport being a prerequisite for the other. Nuclear import of several 
proteins such as Sp100, PML, and Rad52 was essential for their efficient sumoylation 
(Duprez et al., 1999; Sternsdorf et al., 1999; Ohuchi et al., 2008). In line with these findings, 
it was also reported that the sumoylation of a consensus motif fused to a carrier protein 
was only possible when the protein was forced to the nucleus by addition of an NLS 
(Rodriguez et al., 2001). While many proteins required active nuclear import to be 
sumoylated, many others required sumoylation to enrich in the nucleus. For instance, 
sumoylation of the viral protein E1B-55kDa (Endter et al., 2001) and bovine 
papillomavirus E1 (Rangasamy et al., 2000) was shown to change the localization of the 
proteins from the cytoplasm to the nucleus. Similarly, Drosophila cells, which had a 
mutation in the semushi gene, the homolog of Ubc9, had a defect in the import of the 
transcription factor bicoid, indicating a correlation between sumoylation and nuclear 
import (Epps and Tanda, 1998). Although many examples indicate a link between 
sumoylation and import, nuclear export has also been observed to be regulated by 
sumoylation. For example, it was shown for the transcriptional repressor TEL that the 
mutations which impair sumoylation lead to the accumulation of the TEL in nucleus due 
to the defects in its nuclear export (Wood et al., 2003). Besides the individual examples 
where nucleocytoplasmic transport and sumoylation are interlinked, there has been a 
more global regulation described when Kathrin Stade and her colleagues reported that 
cNLS-dependent import was impaired in temperature sensitive ulp1 or uba2 yeast strains 
(Stade et al., 2002). They also showed that the importin α homolog in yeast, Srp1, 
accumulates in the nucleus in those yeast strains. This study clearly indicated that in the 
absence of sumoylation in yeast, Imp α/β-dependent import is defected. However, the 
underlying mechanisms for why Imp α accumulates in nucleus and the contribution of 
SUMO remained elusive. 
 
Over the last decade, some components of the SUMO pathway have been discovered to 
be localized to NPCs (reviewed in Palancade and Doye, 2008), which strengthened the 
link between sumoylation and nucleocytoplasmic transport (Fig. 4). The first example was 
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the discovery of the yeast isopeptidase Ulp1 (Li and Hochstrasser, 1999), which was 
found to be localized to the nuclear basket via interactions with nucleoporins (Takahashi 
et al., 2000; Li and Hochstrasser, 2003). Localizing a SUMO isopeptidase to nuclear pore 
complexes turned out to be highly conserved during evolution. Ulp1’s orthologs in 
S.pompe, D. melanogaster, A.thaliana, and mammals were discovered to localize to the NPCs 
as well (Hang and Dasso, 2002; Taylor et al., 2002; Zhang et al., 2002; Murtas et al., 2003; 
Smith et al., 2004). Another example came with the discovery that RanBP2/Nup358, the 
main component of the cytoplasmic filaments of NPCs, is a SUMO E3 ligase (Pichler et al., 
2002). Intriguingly, a small fraction of the otherwise nuclear SUMO E2 conjugating 
enzyme Ubc9, was found to be in complex with RanBP2 together with sumoylated 
RanGAP1 (Saitoh et al., 1997; Swaminathan et al., 2004; Zhu et al., 2006). RanBP2 or 
RanGAP1 localization at the cytoplasmic face of the NPCs, however, is not completely 
conserved during evolution. The RanGAP1 ortholog in budding yeast, Rna1, for instance, 
is not sumoylated and exclusively cytoplasmic (Hopper et al., 1990). Interestingly  in 
plants, RanGAP localizes to NPCs although it lacks the C-terminal tail region (Pay et al., 
2002), which is sumoylated and necessary for targeting mammalian RanGAP1 to the  
 
 
Fig. 4:  Components of the SUMO pathway are localized at nuclear pore complexes in yeast and 
human. In mammals, RanBP2, which forms the cytoplasmic filaments of nuclear pore complexes, 
interacts with sumoylated RanGAP1 and Ubc9 and has SUMO E3 ligase activity. Similarly, the 
SUMO isopeptidase SENP2 is localized to the nuclear basket. In yeast, however, RanBP2 protein 
does not exist. The yeast ortholog of RanGAP1, which is Rna1, is not sumoylated and localized to 
the cytoplasm. Localizing a SUMO isopeptidase to the nuclear basket, on the other hand, is 
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NPCs. Instead, RanGAP in A.thaliana has a plant-specific N-terminal extension  
responsible for the localization of RanGAP at nuclear pores. RanBP2 orthologs, on the 
other hand, do not exist in yeast or plant genome (Rout et al., 2000; Miller et al., 2010). 
Finally, during the course of this work, there have been many screens in which 
sumoylated proteins from total cell extracts were affinity purified and identified by mass 
spectrometry. Amongst hundreds of candidates in the resulting lists are several nuclear 
transport receptors including Crm1, Imp β, CAS, Imp α, and Importin 5. In two of these 
screens (Golebiowski et al., 2009; Bruderer et al., 2011) heat shock was used to increase 
sumo conjugation globally. It is known that cellular stress conditions such as heat shock 
increase the levels of sumoylated proteins especially modified with SUMO2/3 (Saitoh and 
Hinchey, 2000). Recently, one possible mechanism for this was suggested by the 
observation that the activities of several SENPs including SENP1-3 and SENP7 decrease 
upon heat shock (Pinto et al., 2012). In line with these observations, during the last year of 
my PhD work, the first nuclear transport receptor was shown to be sumoylated in yeast 
(Rothenbusch et al., 2012). In this work, Rothenbusch and her colleagues demonstrated 
that the yeast Kap114 (Imp 9 homolog) is sumoylated by the E3 ligase Mms21, and 
sumoylation/desumoylation cycles were required for proper recycling of the import 
receptor. 
 
3.1. Multisubunit SUMO E3 ligase RanBP2 
RanBP2/Nup358 is a giant nucleoporin (~358kDa) in vertebrates, and localizes to the 
cytoplasmic filaments of nuclear pore complexes during interphase (Wu et al., 1995; 
Yokoyama et al., 1995). It has several domains including a zinc finger domain, four Ran-
binding domains, a leucine-rich domain, an E3 ligase region, a cyclophilin-homology 
domain as well as several FG and FxFG repeats (refer to Fig. 5). Via its Ran-binding 
domains and FG repeats, RanBP2 provides a transient interaction platform for RanGTP 
and nuclear transport receptors, respectively. It interacts stably with sumoylated 
RanGAP1 and Ubc9 (RanBP2 complex) (Mahajan et al., 1997; Saitoh et al., 1997; Lee et al., 
1998; Pichler et al., 2002), which stays as a soluble entity in mitosis after nuclear envelope 
disassembly (Swaminathan et al., 2004). Of note, within the stable RanBP2 complex, 
sumoylated RanGAP1 is resistant to SUMO isopeptidases (Zhu et al., 2009), which makes 
RanGAP1 a unique SUMO substrate.  
 
During the last year of this work, it was discovered in our lab that there is no free RanBP2 
in cells neither in interphase nor in mitosis, and that the RanBP2 complex acts as a multi-
subunit SUMO E3 ligase (Werner et al., 2012). This discovery is very crucial to study 
RanBP2-dependent sumoylation since biochemical features of small RanBP2 fragments in 
isolation and the RanBP2 complex differ significantly. RanBP2 is a unique SUMO E3 
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ligase (Pichler et al., 2002) without homology to other known ubiquitin or SUMO E3 
ligases (Pichler et al., 2004). The E3 ligase activity of RanBP2 was mapped to a small 
region comprised of internal repeat 1 (IR1) and internal repeat 2 (IR2), which are 50 aa 
each and separated by a short linker region called M region (20 aa) (Fig. 5). Both IR1 and 
IR2 regions can interact with Ubc9 and stimulate sumoylation, although IR2 is much less 
efficient than IR1 in vitro (Pichler et al., 2004; Tatham et al., 2005). Surprisingly, 
sumoylated RanGAP1 and Ubc9, as part of the stable RanBP2 complex, occupy the IR1 
region both in vitro and in vivo (Reverter and Lima, 2005; Werner et al., 2012). Therefore, 
it was initially suggested that in vivo RanBP2 complex can not be active and only 
represents an inactive trapped E2/E3 complex (Reverter and Lima, 2005). This idea was 
first challenged with the identification of the two in vivo targets of RanBP2: 
Topoisomerase IIα and Borealin (Dawlaty et al., 2008; Klein et al., 2009), both of which are 
sumoylated during mitosis, when a pool of RanBP2/Ubc9/RanGAP1*SUMO complex 
enriches at kinetochores and mitotic spindles (Joseph et al., 2002). The molecular 












Fig. 5: The domain structure of ~358kDa RanBP2. The scheme shows several different domains of 
the nucleoporin RanBP2: N-terminal leucine rich domain (Leu-rich), four Ran-binding domains 
(numbered as 1-4), zinc-finger domain (Zn-fingers), E3 ligase region (E3), cyclophilin-homology 
domain (Cy), and several FG and FxFG (x: any amino acid) repeats, which are represented by small 
circles and triangles, respectively. Amino acid positions are shown as numbers at the top of the 
figure. The E3 ligase region (aa 2631-2771) is enlarged to visualize the binary interactions of the 
components of RanBP2 complex. This region of RanBP2 has two internal repeats (IR1 and IR2), 50 
amino acids each, separated by a 20 amino acid middle region (M). Sumoylated RanGAP1 and the 
SUMO E2 conjugating enzyme, Ubc9, bind to the IR1+M region as depicted.  
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that upon complex formation, the catalytic center switches from IR1 to IR2, enabling IR2 
to catalyze the in vitro sumoylation of physiological substrates such as Borealin much 
more efficiently than IR2 in free RanBP2 (Werner et al., 2012).  
 
RanBP2 is part of the cytoplasmic filaments of NPCs and actively involved in 
nucleocytoplasmic transport. Different groups tried to adress the exact role of RanBP2 in 
transport with sometimes conflicting answers. Initially, it was shown that extensive 
blocking of RanBP2 with gold particles or NPCs formed from Xenopus egg extracts 
depleted for RanBP2 did not have any effect on Imp α/β- and transportin-depedendent 
import (Walther et al., 2002). On the other hand,  it was shown that the cells depleted for 
RanBP2 had dramatically reduced rates for Imp α/β- and transportin-dependent import 
with model cargos (Hutten et al., 2008; 2009), although the import was not inhibited 
completely. Protein export, however, was only slightly affected by RanBP2 knockdown 
(Hutten and Kehlenbach, 2006). Studies with embryonic fibroblasts from RanBP2 
conditional knockout mice clearly indicated that RanBP2 is required for cell viability, and 
it is the transport-related functions rather than mitotic functions that were indispensable 
(Hamada et al., 2011). Moreover, RanBP2 was also recently shown to affect the nuclear 
localization of a subset of cellular proteins (Wälde et al., 2012), without affecting the 
import of many others.  
 
5. Aims of this work: 
In light of the above mentioned links between sumoylation and nucleocytoplasmic 
transport, preliminary mass spectrometry evidence, and the intriguing architecture of the 
RanBP2 complex, the nuclear transport receptors and/or the small GTPase Ran may be 
regulated by RanBP2-dependent sumoylation. In this work, I aimed to test this hypothesis 
and further investigate the mechanistics and the functional consequences of nuclear 
transport receptors and/or Ran sumoylation during interphase. 
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MATERIALS & METHODS 
1. MATERIALS 
1.1. Technical Equipment 
Axioskop 2 Fluorescence Microscope  Zeiss 
Axiocam digital camera  Zeiss 
Bacterial incubator ISF-1-w, ISF-1-x Kühner 
Balance PC4400 Mettler 
BD FACSCantoTM II   BD Biosciences 
Cell culture hood Hera Safe Heraeus 
Cell culture incubator Hera cell Heraeus 
Cell culture incubator Incucell MMM medcenter 
Centrifuge Allegra X-22R Beckman Coulter 
Centrifuge Heraeus Multifuge 1S Thermo Scientific 
Centrifuge RC 3BP+, RC 6+ Sorvall 
Centrifuges 5415C, 5430, 5417R Eppendorf 
Chromatography system Äkta Purifier GE Healthcare 
Electrophoresis Power Supply EPS300/301 Pharmacia Biotech 
Electrophoresis Power Supply Power Pac HC Bio-rad 
Electrophoresis and blotting chambers Workshops at MPI, Martinsried 
          and Biochemistry I, Göttingen 
EmulsiFlex-C5 Avestin 
Film developing machine Curix60 Agfa 
Film developing machine X-OMAT 2000 Processor Kodak 
Freezers, Refrigerators Liebherr 
Gelfiltration columns:  GE Healthcare 
Superdex200 10/300 GL 
MonoQ 5/50 GL 
HiLoadTM 26/60 SuperdexTM 75  prep grade 
HiLoadTM 26/60 SuperdexTM 200  prep grade  
Heating blocks Störk-Tronic 
HeraFreeze Thermo Scientific 
Icemachine Scotsman 
Incubation water bath 1008 GFL 
Leica DMIL LED microscope  Leica 
Leica SP2 confocal miscroscope Leica 
Luminescent Image Analyzer LAS-4000 Fujifilm 
Magnetic stirrer MR Hei-Mix L Heidolph 
Microwave R-93ST-A Sharp 




NanoDrop ND-1000 Thermo Scientific 
pH-meter 720 WTW 
UV/Visible SpectroPhotometer Ultraspec 3100 pro Amersham Biosciences 
Pipettes  Gilson, Eppendorf 
Precision balance TE601, Mettler PC4400,  Sartorius 
Micro balance CP 60-OCE 
Reciprocating shaker 3005, 3015 GFL 
Rotor S45A Sorvall 
Rotors TLA45, Type45Ti, Type70.1Ti Beckman Coulter 
Rotors: FiberLite F13 – 14x50cy, F9-4x1000y Piramoon Technologies Inc. 
F10-6x500y 
Scanner 4990 Photo, V700 Photo Epson 
Shaker DRS-12 Neolab 
Sonifier Sonopuls GM 200 Bandelin 
Thermocycler Primus MWG Biotech 
Thermocycler T3000 and Tprofessional Biometra 
Thermomixer Compact Eppendorf, Hamburg 
Ultracentrifuge DiscoveryTM 90SE, M120 SE Sorvall 
Ultrasonic bath Sonorex RK 100 Bandelin 
UV-table UVT-20L Herolab 
UV-transilluminator Peqlab Biotechnologie GmbH 
Vacuum pump Laboport N480.3FTP KNF Neuberger 
Vortex 7-2020 Neolab 
Water purification system MembraPure  MembraPure GmbH 
 
1.2. Software 
Adobe Acrobat 9 Pro Adobe 
Adobe Creative Suite 4 Adobe 
DNASTAR Lasergene  DNAStar Inc. 
Papers 2.1.12  Mekentosj   
Image Reader LAS 4000 Fujifilm 
Image J 1.43u Wayne Rasband, National Institutes of Health, USA 
MacPyMOL  DeLano Scientific LLC 
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1.3. Consumables 
Autoradiography Films (HyperfilmTM ECL, SuperRX) GE Healthcare, Fujifilm 
Canulas, syringes (different sizes) Braun, Discardit II, Mediware 
Cell culture consumables Sarstedt, TPP 
Centrifugal filter units Millipore, Vivaspin 
Dialysis tubing Spectra-Por Roth 
Disposable plastic columns Bio-Spin, Poly-Prep, Econo-Pac Bio-Rad 
Filter paper 3MM Whatman Whatman 
Glass slides, coverslips Roth 
Glassware Schott 
Gloves (Rotiprotect-LATEX, -NITRIL, Peha-soft) Roth, Hartmann 
Pipette tips (combi tips, filter tips) Sarstedt, Eppendorf, Nerbe, Plus, Biozym 
  Ratiolab 
Plastic pasteur pipettes Roth 
Protein low binding reaction tubes  Sarstedt, Eppendorf 
PROTRAN Nitrocellulose Schleicher & Schuell 
Reaction tubes Sarstedt, Eppendorf 
Scalpels Lance Paragon LTD 
Sterile filters and membranes (0.22-0.45µm) Millipore, Pall, Sartorius 
5mm Polystyrene Round-Bottom tubes  BD Falcon 
 
1.4. Chemicals, reagents, and enzymes 
Common chemicals were obtained from AppliChem, CARL ROTH GmbH, Merck, Serva, 
and Sigma-Aldrich. Some selected chemicals, reagents, and enzymes are listed below: 
  
Acrylamide solution (30%) AppliChem 
Alexa Fluor 488 C5 Maleimide Invitrogen 
Aprotinin Biomol 
Apyrase Sigma-Aldrich 
ATP Sigma-Aldrich  
BSA, fraction V AppliChem 
Creatine Phosphate, Dipotassium Salt Calbiochem 
Creatine Phosphokinase Calbiochem 
Cyanogen bromide-activated sepharose 4B Sigma-Aldrich 
Digitonin, high purity  Calbiochem 
DEAE Sepharose  Sigma-Aldrich 
DMEM (high glucose) Gibco, PAA 
DMSO AppliChem 




DMP  Thermo Scientific 
dNTPs  Fermentas, Roche 
ECL (Pierce ECL Western Blotting Substrate, Millipore, Pierce 
Immobilon Western Chemiluminescent HRP Substrate) 
Ethidium bromide AppliChem 
Fetal bovine serum (FBS) Gibco 
Formaldehyde Solution, 37%  AppliChem 
Fugene HD transfection reagent  Promega 
GDP & GTP  Sigma-Aldrich 
GeneRuler DNA ladder (1kb) Fermentas 
Glutamine (cell culture grade) Gibco 
Glutathione Sepharose GE Healthcare, Macherey & Nagel 
Glycerol 87% (Glycerin)  AppliChem 
GMP-PNP  Sigma-Aldrich 
Hexokinase Sigma-Aldrich 
HyClone RNase-free water  Thermo Scientific 
IPTG  Fermentas 
Joklik’s modified minimal essential medium  Sigma-Aldrich 
Leupeptin Biomol 
Lipofectamine RNAiMAX reagent  Invitrogen 
N-Ethylmaleimide (NEM) Sigma-Aldrich 
Newborn calf serum (NCS)  Gibco 
Ni-NTA agarose Qiagen 
Normal mouse IgG  Invitrogen 
Oligonucleotides Operon, Sigma-Aldrich 
OptiMEM  Invitrogen  
Ovalbumin Sigma-Aldrich 
PageRuler prestained protein ladder Fermentas 
PageRuler unstained protein ladder Fermentas 
PD10-column GE Healthcare 
Penicillin/Streptomycin Gibco, PAA 
Pepstatin Biomol 
Phusion polymerase Finnzymes, NEB 
PMSF Sigma 
Protein G agarose Roche 
Restriction enzymes Fermentas, NEB 
Slow Fade Gold antifade reagent  Invitrogen 
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T4 DNA ligase Fermentas 
TEMED AppliChem 
Trypsin/EDTA Gibco, PAA 
 
1.5. Kits 
NucleoBond PC100, PC500 Macherey & Nagel 
660nm Pierce Protein Detection Kit and  Pierce 
Ionic detergent compatibility reagent (IDCR) 
Nucleospin Extract II Macherey & Nagel 
Nucleospin Plasmid Macherey & Nagel 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
Quick StartTM Bradford Protein Assay Bio-Rad 
 
1.6. Buffers and Stock Solutions 
Buffers and stock solutions were prepared using deionized water unless noted otherwise.  
Setting the pH was carried out by titrating either NaOH or HCI unless noted otherwise. 
Stock solutions were either stored at -20°C as aliquots or prepared freshly. 
 
Buffers 
DNA Loading dye (6X) 60mM EDTA, 60% (v/v) glycerol, 0.2% (w/v) 
  bromophenol blue, 0.2% (w/v) xylencyanol 
 
Colloidal Coomassie 2% (v/v) ortho-phosphoric acid, 10% (w/v) 
dye stock solution  ammonium sulfate, 0.1% (w/v) Coomassie G-250 
 
Coomassie Destainer 10% (v/v) acetic acid, 45% (v/v) methanol 
 
Coomassie staining solution 0.25% (w/v) Coomassie brilliant blue R-250, 
  10% (v/v) acetic acid, 45% (v/v) methanol 
 
Laemmli running buffer 25mM Tris, 192mM glycine, 0.05% (v/v) SDS, 
  prepared as 10x stock solution 
 
Phosphate buffered saline (PBS)  140mM NaCI, 2.7mM KCI, 10mM Na2HPO4 
  1.5mM KH2PO4, pH 7.3; prepared as 10x stock solution 
 
PBS-Tween  PBS supplemented with 0.2% (v/v) Tween20 





Ponceau-S  0.5% (w/v) Ponceau-S, 1% (v/v) acetic acid 
 
RIPA buffer 20mM Na2HPO4 pH 7.4, 150mM NaCI, 1% (v/v) Triton-X100 
  0.5% (w/v) Na-deoxycholat, 0.1% (v/v) SDS 
 
SDS sample buffer 50mM Tris/HCI pH 6.8, 2% (v/v) SDS, 0.1% (w/v) 
  bromophenol blue, 10% (v/v) glycerol, 100mM DTT 
  prepared as 1x, 2x, and 4x stock solutions 
 
Sumoylation Assay Buffer (SAB) TB supplemented with 0.2mg/mL 
  ovalbumine, 0.05% (v/v) Tween20, 1mM DTT, 
  1µg/mL AP and LP 
 
TAE (Tris-Acetate-EDTA) Buffer 40mM Tris pH 7.7, 1mM EDTA, 0.1% (v/v) 
  acetic acid, prepared as 50x stock solution 
 
Transport Buffer (TB) 110mM K-acetate, 2mM Mg-acetate, 1mM EGTA 
  20mM HEPES pH 7.3 titrated with KOH 
  prepared as 10x stock solution 
 
Western blot Buffer (WB)  25mM Tris/HCI, 193mM glycine, 20% 
  (v/v) methanol, 0.04% (v/v) SDS 
  prepared as 10x stock solution 
Stock Solutions 
Ampicillin  100mg/mL 
Aprotinin (1000x)  1mg/mL 
ATP  100mM ATP, 100mM Mg-acetate, 20mM HEPES, pH 7.4 
Chloramphenicol (1000x) 30mg/mL 
Digitonin   10% (w/v) in DMSO 
Dithiothreitol (DTT)  1M 
GDP/GTP  10mM GDP/GTP, 10mM MgCI2, 20mM HEPES 
   pH 7.4 titrated with NaOH 
Hoechst 33258  1mg/mL 
Kanamycin (1000x) 30mg/mL 
Leupeptin/Pepstatin (LP) (1000x)  1mg/mL each, in DMSO 
N-ethylmaleimide (50x)  500mM in DMSO, prepared freshly 
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Nocodazole  5mg/mL in DMSO 
Pefabloc (100x)  100mM 
PMSF  100mM in 2-propanol 
 
1.7. Media 
Bacterial media were sterilized by autoclaving whereas mammalian cell culture media 
were sterile-filtered. 
Bacterial cell culture media 
LB Medium  1%  (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 
  1% (w/v) NaCI, pH 7. LB was supplemented with 
  1.5% (w/v) bacto-agar for agar plates 
SOC Medium  2% (w/v) tryptone, 5% (w/v) yeast extract, 
  50mM NaCI, 2.5mM KCI, 10mM MgCI2, 10mM MgSO4 
 
Mammalian cell culture media 
Supplemented DMEM  Dulbecco’s modified eagle medium (DMEM), 10% 
  (v/v) FBS, Penicillin/Streptomycin (0.1 U/mL/100 µg/mL) 
  2mM L-glutamine 
Jokliks Medium 
Jokliks medium was prepared by dissolving Jokliks MEM powder (Sigma), 20g sodium 
hyrogen carbonate (NaHCO3), and 23.8g HEPES in 10L ultrapure water. The pH of the 
medium was titrated to 7.1 with sodium hydroxide followed by filter-sterilization. The 
medium was stored at 4°C protected from light. 
Other cell culture media and supplements were obtained commercially. 
 
1.8. Cell lines 
Bacterial strains 
DH5α  F-φ80lacZ ΔM15 (lacZYA-argF) U169 deoR recA1 endA1 
  hsdR7 (rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ- 
BL21 (DE3)    F- ompT hsdSB (rB- mB-) gal dcm λ(DE3) 
BL21 (DE3) pLysS  F- ompT hsdSB (rB- mB-) gal dcm λ(DE3), pLysS(CmR) 
TOP10  F-mcrAΔ (mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
  araD139Δ (ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG λ- 
Rosetta2 (DE3)  F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CmR) 
JM109   e14- (McrA-), endA1, recA1, gyrA96, thi-1 hsdR17 (rk–, mk+), relA1 
  supE44, Δ( lac-proAB), (F´ traD36, proAB, lacIqZΔM15)    
 




Mammalian cell lines 
HEK 293T  Human embryonic kidney cell line 
HeLa (obtained from Francis Barr)  Human cervix carcinoma cell line 
HeLa suspension cells (CSH HeLa strain)  Human cervix carcinoma cell line  
1.9. Oligonucleotides, vectors, and plasmids 
 
 































































































































































































untagged Ran wt 
 
Lab common stock 



























































His-Aos1/Uba2 (SUMO E1 enzyme) 
 
Lab common stock^ 
 
Ubc9 (SUMO E2 enzyme) 
 








Dr. Andreas Werner* 
 
His-RanBP2/Ubc9/acidic RanGAP1 tail - SUMO1 
complex 
 









































































Moutty*, PhD Thesis 
 












































































































GST-PIAS1, GST-PIASxα , PIASxβ, PIAS3 
GST-PIASy 
 




Lab common stock^ 
 
* These people are current or former members of Melchior lab except for following people: 
Prof. Dr. Ralph Kehlenbach, University of Göttingen 
Prof. Dr. Dirk Görlich, MPIbpc, Göttingen 




^ These proteins were purified by various members of Melchior lab and are available as common 
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Horseradish peroxidase-conjugated secondary antibodies for western blot analysis were 
obtained from Jackson ImmunoResearch Laboratories distributed by Dianova and used at 
a dilution of 1:10000. Secondary antibodies for immunofluorescence conjugated to 
Alexa488 and Alexa594 were obtained from Molecular Probes (as 2mg/mL stock 
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2. METHODS 
Standard procedures in molecular biology, biochemistry, and cell biology were performed 
on the basis of „Molecular Cloning: A Laboratory Manual“ Maniatis T., Fritsch E.F., 
Sambrook J. (Cold Spring Harbor Laboratory, New York, 1982), „Current Protocols in 
Protein Science” Coligan, J.E., Dunn B.M., Speicher, D.W., Wingfield, P.T. (John Whiley & 
Sons, 2003), and “Current Protocols in Cell Biology” Bonifacino, J.S., Dasso, M., Harford, 
J.B., Lippincott-Schwartz, J., Yamada, K.M. (John Whiley & Sons, 2000).  
 
2.1. Molecular biology techniques 
2.1.1. Culturing and storage of bacteria 
Bacteria were cultured at 37°C in LB medium supplemented with the required antibiotics 
(ampicillin 100µg/mL, kanamycin 30µg/mL or chloramphenicol 30µg/mL for liquid 
cultures, half the concentration for plates) to maintain the transformed plasmid. Liquid 
cultures were shaken constantly at 180 rpm. For long-term storage, cultures were grown 
overnight, and supplemented with 50% glycerol followed by flash freezing in liquid 
nitrogen. Glycerol stocks were stored at -80°C. 
 
2.1.2. Plasmid preparation 
Plasmids were prepared mostly from DH5α bacteria at different scales (mini-, midi-, and 
maxi-preps) depending on the following applications such as cloning, clone screening via 
restriction enzyme digestion, mutagenesis, sequencing, storage, or transfection into 
mammalian cells. All plasmid purifications were performed with Macherey-Nagel DNA 
purification kits according to the manufacturer’s instructions. In short, cells were grown 
overnight at 37°C, and harvested by centrifugation. Collected cells were resuspended in 
50mM Tris-HCI, pH 8.0 supplemented with 10mM EDTA and 100µg/mL RNase A, and 
lysed with alkaline lysis buffer (200mM NaOH, 1% (v/v) SDS) (described by Birnboim 
and Doly, 1979). Cell debris and proteins were precipitated by the addition of 
neutralization buffer (2.8M KAc, pH 5.1). The soluble fraction was separated from the 
precipitated material by either  loading the bacterial lysate onto filters and collecting the 
flow through or by centrifugation. The DNA was precipitated out of the solution by 
adding room-temperature isopropanol.  The precipitated DNA was collected by 
centrifugation, washed with 70% (v/v) ethanol, dried, and reconstituted in TE buffer 
(10mM Tris-HCI, pH 8.0, 0.1mM EDTA) or sterile deionized H2O. DNA concentration and 
the purity were determined by measuring the absorption at 230, 260, and 280nm by 









Polymerase chain reaction (PCR) techniques 
PCR reactions were set up in a final volume of 50µL using up to 10ng plasmid DNA as a 
template, 0.5µM final concentration of forward and reverse primer (can be varied in a 
range of 0.2-1µM), 200µM of each dNTPs, and 1 unit of Phusion polymerase (Finnzymes) 
in Phusion HF buffer. The annealing temperature (Tm) for the primers used was 
calculated according to the online calculators, 
(Phusion: http://www.finnzymes.com/tm_determination.html). 
For primers > 20nt, 3°C was added to the calculated temperature whereas for primers < 
20nt, calculated temperature for the primer with the lower Tm value was used. If the Tm 
values were at least 69°C (for primers >20nt) or 72°C (for primers <20nt), a 2-step protocol 
was used with the combined annealing/extension step at 72°C even when the Tm values 
of primers exceeded 72°C. Annealing time for Phusion polymerase was usually used in 
the range of 10-30 seconds, whereas the extension time was calculated depending on the 
length of the amplicon (15 seconds per 1kb of DNA). In most cases, the following 2-step 
program was used: 
 
Initial Denaturation 98°C 30 sec  
    
Denaturation 98°C 5 sec 
Annealing 72 °C 20 sec 
Elongation 72 °C 15 sec / kb 
30 cycles 
    
Final elongation 72 °C 10 min  
    
Hold 4 °C   
 
Restriction of DNA by endonucleases 
Restriction enzymes were obtained from New England Biolabs. Digestion reactions were 
set up either in 20µL or 50µL reactions depending on whether vector DNA or amplified 
PCR fragment is to be cut. For vector DNA, in general 2-5µg DNA were cut, whereas for 
the amplified PCR fragments, everything that could be purified was used for the reaction. 
In most cases, 20 units of the restriction enzymes were used, and under no circumstances 
should the volume of the enzyme exceed 1/10th of the reaction volume. In case of double 
restrictions, the appropriate buffer was chosen with the „Double digest finder“ tool from 
the website of NEB. Where necessary, reactions were supplemented with BSA and 
incubated in 37°C room for at least 2hours.  
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Agarose gel electrophoresis and DNA extraction 
The amplified PCR fragments or digested plasmid DNAs were resolved by agarose gel 
electrophoresis. In most cases, 1-2% (w/v) agarose gels, chosen to provide optimal 
resolution, were prepared by dissolving the required amount of agarose powder in TAE 
buffer (refer to section 1.6. Buffers and Stock solutions) upon heating. The solution was 
allowed to cool down in a special chamber with combs to form the agarose gel. DNA 
samples were supplemented with 6x DNA loading dye (60mM EDTA, 60% (v/v) glycerol, 
0.2% (w/v) bromophenol blue, 0.2% (w/v) xylenecyanol in H2O) to have a final 
concentration of 1x, loaded into the pockets of the gel, and resolved at 80-100 Volts for 1-2 
hours. Afterwards, the gel was incubated for ~30 min in a TAE bath supplemented with 
1µg/mL ethidiumbromide to stain the DNA.   Visualization of the DNA was performed 
using UV light (365nm), and the exposure time was kept minimal to avoid DNA damage. 
The DNA fragments of interest were excised from the agarose gels with sterile scalpels 




Ligation of DNA fragments were carried out in 10µL reaction volumes. In most cases, 50-
400ng of linear vector together with an amount of insert DNA that provides a molar ratio 
of 3:1 (insert/vector)  were incubated together with 1µL of T4 DNA ligase (New England 
Biolabs) in 1x T4 DNA ligase reaction buffer (50mM Tris-HCI pH 7.5, 10mM MgCI2, 1mM 
ATP, 10mM DTT) provided by the company. The reaction was further supplemented with 
10mM ATP, and incubated at 16°C for 10hours. 
 
Transformation of competent bacteria 
Transformation describes the genetic alteration of a bacterial cell resulting from the 
naturally or artificially introduced exogenous DNA. Bacterial cells that are in the state of 
being able to uptake the exogenous genetic material are called competent, and there are 
different ways of artifically-inducing competence. The most routinely-used method for 
preparation of competent bacteria utilizes CaCI2, and the protocol was originally 
described by Morton Mandel and Akiko Higa (Mandel and Higa, 1970). For 
transformation, frozen aliquots of chemically competent E.coli cells were thawed on ice, 
and the plasmid DNA to be transformed was added followed by incubation on ice for 
30min. Following incubation, the cells were heat-shocked at 42°C for 45-60 seconds and 
incubated on ice for an additional 2 minutes before LB or SOC medium was added. 
Subsequently, the cells were allowed to recover for 1h at 37°C by shaking before they 
were finally plated out or inoculated into liquid cultures supplemented with antibiotics. 





All the plasmids constructed by PCR amplification during the course of this work were 
confirmed by DNA sequencing, which is based on the chain-termination reaction 
developed by Frederick Sanger (Sanger et al., 1977) (Sanger F. et al., 1977). The key 
principle behind this technique, also known as Sanger method, is the use of 
dideoxynucleotide triphosphates (ddNTPs), which can no longer be elongated due to the 
lack of 3’-OH group required for the formation of phosphodiester bond between two 
nucleotides. Currently, there are several advancements in DNA sequencing methods, and 
one key development which set the stage for automated, high-throughput DNA 
sequencing was the use of fluorescently labeled ddNTPs and primers (Smith et al., 1985; 
1986) (Smith et al., 1985 & 1986). The sequencing reactions were carried out from 20µL 
plasmid DNA (30-100ng/µL) and 20µL custom primers (10pmol/µL) (alternatively 
standard primers provided by company) by GATC Biotech. The sequences obtained were 
analyzed by DNASTAR softwares. 
 
2.1.5. Site-directed mutagenesis 
Site-directed mutagenesis was originally described in 1978 (Hutchison et al., 1978) 
(Hutchison C.A. et al., 1978) and used to introduce either site-specific point mutations or a 
pair of mutations if the sites for mutation were close enough to each other. The protocol 
was based on a manual provided with the QuickChange Site-Directed Mutagenesis Kit, 
Stratagene. The principle behind site-directed mutagenesis is the use of two 
complementary primers, each having the desired mutation, which are then used for the 
amplification of the whole plasmid DNA. Following amplification, the 
methylated/hemimethylated parental DNA template is eliminated by the endonuclease 
DpnI, which then selects for the mutation-containing DNA only. The reactions were set 
up as 50µL, and included 5-50ng template plasmid DNA, ~0.25µM of each 
complementary primers, 200µM of each dNTPs, and 1.25 units of PfuUltra DNA 
polymerase. The 50µL reaction mix was split into 10µL samples, and gradient PCR was 
























Annealing 50 - 70°C 1 min 









    
Hold 4°C   
 
Following gradient PCR, each 10µL sample was digested with 5units of DpnI 
endonuclease at 37°C for 4-5 hours, and then transformed into DH5α E.coli cells. 
 
2.1.6. Vectors and plasmids constructed in this work: 
pET11d-Ran K130,132,134R: pET11d-Ran wt was subjected to site-directed mutagenesis 
to introduce three mutations at lysines 130,132, and 134 (with oligos #1666, 1667 in 
common stocks) 
 
pEGFP-C1-Ranwt and RanK130,132,134R: Ranwt and Ran triple mutant were PCR-
amplified (#2180, 2181) introducing a 5’ SacI and 3’ EcoRI restriction sites followed by 
cloning into pEGFP-C1. 
 
pQE80-Imp13 variants: pQE80-Imp13 wt was subjected to site-directed and multi-site-
directed mutagenesis to construct three plasmids: Two plasmids had single amino acid 
exchange at positions 856 or 553, whereas the third one had both mutations (#1670, 1671 
and #1672, 1673).  
 
pGEX-6P-1-Ubc9: Mouse Ubc9 coding sequence was PCR-amplified from pET23a-mUbc9 
(Pichler et al., 2002) and cloned into BamHI and XhoI sites of pGEX-6P-1. 
 
pET23a-Impβ : Impβ was PCR-amplified (#1493,1494) from pET30a-Impβ (kindly 
provided by Prof. Ralph Kehlenbach, University of Göttingen) introducing a 5’ BamHI 










2.2. Biochemical techniques 
2.2.1. Measurement of protein concentration 
Concentrations of recombinant proteins purified were usually determined by the 
combination of two methods. As a first choice of method, the Bradford assay was utilized 
to estimate the concentrations, which was followed by the direct comparison of the 
differing amounts of recombinant protein of interest with defined amounts of BSA 
(Pierce) on the same gel stained with coomassie. The Bradford protein assay was 
developed by Marion M.Bradford (Bradford, 1976), and it is based on the fact that the 
cationic free form of the dye Coomassie brilliant Blue G-250 can bind to basic amino acids 
(arginine, lysine, and histidine) as well as amino acids with aromatic side chains under 
acidic conditions, which, in turn, stabilizes the anionic form of the dye. The protein-dye 
complex formation results in blue color, which is due to the spectral shift of the dye that 
can be easily detected at 595nm. Therefore, 10-15µL of the unknown protein solutions 
together with a series of BSA proteins with known concentrations were mixed with 750µL 
of Bradford 1x dye reagent, and absorbance values at 595nm were recorded. A standard 
curve for BSA protein was prepared, and the concentration of the unknown samples were 
estimated from the standard curve. 
 
For the quantification of total protein amounts of mammalian cell lysates, the „660nM 
Protein assay“ from Pierce was used according to the manufacturer’s instructions. This 
assay is based on the binding of the proteins to a proprietary dye-metal complex under 
acidic conditions, which results in a shift in the dye’s absorption maximum. If required, 
this assay was used in combination with the ionic detergent compatibility reagent (IDCR) 
provided by the company, which tolerates high concentrations of detergents or other 
interfering reagents. 
 
2.2.2. SDS-PAGE and protein detection methods 
SDS-PAGE 
SDS polyacrylamide gel electrophoresis was used to resolve proteins with different 
molecular weights and modified from the original description by Ulrich K. Laemmli 
(Laemmli, 1970). In most cases, continuous gradient gels (5-20%) were used, although 
depending on the exact need, 8% gels were also employed. The gels were prepared in a 
special apparatus which can accommodate eight gels simultaneously. In order to have 5-
20% gels, a double cylindrical gradient mixer was filled with equal volumes of 5% and 
20% polyacrylamide solutions in 400mM Tris-HCI pH 8.8, 0.1% (v/v) SDS. Immediately 
after the polymerization was started by adding approximately equimolar amounts of APS 
(final concentration of 2.2mM) and TEMED (final concentration of 3.3mM), the two 
 MATERIALS & METHODS    
 53 
cylindrical chambers were allowed to mix, yielding a polyacrylamide gradient of 5-20% 
from top to the bottom of the gel. An overlay of isopropanol was applied to the top, and 
only removed after the completion of polymerization. After washing off isopropanol 
thoroughly, the stacking gel (5% (w/v) polyacrylamide, 140mM Tris-HCI pH 6.8, 0.1% 
(v/v) SDS, 2.5mM APS, 3.7mM TEMED, and 0.0007% (w/v) bromophenolblue) was 
poured. The gels were allowed to polymerize for at least 1h before running. Additional 
gels were stored in wet paper at 4°C. Gels with samples were run with Laemmli buffer 




Mostly, the gels to be analyzed by coomassie staining were first fixed with a solution 
having 40% (v/v) ethanol and 10% (v/v) acetic acid for half an hour. Following the 
precipitation of proteins, the gels were rehydrated in H2O for 5-10 minutes, and finally 
stained with 0.005% (w/v) coomassie R-250 in 10% acetic acid till the protein bands were 
clearly visible. For most purposes destaining was not required. However, if required, the 
gels were briefly destained in a solution with 10% (v/v) ethanol and 2% (v/v)  phosphoric 
acid to get rid of the background staining. 
 
In cases where higher sensitivity was required (for instance, the visualization of 
sumoylated proteins), colloidal coomassie staining was of choice. For this purpose, a dye 
stock solution (0.1% (w/v) Coomassie brilliant blue G250, 2% (w/v) ortho-phosphoric 
acid, 10% (w/v) ammonium sulfate) was prepared at least 24h before staining. The gel to 
be stained was initially fixed with 40% (v/v) ethanol and 10% (v/v) acetic acid for an 
hour followed by rehydration of the gel with H2O for a total of 20 min. The gel was then 
stained overnight in a solution having 4 volumes of dye stock solution and 1 volume of 
methanol. Excess coomassie particles and background staining were subsequently 




Immunoblotting was the method of choice when a specific protein was needed to be 
detected in complex mixtures. The technique, developed in the lab of George Stark, is 
based on the transfer of separated proteins from gels to a more stable platform such as 
membranes followed by detection of the protein of interest with specific antibodies 
(Renart et al., 1979). In general, the proteins resolved by SDS-PAGE were transferred from 
gels on nitrocellulose membranes. This was carried out by first placing the gel on top of 
nitrocellulose membrane, which was then mounted between whatman papers soaked in 




western buffer. The transfer was done for 2hours with a semi-dry western blot apparatus 
applying 200 mAmp per gel. The efficiency of the transfer was subsequently evaluated by 
staining the membrane with 0.5% (w/v) Ponceau S in 1% (v/v) acetic acid for 1-2 minutes 
followed by the removal of the background staining by washing the membrane with 1% 
(v/v) acetic acid solution for a couple of times. Prior to the application of primary 
antibodies, unspecific binding sites were blocked by incubation of the membrane in 
blocking buffer (5% (w/v) skim milk prepared in PBST) for 30 minutes. Primary and 
horseradish peroxidase-coupled secondary antibodies were diluted in blocking buffer. 
Primary antibodies were applied overnight at 4°C, whereas secondary antibodies were 
applied for 45 minutes at room temperature. After the incubation of the membrane with 
primary and secondary antibodies, the membrane was washed three times with PBST for 
30min. Bound antibody was detected by chemiluminescence produced by the reaction of 
horseradish peroxidase with its enhanced luminol-based chemiluminescent substrate 
provided in ECL kits from Pierce and Millipore. Afterwards, chemiluminescence-exposed 
X-ray films were developed using an automatic developing machine. In case the same 
membrane was to be used to detect another protein of interest, the primary antibody of 
the second protein was applied in the presence of 2mM sodium azide (NaN3), which 
irreversibly blocks the horseradish peroxidase (Ortiz de Montellano et al., 1988). This, in 
turn, allows the detection of the signal only coming from the last antibody applied 
provided that the primary antibodies are from different species. 
 
2.2.3. Sample Preparation  
In most cases, protein samples were diluted 1:1 with 2x sample buffer supplemented 
freshly with 200mM DTT and boiled at 95°C for 5-10 min before loading on the gels. If the 
samples were to be to stored, they were flash-frozen in liquid nitrogen and were kept at -
80°C till use. 
 
Methanol-Chloroform Precipitation 
In certain cases, the samples had more volume than could be accommodated by the gel 
pockets. Therefore, the proteins were concentrated by methanol-chloroform precipitation 
(Wessel and Flügge, 1984). The method is based on a defined mixture of methanol-
chloroform-water, which is separated into organic and aqueous phases. Proteins having 
both hydrophilic and hydrophobic groups precipitate at the interface of the two phases, 
which is followed by the removal of the aqueous layer. In the final step, proteins are 
pelleted again. In short, 1 volume of the sample (usually ~200µL) was mixed with 3 
volumes of methanol and 1 volume of chloroform followed by vortexing. After the 
addition of 3 volumes of H2O, the samples were mixed thoroughly followed by 
 MATERIALS & METHODS    
 55 
centrifugation. The aqueous layer was then carefully removed without disturbing the 
protein layer at the interface, and subsequently 3 volumes of methanol was added. The 
proteins were pelleted at the bottom of the tube by centrifugation, dried at 37°C for a few 
minutes, and reconstituted in 2x sample buffer prior to loading on gels. 
 
Trichloroacetic acid (TCA) Precipitation 
Methanol-chloroform precipitation was of choice when the protein solution was too 
dilute. However if the solutions were more concentrated, TCA precipitation was 
employed. It is also a very effective way of precipitating proteins. Although the 
underlying principle is not fully understood, it was suggested that the method is based on 
hydrophobic aggregation (Sivaraman et al., 1997). The method was perfomed by mixing 
the protein samples with TCA solution to have a final concentration of ~14% TCA, and 
letting them stay on ice for an hour. The samples were then centrifugued for half an hour 
at 4°C at 14.000g, followed by the aspiration of the supernatant. Subsequently, the pellet 
was washed with ice-cold 100% acetone at least twice, and the proteins were collected by 
a final centrifugation for 15min at 4°C at 14.000g. In the final step, the proteins were dried 
about half an hour, and solubilized in 2x sample buffer. Residual amounts of TCA, 
indicated by the yellow color of the dye at acidic pH, was neutralized by 1M Tris-HCI, pH 
8 before loading on gels. 
 
2.2.4. Immobilization of proteins to Cyanogenbromide (CNBr)-activated sepharose beads 
Cyanogenbromide-activated sepharose beads (Sigma-Aldrich) are formed due to the 
reaction of cyanogen bromide in base with –OH groups on sepharose, which results in the 
formation of either cyanate esters or imidocarbonates. The coupling reaction is based on 
the high reactivity of such groups with primary amines, which results in covalent bond 
formation between proteins and the matrix. For coupling of the protein of interest to the 
bead material, the protein was dialyzed extensively against 0.2M Na2CO3 buffer, pH 8.9 to 
get rid of all traces of primary amines, which would otherwise be coupled to the beads. 
Cyanogenbromide-activated sepharose beads were swollen in 1mM HCI for 10 min, and 
washed with carbonate buffer once. Immediately after washing, the protein of interest 
was incubated with the activated bead material (at a ratio of ~1mg protein/mL beads) for 
1h at room temperature, followed by overnight incubation at 4°C. The beads were washed 
a couple of times with carbonate buffer, and the remaining coupling sites were blocked by 
incubation with 100mM ethanolamine for an hour. As a final step, the beads were washed 
again with carbonate buffer a couple of times, reequilibrated in PBS, and stored at 4°C. 








2.2.5. Generation of Crm1 antibodies 
Generation of antibodies was essentially performed based on an established lab protocol. 
In short, for the generation of Crm1 antibodies, the goat was immunized with pure full-
length hCrm1 protein which was C-terminally His-tagged. Total of four injections were 
performed by the personal of the animal house over a period of four months. The blood of 
the animal was tested 10 to 14 days post-injection for the presence of antibodies against 
Crm1 before the final bleed. The serum of the animal was obtained by centrifugation of 
the blood which was allowed to wait for 1h at room temperature followed by overnight 
incubation at 4°C. Subsequently, the serum was aliquoted and stored at -20°C before it 
was used for affinity purification.  
 
2.2.6. Antibody purification 
Affinity purification of antibodies was carried out to enrich the specific antibodies of 
interest from the complex milieu of serum. For this purpose, 1-2mL of affinity matrix was 
incubated with 20mL serum diluted 1:1 with PBS at 4°C overnight. The affinity matrix 
was subsequently collected in a column, and washed with 100 column volumes of PBS 
with 500mM NaCI. The antibodies were eluted with 10 column volumes of 0.2M acetic 
acid, pH 2.5. 500µL eluates were immediately neutralized by the addition of 100µL 1M 
Tris base. The eluates with the antibodies were pooled, dialyzed against PBS, and 
concentrated. The antibody concentrations were estimated by NanoDrop (OD280=1 
corresponds to ~0.8mg/mL of IgGs). For long-term storage, antibodies were diluted 1:1 
with 87% glycerol, and kept at -20°C. 
 
2.2.7. Recombinant protein expression and purification 
In general, recombinant proteins were purified after overexpression in bacteria. 
Expression plasmids for recombinant proteins were transformed into E.coli expression 
strains (BL21(DE3), BL21(DE3)pLysS, or Rosetta2). Transformed bacteria were either 
directly inoculated into pre-culture media supplemented with antibiotics or plated out on 
antibiotic-containing LB plates. For the latter, a single colony was picked the next day, 
and inoculated into the pre-culture. Pre-cultures were grown O/N at 37°C, and diluted 
1:40-1:100 the next day with fresh medium (LB or 2YT medium) supplemented with fresh 
antibiotics to maintain the desired expression plasmids. The bacteria were grown up to 
logarithmic phase (OD600~ 0.6), and the protein expression was induced with 0.1-1mM 
IPTG for differing time periods. After induction, the bacteria were harvested, and kept at -
80°C until purification. Protein purifications were carried out by utilizing different 
strategies such as ammonium sulfate precipitation, affinity tag pulldowns, gel filtration, 
and ion-exchange chromatography. If not stated otherwise, the buffers used during the 
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purification were supplemented with 1mM DTT, 0.1mM PMSF, 1µg/mL of leupeptin, 
pepstatin, and aprotinin to prevent oxidation and degradation of proteins. As a general 
final step, purified proteins were brought to the desired concentration, aliquoted, flash 
frozen in liquid nitrogen, and stored at -80°C. 
 
Untagged Ran WT and its variants 
Ran was expressed and purified essentially as described by Melchior et al. (Melchior et al., 
1993). In short, Ran in pET11d was expressed in BL21(DE3) cells by 0.6mM IPTG 
induction for 3 hours at 37°C. Cells were harvested and resuspended in 50mM Tris-
HCI/pH 8, 75mM NaCI, 1mM MgCI2, 1mM DTT, 0.1mM PMSF, 1µg/mL of leupeptin, 
pepstatin,  and aprotinin (50mL lysis buffer/2L of bacterial culture). Lysis was done by 
passing the cells through EmulsiFlex three times, and the cell lysate was cleared by 
centrifugation at 29,000rpm for 30 minutes. As the first step for purification, total cell 
lysate (~50mL) was passed over pre-equilibrated DEAE column (~20mL) (Sigma Aldrich). 
Flow through as well as 20mL of the subsequent wash was collected. Ran was 
precipitated from the solution by adding ammonium sulfate gradually up to ~53% 
saturation. The precipitate was resuspended in 4mL transport buffer (TB: 20mM HEPES 
pH 7.3, 110mM K-acetate, 2mM Mg-acetate and 1mM EDTA) supplemented with 2mM 
DTT, 1µg/mL of leupeptin, pepstatin, aprotinin, and 250µM GDP or GTP. The 
resuspended precipitate was resolved through a preparative Superdex200 (S200) column 
with a flow rate of 1mL/min, and 5mL fractions were collected. Ran containing fractions 
were pooled, concentrated to the final volume of ~5mL, and applied to MonoQ column. 
The protein was eluted with a salt gradient (up to 300mM NaCI). The elution order of 
proteins was RanGDP (~60mM NaCI) and RanGTP (~130mM NaCI). Excess salt was 
removed by another run over preparative Superdex75 column in transport buffer. 
  
Average Yield: ~3mg RanGDP or ~1mg RanGTP/L of bacterial culture 
 
His-Importin β 
Imp β was expressed and purified essentially as described by Chi et al. (Chi et al., 1996). 
Briefly, Imp β in pET23a was expressed as His-tagged recombinant protein in 
BL21(DE3)pLysS cells by 0.5mM IPTG induction for 4h at 25°C. Cells were harvested and 
resuspended in 50mM Na-PO4 buffer/pH 7.5 with 500mM NaCI, 2mM MgCI2, 1mM β-
mercaptoethanol, leupeptin, pepstatin, and aprotinin (1µg/mL of each) (70mL 
resuspension buffer/2L of bacterial culture).  Lysis was done by passing the cells through 
EmulsiFlex three times, and the cell lysate was cleared by centrifugation at 29,000rpm for 
30 minutes. The cell lysate (~70mL) was incubated with ~3mL Ni-NTA agarose beads 
(Qiagen) for an hour in the presence of 20mM imidazole to prevent unspecific binding. 




The beads were centrifuged down and washed with 100 column volumes of resuspension 
buffer supplemented with 20mM imidazole.  Elution of the His-tagged proteins was done 
with resuspension buffer with 300mM imidazole. Ni++ pulldown fractions (1mL) were 
collected, and the presence of proteins was checked with Ponceau stain. Protein 
containing fractions were pooled and resolved through a preparative S200 column in 
transport buffer. Finally, His-Importin β containing fractions were pooled and 
concentrated via 30,000da MWCO concentrators (Vivaspin) followed by flash freezing in 
liquid nitrogen.  
 
Average Yield: ~10mg Impβ/L of bacterial culture 
 
His-Impα 
His-Impα was expressed and purified essentially as described by Hu et al. (Hu et al., 
1996). Imp α in prSETb (kindly provided by Prof. Ralph Kehlenbach/University of 
Göttingen) was expressed as His-tagged recombinant protein in BL21(DE3) cells by 1mM 
IPTG induction for 5h at 25°C. Cells were harvested and resuspended in 50mM Na-PO4 
buffer/pH 7.5 with 500mM NaCI, 2mM MgCI2, 1mM β-mercaptoethanol, leupeptin, 
pepstatin, and aprotinin (1µg/mL of each) (50mL resuspension buffer/2L of bacterial 
culture). Lysis was done by passing the cells through EmulsiFlex three times, and the cell 
lysate was cleared by centrifugation at 29,000rpm for 30 minutes. Subsequently, the Ni++ 
pulldown and gel filtration were performed as described for His-Impβ (see above). In the 
final step, His-Impα was concentrated, flash frozen in liquid nitrogen, and stored at -80°C.  
 
Average Yield: ~3-4mg Impα/L of bacterial culture 
 
His-Importin 13 and its variants 
His-Imp13 was expressed and purified according to an established protocol kindly 
provided by Dr. Ralph Kehlenbach. Imp13 in pQE80 was expressed as His-tagged 
recombinant protein in JM109 cells. A single colony after transformation was picked and 
grown in 2YT medium supplemented with 2% (w/v) glucose, 30mM K2HPO4 pH 7.0, and 
ampicillin (100µg/mL) at 37°C overnight. Next day, the bacteria was pelleted and 
resuspended in fresh 2YT medium supplemented with 2% (v/v) glycerin, 30mM K2HPO4 
pH 7.0, and ampicillin (100µg/mL). The cells were grown until OD600 is ~1.0 at 37°C, 
diluted 1:1.5 with fresh 2YT medium, and further grown until OD600 is ~0.75 at 16°C. The 
expression of the recombinant protein was induced with 0.1mM IPTG for ~18 hours at 
16°C. Subsequently, cells were harvested and resuspended in 50mM Hepes buffer pH 7.5 
with 500mM NaCI, 2mM MgCI2, 1mM β-mercaptoethanol, leupeptin, pepstatin, and 
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aprotinin (1µg/mL of each) (50mL resuspension buffer/2L of bacterial culture). Lysis was 
carried out by passing the cells through EmulsiFlex three times, and the cell lysate was 
cleared by centrifugation at 29,000rpm for 1 hour. The cell lysate (~50mL) was incubated 
with 1.5mL Ni-NTA agarose beads to pulldown the His-tagged protein. The Ni++ 
pulldown and gel filtration were performed as described for His-Impβ (see above). In the 
final step, His-Imp13 was concentrated, flash frozen in liquid nitrogen, and stored at -
80°C.  
 
Average Yield: ~5-6mg Imp13/L of bacterial culture 
 
His-Transportin 
His-Transportin was expressed and purified essentially as described by Baake et al. 
(Matunis et al., 1996; Baake et al., 2001). Transportin in pQE32 was expressed as His-
tagged recombinant protein in JM109 cells. The cells were grown until OD600 is ~0.75, and 
the expression was induced by 0.5mM IPTG for 4h at 25°C. Cells were harvested and 
resuspended in 50mM Na-PO4 buffer/pH 7.5 with 500mM NaCI, 2mM MgCI2, 1mM DTT, 
leupeptin, pepstatin, and aprotinin (1µg/mL of each) (50mL resuspension buffer/2L of 
bacterial culture). Lysis was done by passing the cells through EmulsiFlex three times, 
and the cell lysate was cleared by centrifugation at 29,000rpm for 30 minutes. The cell 
lysate (~50mL) was incubated with ~1.5mL Ni-NTA agarose beads (Qiagen) for an hour 
in the presence of 20mM imidazole to prevent unspecific binding. The beads were 
centrifuged down and washed with 100 column volumes of resuspension buffer 
supplemented with 20mM imidazole.  Elution of the His-tagged proteins was done with 
resuspension buffer with 300mM imidazole. Ni++ pulldown fractions (1mL) were 
collected, and the presence of proteins was checked with Ponceau stain. Protein 
containing fractions were pooled and resolved through a preparative S200 column in 
transport buffer. Finally, His-Transportin containing fractions were pooled and 
concentrated via 30,000da MWCO concentrators (Vivaspin) followed by flash freezing in 
liquid nitrogen.  
 
Average Yield: ~5mg Transportin/L of bacterial culture 
 
His-YFP-M9 
His-YFP-M9 was expressed and purified according to an established protocol kindly 
provided by Prof. Ralph Kehlenbach. His- and YFP-tagged M9 in pET28a (kindly 
provided by Prof. Ralph Kehlenbach/Uni. of Göttingen) was expressed in BL21(DE3) cells 
by 0.5mM IPTG induction for 6h at 37°C. Cells were harvested and resuspended in 50mM 
Na-PO4 buffer/pH 7.5 with 500mM NaCI, 2mM MgCI2, 1mM DTT, leupeptin, pepstatin, 




and aprotinin (1µg/mL of each) (70mL resuspension buffer/3L of bacterial culture). Lysis 
was done by passing the cells through EmulsiFlex three times, and the cell lysate was 
cleared by centrifugation at 29,000rpm for 30 minutes.  The cell lysate (~70mL) was 
incubated with 2mL Ni-NTA agarose beads (Qiagen) for an hour in the presence of 20mM 
imidazole to prevent unspecific binding. The beads were centrifuged down and washed 
with 100 column volumes of resuspension buffer supplemented with 20mM imidazole.  
Elution of the His-tagged proteins was done with resuspension buffer with 300mM 
imidazole. Ni++ pulldown fractions (1mL) were collected, and the presence of proteins 
was checked with Ponceau stain. Protein containing fractions were pooled and resolved 
through a preparative S75 column in transport buffer. Finally, His-YFP-M9 containing 
fractions were pooled, concentrated via 10,000da MWCO concentrators (Vivaspin), flash 
frozen in liquid nitrogen, and stored at -80°C.  
 
Average Yield: ~6mg His-YFP-M9/1L of bacterial culture 
 
His-Crm1 
His-Crm1 was expressed and purified essentially as described by Guan et al. (Guan et al., 
2000). Crm1 in pQE60 was expressed as His-tagged recombinant protein from a glycerol 
stock of E.coli TG1 cells (kindly provided by Prof. Ralph Kehlenbach/Uni. of Göttingen) 
without IPTG induction. The bacteria were allowed to grow at 37°C overnight with 
constant shaking at 180rpm. Subsequently, the bacteria were harvested and resuspended 
in 50mM Hepes buffer pH 7.5 with 500mM NaCI, 2mM MgCI2, 1mM β-mercaptoethanol, 
leupeptin, pepstatin, and aprotinin (1µg/mL of each) (40mL Resuspension Buffer/1.5L of 
bacterial culture). Lysis was carried out by passing the cells through EmulsiFlex three 
times, and the cell lysate was cleared by centrifugation at 29,000rpm for 1 hour. The cell 
lysate (~40mL) was incubated with 1mL Ni-NTA agarose beads (Qiagen) to pulldown the 
His-tagged protein. The Ni++ pulldown and gel filtration were performed as described for 
His-Impβ (see above). After gel filtration, another purification step was included since the 
purity of the protein was not sufficient. Pooled fractions containing the recombinant 
protein were concentrated and applied on MonoQ anion exchange column. The bound 
proteins were eluted with a salt gradient (up to 500mM NaCI). The fractions containing 
Crm1 were pooled and reapplied to gel filtration to remove the excessive salts and to 
change the buffer to TB supplemented with 1mM DTT, leupeptin, pepstatin, and 
aprotinin (1µg/mL of each). His-Crm1 fractions were concentrated, flash frozen in liquid 
nitrogen, and stored at -80°C.  
 
Average Yield: ~1mg Crm1/1.5L of bacterial culture 




Ubc9 in pGEX-6P-1 was expressed as GST-tagged recombinant protein in BL21(DE3) cells 
by 1mM IPTG induction for 3h at 37°C. Cells were harvested and resuspended in 50mM 
Tris-HCI, pH 8.0, 100mM NaCI supplemented with 1mM DTT, leupeptin, pepstatin, and 
aprotinin (1µg/mL of each) (40mL GST buffer/2L of bacterial culture). Lysis was done by 
passing the cells through EmulsiFlex two times, and the cell lysate was cleared by 
centrifugation at 29,000rpm for 30 min. The cell lysate (~40mL) was incubated with ~4mL 
pre-equilibrated glutathione-sepharose beads (Macherey-Nagel) under constant rotation 
for an hour at 4°C. The mixture was transferred into a column, and washed with ~50 bed 
volumes of GST buffer. The bound proteins were eluted with GST buffer supplemented 
with 10mM glutathione, pH 8.0. The fractions with the recombinant protein were pooled, 
concentrated, and applied to S200preparative gel filtration column equilibrated in TB 
supplemented with 1mM DTT, leupeptin, pepstatin, and aprotinin (1µg/mL of each). As a 
final step, GST-Ubc9 was concentrated, flash frozen in liquid nitrogen, and stored at -
80°C.  
 
Average Yield: ~10mg GST-Ubc9/1L of bacterial culture 
 
GST-Rcc1 
Rcc1 in pGEX-TEV was expressed as GST-tagged recombinant protein in Rosetta2 (DE3) 
cells by 0.3mM IPTG induction for 4-5h at 25°C. Cells were harvested and resuspended in 
50mM Tris-HCI, pH 8.0, 100mM NaCI supplemented with 1mM DTT, leupeptin, 
pepstatin, and aprotinin (1µg/mL of each) (40mL GST buffer/1.5L of bacterial culture). 
Lysis was done by passing the cells through EmulsiFlex two times, and the cell lysate was 
cleared by centrifugation at 29,000rpm for 30 minutes. Subsequently, GST pulldown and 
S200 preparative gel filtration were performed as described for the purification of GST-
Ubc9 (see above). As a final step, GST-Rcc1 was concentrated, flash frozen in liquid 
nitrogen, and stored at -80°C.  
 
Untagged NTF2 
NTF2 was expressed and purified essentially as described by Ribbeck et al. (Ribbeck et al., 
1998). NTF2 in pET vector (kindly provided by Prof. Dirk Görlich/MPIbpc, Göttingen) 
was expressed in BL21(DE3) cells by 0.5mM IPTG induction for 3 hours at 37°C. Cells 
were harvested and resuspended in TB supplemented with 1mM DTT, 0.1mM PMSF, 
1µg/mL of leupeptin, pepstatin, and aprotinin (50mL TB/2L of bacterial culture). Lysis 
was done by passing the cells through EmulsiFlex three times, and the cell lysate was 
cleared by centrifugation at 29,000rpm for 1h. As the first step for purification, NTF2 was 




precipitated out of the solution by adding ammonium sulfate gradually up to ~50% 
saturation. The precipitate was resuspended in ~5mL transport buffer (TB: 20mM HEPES 
pH 7.3, 110mM K-acetate, 2mM Mg-acetate and 1mM EDTA) supplemented with 1mM 
DTT, 1µg/mL of leupeptin, pepstatin, and aprotinin. The resuspended precipitate was 
resolved through a preparative S200 column in TB, and 5mL fractions were collected. 
NTF2 containing fractions were pooled, concentrated, and flash-frozen in liquid nitrogen 
before storing at -80°C. 
 
Average Yield: ~1mg NTF2/1L of bacterial culture 
 
2.2.8. Labeling of GST-Ubc9 with Alexa Fluor 488 
For labeling of proteins with fluorescent reactive dyes, thiol-reactive probes (Invitrogen) 
were chosen. 2.5mL GST-Ubc9 (~3.3mg/mL) in TB, pH 7.3 was thawed, and fresh 1mM 
DTT was added to reduce any oxidized thiol groups. Excess DTT was subsequently 
removed by PD10 column, and 1mL freshly prepared dye solution (1mg/mL in DMSO) 
was dropwise added to 3.5mL protein solution (~1mg/mL). The mixture was stirred for 
2h at room temperature, protected from light. The molar ratio of reactive dye:protein was 
approximately 16:1. Upon completion of the reaction, 2mM DTT was added to consume 
excess thiol-reactive reagent. The unconjugated dye was removed from the protein by 
another run on a PD10 column. The protein labeled with the dye was concentrated, flash 
frozen in liquid nitrogen, and stored at -80°C. 
 
2.2.9. Pulldown assays with immobilized Rcc1 and NTF2 
For GST pulldowns, equimolar amounts of GST-Rcc1 (~12µg) and GST (~5µg) were 
bound to 20µL glutathione beads separately by mixing each protein together with the 
beads for an hour at 4°C. Afterwards, the beads were washed three times with TB and 
incubated with the recombinant protein (~6µg Ran wild type and the mutant) to be tested 
in TB on a rotating wheel for an hour at 4°C. Subsequently the beads were centrifuged, 
and the supernatant was discarded. After washing the beads three times with TB, bound 
proteins were eluted with 50µL 2x sample buffer. Subsequent analysis was performed by 
SDS-PAGE and colloidal coomassie staining. 
 
Pulldowns with NTF2 coupled to CNBr-activated sepharose beads (see above) were 
performed in the presence of 20µL beads preequilibrated in TB (1mg NTF2/1mL beads). 
The beads were incubated with ~12µg Ran wild type or mutant (final concentration of 
500nM) on a rotating wheel for an hour at 4°C. Following binding, the beads were 
centrifuged and the supernatant was discarded. After washing the beads three times with 
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TB, bound proteins were eluted with 40µL 2x sample buffer supplemented freshly with 
200mM DTT. Subsequent analysis was performed by SDS-PAGE and colloidal coomassie 
staining. 
 
2.2.10. Cultivation of hybridoma cells for SUMO1 and SUMO2/3 antibodies 
Mouse-hybridoma cells (SUMO1 21C7, SUMO2 8A2) producing SUMO1 and SUMO2/3 
antibodies were obtained from Developmental Studies Hybridoma Bank, University of 
Iowa (Matunis et al., 1996; Zhang et al., 2008b). The cultivation of the cells were 
performed routinely by another member of the lab, Dr. Janina Becker and described in 
great detail in her PhD Thesis („Endogenous sumoylation in cells and tissues“, Dr. Janina 
Becker). 
 
2.2.11. Crosslinking of SUMO antibodies to beads  
Monoclonal SUMO1 and SUMO2/3 antibodies were incubated with Protein G agarose 
(Roche) equilibrated in 20mM Na-phosphate buffer, pH 7.0 for 1h at 4°C (8mg 
antibodies/mL Protein G agarose). Afterwards the beads were collected by centrifugation 
at 700g for 5min and washed with 10 volumes of 20mM Na-phosphate buffer, pH 7.0. 
Subsequent crosslinking of antibodies to the bead material was performed in 50mM 
borate buffer, pH 9.0 supplemented with 20mM DMP (Thermo Scientific) for an hour at 
room temperature. The beads were collected and incubated with 50mM Tris-HCI pH 8.0 
for quenching. In the final step, protein G agarose coupled to antibodies were washed 
twice with 20mM Na-phosphate buffer, pH 7.0 and stored at 4°C in the same buffer 
supplemented with 5mM sodium azide. 
 
2.2.12. SUMO Immunoprecipitations (IPs) 
Prior to each IP, ~250mL HeLa suspension cells (1x106 cells/mL) were either incubated at 
37°C or heat shocked at 43°C in a water bath for half an hour. Following heat shock, the 
cells were treated immediately with 20mM freshly prepared NEM and centrifuged at 200g 
for 5min at room temperature. Cells were subsequently washed with cold PBS 
supplemented with 10mM NEM, and the pellet was flash frozen in liquid nitrogen until 
IPs were performed.   
 
Each IP was performed from 250mL cell pellet. Cells were lysed with lysis buffer (20mM 
Na2HPO4 pH 7.4, 150mM NaCI, 1% TritonX-100, 0.5% sodiumdeoxycholate, 1% SDS, 
10mM NEM, 1mM DTT, and protease inhibtiors leupeptin, pepstatin, and aprotinin 
(1µg/mL of each)). The lysate obtained was sonified briefly and diluted 1:10 with dilution 
buffer (Lysis buffer without SDS). The diluted lysate was sonified, centrifuged, and 
filtered to get rid of the undissolved cellular debris and aggregates. The cleared lysate was 




incubated with ~400µL Protein G beads crosslinked to monoclonal SUMO antibodies at 
4°C overnight on a rotating wheel. The beads were collected by centrifugation and 
washed three times with washing buffer (20mM Na2HPO4 pH 7.4, 150mM NaCI, 1% 
TritonX-100, 0.5% sodiumdeoxycholate, 0.1% SDS, 10mM NEM, 1mM DTT, and protease 
inhibitors leupeptin, pepstatin, and aprotinin (1µg/mL of each)). Following washing, the 
beads were incubated with elution buffer without epitope peptide (20mM Na2HPO4 pH 
7.4, 500mM NaCI, 1% TritonX-100, 0.5% sodiumdeoxycholate, 0.1% SDS, 10mM NEM) on 
ice for 15min. The beads settled down, and the supernatant was removed. The following 
elution step was carried out in two steps. First, the prewarmed (at 30°C) elution buffer 
with epitope peptide (0.5mg/mL final concentration) was added to the beads, which were 
then incubated at 30°C for 30min constantly shaking at 1400rpm. Afterwards, the beads 
were centrifuged and the supernatant (eluate) was kept on ice. The elution step was 
repeated once with fresh elution buffer with the epitope peptide, and the two eluates 
were pooled before proceeding with TCA precipitation of the samples, which were 
performed as described previously (Section 2.2.3.). 
 
2.2.13. Permeabilization of HeLa suspension cells with digitonin 
50mL Hela suspension cells (growing at 4-6x105 cells/mL)	  were centrifuged at 70g for 
5min and washed with TB. Subsequently, the cells were resuspended in 5mL TB 
supplemented with 0.007% digitonin and incubated on ice for 4-6 min. The degree of cell 
permeabilization was controlled by staining the cells with Trypan blue. If 
permeabilization was sufficient   (>95%), the cells were diluted 1:10 with TB and 
centrifuged again. The pellet was resuspended in TB (volume depending on following 
application). The concentration of the suspension was determined by measuring the OD550 
values and comparison to a standard curve (OD550 vs cell number determined with a 
hemocytometer).  
 
2.2.14. In vitro sumoylation assays with recombinant proteins 
In vitro sumoylation assays were set up in 20µL reaction volumes and contained purified 
recombinant proteins. In general, the reaction mixtures included 69nM E1, 83nM E2, and 
15µM SUMO1 or SUMO2 in sumoylation assay buffer (SAB) supplemented with 0.2 
mg/mL ovalbumin or BSA. The target proteins to be tested for sumoylation were used in 
the range of 200-500nM, whereas the E3 ligase (RanBP2 fragment or RanBP2 complex) 
concentrations changed between 50-150nM. The reactions were started by adding 5mM 
ATP, incubated at 30°C or 37°C for a duration of 30-60 minutes, and stopped with the 
addition of 2x SDS sample buffer. If the samples were not analyzed immediately by SDS-
PAGE and immunoblotting, they were frozen in liquid nitrogen and stored at -80°C until 
analysis. 
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2.2.15. In vitro sumoylation of Ran with semi-permeabilized cells 
Sumoylation assays employing semi-permeabilized cells were set up in 60µL reaction 
volumes and contained recombinant Ran (5µM), ATP-regenerating system (1.3mM ATP, 
3.2mM creatine phosphate, 13 U/mL creatine phosphate kinase), YFP-SUMO1 or YFP-
SUMO2 (5µM for each), and semi-permeabilized HeLa suspension cells (total of 3 x 106 
cells) in SAB supplemented with BSA. Semi-permeabilized cells were prepared as 
described in 2.2.13. Cells were brought to a concentration of 105 cells/µL, and 30µL of cells 
were pipetted to the rest of the reaction mix to start the sumoylation. Reactions were 
incubated at 30°C for 30min and stopped by adding 2x SDS sample buffer. If the samples 
were not analyzed immediately by SDS-PAGE and immunoblotting, they were frozen in 
liquid nitrogen and stored at -80°C until analysis. 
 
Where indicated, the sumoylation reaction was boosted either with the addition of 120nM 
E1 and 155nM E2 enzymes or by blocking isopeptidases. For the latter,  suspension cells 
were divided into two parts after semi-permeabilization. The first half was incubated with 
HA-SUMO2-Vinylmethylester (Schulz et al., 2012) (0.5 µg/mL final concentration was 
sufficient to block isopeptidases) for half an hour on ice, whereas the second half was left 
on ice unperturbed prior to mixing with the rest of the reaction mix. 
 
2.2.16. Mass spectrometry analysis of SUMOylation sites 
20µL in vitro sumoylation reactions of Imp13 and Ran were upscaled to 200µL and 
resolved on 5-20% gradient gels, which were then stained with colloidal coomassie. The 
regions corresponding to the sumoylated proteins were excised and sent for analysis by 
mass spectrometry (In collaboration with Prof. Henning Urlaub/ MPIbpc). In-gel 
digestion with trypsin, mass spectrometry, and data analysis were carried out by Dr. He-
Hsuan Hsiao from the group of Prof. Henning Urlaub. 
 
2.3. Cell biological techniques 
2.3.1. Cultivation and storage of mammalian cells 
Adherent HeLa cells were cultured in DMEM (Dulbecco’s modified eagle medium) 
(including D-Glucose 4.5g/L, L-glutamine ~4mM, and sodium pyruvate 110mg/L) 
supplemented with 10% (v/v) fetal bovine serum (FBS), and penicillin 
(100units/mL)/streptomycin (100µg/mL) at 37°C and 5% CO2. Before reaching 100% 
confluency, they were split at a 1:10 or 1:20 ratio. For this purpose, cells were washed once 
with sterile PBS, trypsinized, and diluted with fresh medium. HeLa suspension cells, on 
the other hand, were cultured in Jokliks medium supplemented with 5% (v/v) newborn 
calf serum (NCS), 5% FBS (v/v), 2mM glutamine, and penicillin 




(100units/mL)/streptomycin (100µg/mL). They were continuously stirred at 100rpm in 
spinner flasks at 37°C. The cells were split every day and kept at a density of 3-10 x 105 
cells/mL. For long term storage, exponentially growing cells were trypsinized, mixed 
with fresh medium, and centrifuged at 70g for 5min. The supernatant was removed, and 
the cells were resuspended in 9 volumes of FBS followed by the dropwise addition of 1 
volume of DMSO. Aliquots were frozen to -80°C at a rate of ~ 1°C/minute in an 
isopropanol jacketed freezing box, which circumvents the negative effects of rapid 
freezing. Once -80°C is reached, the vials were transferred to the liquid nitrogen tanks. 
 
2.3.2. Cell cycle arrest  
Exponentially growing HeLa suspension cells were arrested in prometaphase by addition 
of 75ng/mL nocodazole for ~20 hours. The cells were confirmed to be arrested in 
prometaphase by either analyzing the DNA content by staining the cells with propidium 
iodide followed by flow cytometric analysis or by staining the DNA with Hoechst 33258 
followed by fluorescent microscopy.  
 
2.3.3. Transient transfection of mammalian cells 
Transfection of mammalian cells with plasmids 
Transient transfections were carried out with FuGENE HD transfection reagent 
according to manufacturer’s instructions mostly in 12-well plate format. In short, HeLa 
cells were seeded the day before transfection at a density of no more than 30-40% 
confluency in an antibiotic-free medium. Reagent and DNA (1µg/well) were mixed at a 
ratio of 3:1 in reduced serum medium (Opti-MEM) and incubated at room temperature 
for 5min to allow complex formation. The complex was subsequently applied to the cells, 
and the medium was changed 4-6 hours post-transfection.  
 
Transfection of mammalian cells with siRNAs 
To downregulate the levels of Uba2 enzyme, cells were transfected with siRNA 
oligonucleotides directed against Uba2 by using Lipofectamine RNAiMAX reagent. In 
short, cells were seeded the day before the transfection at a density of no more than 15-
20% confluency in an antibiotic-free medium. The reagent and siRNAs were mixed in 
Opti-MEM to have a final concentration of 20nM or 40nM siRNAs. The mix was 
incubated at room temperature for 20min before being added to the cells. The knock-




 MATERIALS & METHODS    
 67 
2.3.4. Lysate preparation from adherent HeLa cells 
Adherent HeLa cells were washed once with sterile PBS and trypsinized. Following 
detachment of cells, they were diluted with normal growth medium and centrifuged at 
200g for 5min. After washing with PBS, cells were directly lysed in 2x sample buffer (50µL 
sample buffer/500.000 cells) and boiled for 10min at 95°C. In order to load equal amounts 
of lysates, protein concentrations were determined using the Pierce 660nm assay in the 
presence of ionic detergent compatibility reagent according to manufacturer’s 
instructions. For SDS-PAGE analysis, 20-30µg of total protein was loaded on gradient gels 
followed by immunoblotting. 
 
2.3.5. Fluorescence-based detection of intracellular proteins 
Overexpression and detection of fluorescent proteins 
N-terminally GFP tagged Ran plasmids were transfected in HeLa cells on glass coverslips 
as described above (Methods, Section 2.3.3.). 48h post-transfection cells were analyzed by 
immunoblotting and immunofluorescence. For immunoblotting, cells were directly lysed 
in 2x SDS sample buffer and boiled for 10min at 95°C. For immunofluorescence, cells were 
fixed in 3.7% (w/v) formaldehyde in PBS, and the nuclei were counterstained with 
Hoechst (final concentration of 1µg/mL). Subsequently, coverslips were mounted in Slow 
Fade gold antifade mounting reagent (Invitrogen) on glass slides. The fluorescence was 
detected with Leica SP2 confocal microscope using the HCX PL APO 63x/1.4 OIL BD UV 
objective and appropriate filter settings. The pictures were processed using Image J 
software. 
 
Indirect immunofluorescence and confocal microscopy 
For immunofluorescence, HeLa cells were seeded on sterile 12mm coverslips at no more 
than 30-40% confluency. The next day, coverslips were washed gently with PBS, and the 
cells were fixed with 3.7% (w/v) formaldehyde in PBS for 10min at room temperature. 
Following fixation, the cells were washed, permeabilized with 0.2% (v/v) TritonX-100 in 
PBS for 5 minutes on ice, and incubated with 2% (w/v) BSA in PBS for half an hour to 
block unspecific binding sites. Subsequently 50µL of primary antibody solution (diluted 
in 2% BSA in PBS) was applied on each coverslip for an hour in a humidified chamber. 
After the removal of excess unbound antibodies by dipping the coverslips several times in 
and out of PBS solution, the secondary antibody solution (diluted in 2% BSA in PBS) 
supplemented with Hoechst 33258 (final concentration of 1µg/mL) was applied on cells 
for 45 min at room temperature under dark. The cells were washed 3x with PBS and 1x 
with H2O before mounting them in 5µL Slow Fade gold antifade mounting reagent on 
glass slides. After a few minutes, the coverslips were sealed with nail polish, and kept at 
4°C for short-term storage. The fluorescence was detected on a Leica SP2 confocal 




microscope using the HCX PL APO 63x/1.4 OIL BD UV objective and appropriate filter 
settings. The pictures were processed using Image J software. 
 
2.3.6. In vitro import assays 
In vitro import assays were essentially carried out and analyzed by flow cytometry as 
described by Melchior F. (Melchior F., 1998). The reactions were set up in a volume of 
40µL, and the assays included differing concentrations of recombinant transport factors, 
fluorescently labeled cargos, and semi-permeabilized cells (originally described in Adam 
et al., 1990). In general, for Imp13-dependent import assays, 1µM Imp13 and 60nM GST-
Ubc9-Alexa488 were used whereas Ran concentrations were titrated in the range of 2-
12µM. For Impα/β-dependent import, 0.5µM Impα/β and 0.5µM FITC-BSA-NLS were 
used together with Ran (titrated in the range of 1-8µM). For the import assay, a premix of 
transport factors, cargos, and Ran was prepared in TB on ice. The mix was supplemented 
with ATP-regenerating system (1mM ATP, 2.5mM creatine phosphate, 10 U/mL creatine 
phosphate kinase). Separately, semi-permeabilized HeLa suspension cells were prepared 
as described above (see section 2.2.13.) and 3 x 105 cells/assay were pipetted onto the 
premix to start import reactions. The whole mixture in 5mL FACS tubes was incubated at 
30°C for 30min in water bath, and the import reactions were stopped by the addition of 
4mL ice-cold TB. The cells were collected at 200g for 5min followed by the aspiration of 
the supernatant except for 300µL. Subsequently, the fluorescence was detected with BD 
FACSCantoTM II with appropriate filter settings. The mean fluorescence values from a 
population of 10.000 cells were used for the data analysis. 
 RESULTS    
 69 
RESULTS 
Chapter I: RanBP2-dependent sumoylation in nuclear transport 
Considering the domain structure of RanBP2 as well as the intriguing molecular 
architecture of the RanBP2 complex, which brings the RanGTPase activity in close 
proximity to the E3 ligase region, nuclear transport receptors and the small GTPase Ran 
are the obvious candidates for RanBP2-dependent sumoylation during interphase. In line 
with this idea, several nuclear transport receptors including Crm1, Impβ, CAS, Impα, and 
Imp5 as well as Ran were identified as potential SUMO targets in mass-spectrometry 
based screens (Rosas-Acosta et al., 2005; Golebiowski et al., 2009; Kaminsky et al., 2009; 
Nie et al., 2009; Bruderer et al., 2011), yet none of them were confirmed in vitro and in 
vivo. Therefore, I aimed to test whether NTRs and/or Ran are endogenously sumoylated, 
and if the RanBP2 complex can serve as their E3 ligase. 
 
1. The nuclear transport receptors Crm1, Imp β , and Imp5 are endogenously 
sumoylated in HeLa cells 
For this purpose, I turned to denaturing SUMO IP experiments, and the protocol I used 
was optimized by another lab member Dr. Janina Becker (refer to her PhD Thesis, 
“Endogenous sumoylation in cells and tissues”). It allowed us to enrich endogenously 
sumoylated proteins with monoclonal SUMO antibodies and elute the bound proteins 
specifically with epitope peptides. In two of the above mentioned screens (Golebiowski et 
al., 2009; Bruderer et al., 2011), heat shock was utilized to induce SUMO2/3 conjugation. 
Therefore, in a similar approach, I used HeLa suspension cells which were either kept at 
37°C or heat-shocked for 30 min at 43°C. Following heat shock, cells were lysed under 
denaturing conditions with lysis buffer supplemented with 1% SDS, and subsequently the 
lysate was diluted to RIPA buffer conditons to perform the immunoprecipitations (IPs). 
SUMO IPs to enrich the sumoylated proteins from interphase cells were carried out by 
using monoclonal SUMO2/3 antibodies, and the bound proteins were specifically eluted 
with epitope peptides (Fig. 6A). To determine the efficiency of the IP protocol as well as to 
control for heat shock, eluates were first analyzed by immunoblotting with α-SUMO2/3 
antibodies. Fig. 6B clearly showed that heat shock rapidly decreased the free SUMO2/3 
levels which was accompanied by the appearance of higher molecular weight species 
(compare lanes 1 and 5), and the IP protocol was very efficient in enriching the 
sumoylated species (compare lanes 1&4 and lanes 5&8). As a positive control for the 
protocol, the eluates were also probed for two known SUMO targets; TRIM28 (Lee et al., 
2007) and PARP1 (Blomster et al., 2009; Martin et al., 2009), for which induction of 
sumoylation upon heat shock was previously described (Golebiowski et al., 2009; Martin 
et al., 2009). The control experiments could confirm the endogenous sumoylation of both 



































Fig. 6: Crm1, Imp β  and Imp5 are endogenously sumoylated with SUMO2/3. (A) General 
experimental setup for denaturing SUMO2/3 immunoprecipitation. For each IP experiment, 
250mL HeLa cells (1.0 x 106 cells/mL) were kept either at 37°C or at 43°C for 30min. Afterwards, 
the cells were harvested by centrifugating in the presence of 20nM NEM at 200g for 5min and 
washed twice with PBS having 10mM NEM. Cells were lysed under denaturing conditions 
(1%SDS), and the SUMO2/3 IP was carried out in RIPA buffer conditions (0.1% SDS). Sumoylated 
proteins were eluted with epitope peptide. (B,C and D) Eluted proteins were analyzed with SDS-
PAGE followed by western blot analysis using antibodies specific for SUMO2/3 (B), TRIM28 and 
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TRIM28 and PARP1 as well as the induction of PARP1 sumoylation upon heat shock (Fig. 
6C). Following establishment of the IP protocol as well as heat shock conditions, another 
IP experiment with SUMO2/3 antibodies was performed, and the samples were probed 
for several nuclear transport receptors. Indeed, three transport receptors, namely the main 
export receptor Crm1 and two import receptors, Imp5 and Impβ, turned out to be 
endogenously sumoylated (Fig. 6D). Surprisingly, the sumoylation pattern for Crm1 and 
Impβ  looked comparable for 37°C and 43°C samples indicating that heat shock was not 
necessary for modification. Imp5, on the other hand, appeared even less sumoylated at 
43°C (Fig. 6D). Of note, similar experiments with SUMO1 antibodies indicated that all 
three transport receptors are also sumoylated with SUMO1 although to a much less extent 
(data not shown and personal communication, Dr.Janina Becker). The sumoylation of 
several other transport receptors (Importin 13, CAS, importin α2) as well as the GTPase 
Ran could not be detected under the same experimental conditions tested (data not 
shown). 
 
2. A catalytic fragment of RanBP2 can stimulate transport receptor sumoylation in vitro 
After confirming the endogenous sumoylation of three nuclear transport receptors, the 
next question I asked was whether RanBP2 could stimulate the sumoylation of transport 
receptors as an E3 ligase. To adress this question, I turned to in vitro sumoylation assays. 
Since RanBP2 is a relatively huge protein (~358kDa) (Fig. 5), an 80kDa RanBP2 fragment 
with two Ran binding domains, E3 ligase region as well as FG and FxFG repeats was 
produced (provided by Dr. Andreas Werner) (Fig. 7A). This fragment is able to interact 
with RanGTP and transport receptors and has the E3 ligase region required for 
sumoylation activity. Therefore, it was used as the source of E3 ligase activity in in vitro 
sumoylation assays for the initial screening of nuclear transport receptors. As described in 
the introduction, all transport receptors belonging to the Imp β superfamily interact with 
RanGTP via their N-terminus (Fried and Kutay, 2003) and RanBP2 has RanGTP binding 
sites. In vitro sumoylation assays were therefore done in the presence and absence of 
RanGDP and RanGTP.  
 
Strikingly, modification of Imp13 was strongly enhanced by the presence of RanGTP but 
not RanGDP (Fig. 7B, compare lanes 2 and 3 for Imp13). Although not as striking, Imp5 
sumoylation was also stimulated by RanGTP (Fig. 7B, compare lanes 3 and 4 for Imp5). 
For Impβ, slight sumoylation was already observed in the presence of RanGDP, and 
exchanging RanGDP to RanGTP further stimulated the reaction (Fig. 7B). Although Crm 
was sumoylated without Ran, the addition of RanGTP also stimulated the modification 
(Fig. 7B, top left panel). Importantly, in vitro sumoylation pattern for Crm1 seemed to be  































Fig. 7 : In the presence of RanBP2 and RanGTP several nuclear transport receptors can be 
sumoylated in vitro. (A) The domain structure of the recombinant 80kDa His-RanBP2 fragment 
used for the in vitro experiments. The E3 ligase region is flanked N- and C-terminally by Ran 
binding domains (RanBD3 and RanBD4) and FG/FxFG repeats. The numbers indicate amino acid 
positions. (B) In vitro sumoylation assays were performed in the presence of 69nM E1, 83nM E2, 
15µM SUMO1 with or without 5mM ATP at 30°C for 30min. Where indicated,  RanBP2 was added 
as E3 ligase (55nM for Crm1 sumoylation and 148nM for other substrates). Recombinant Crm1 was 
used at ~200nM whereas other NTRs were used at ~160nM concentrations. Where indicated, 1µM 
RanGDP or RanGTP was added to the reaction. The reactions were stopped with 2X SDS sample 
buffer and separated by SDS PAGE followed by western blot analysis. Crm1, Imp13, and Imp β 
blots were probed with antibodies directed against proteins themselves whereas Imp5 and Imp9 
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very similar to the pattern observed for the endogenous sumoylation (Compare Fig 6D 
and Fig 7B). Such similarity was, however, not observed for the other transport receptors 
shown to be endogenously sumoylated. Imp9 was not sumoylated under all conditions 
tested (Fig. 7B). Overall, the results indicated that several nuclear transport receptors can 
be sumoylated in the presence of RanBP2 fragment and RanGTP. 
 
3. RanBP2 complex poorly stimulates transport receptor sumoylation in vitro  
During the course of this work, Dr. Andreas Werner (currently a post-doc in Melchior lab) 
established a protocol to reconstitute the RanBP2 complex (Werner et al., 2012). This 
allowed me to test whether the physiologically relevant E3 ligase rather than the free 
RanBP2 fragment could stimulate transport receptor sumoylation. Therefore, I carried out 
in vitro sumoylation assays with Crm1, Imp13, and Impβ in the presence of SUMO1 or 
SUMO2/3. For Imp13 and Impβ, RanGTP is required for efficient sumoylation by RanBP2 
fragment. However, sumoylation assays with RanBP2 complex includes RanGAP1, which 
hydrolyzes RanGTP rapidly and does not allow sumoylation. In order to circumvent this 
problem, I preformed complexes between Imp13 or Impβ and a non-hydrolyzable form of 
RanQ69L loaded with GTP over gel filtration and used them in in vitro sumoylation 
assays with RanBP2 complex. The results showed that Crm1 was in vitro sumoylated with 
RanBP2 complex with SUMO1 but not with SUMO2/3 (Fig. 8A). Imp13 in complex with 
RanQ69L was not sumoylated with neither SUMO1 nor SUMO2/3 (Fig. 8A). 
Overexposure of the blot indicated minor levels of sumoylation with SUMO1, however, 
the reactions were very inefficient. Impβ, on the other hand, was not sumoylated with 
RanBP2 complex neither in the presence of SUMO1 nor SUMO2/3. It was only with 
Impβ* RanQ69L complex that slight sumoylation of Impβ could be observed in the 
presence of SUMO1, but not SUMO2/3 (Fig. 8B, compare the two panels). Overall, 
although the physiologically relevant E3 ligase RanBP2 complex showed activity towards 
Impβ (only in complex with RanQ69L) and Crm1, the sumoylation reactions were rather 
inefficient and not even detectable for Imp13. 
 
4. Recombinant Ran is sumoylated with YFP-SUMO1 in semi-permeabilized cells  
Next, I turned to the GTPase Ran and wanted to test endogenous sumoylation of Ran by 
performing denaturing SUMO1 and SUMO2/3 IPs as described for the identification of 
sumoylated transport receptors (Fig. 6). Several trials to detect sumoylated Ran in non-
stressed and heat shock-treated HeLa cells or interphase and nocodazole-arrested mitotic 
cells, however, failed (data not shown). There are a number of simple explanations why it 
might be challenging to detect Ran sumoylation: As with many other proteins only a 
minor pool of Ran might be sumoylated in cells, and this pool can simply be difficult to be  





Fig. 8: In vitro sumoylation of Crm1, Imp13, and Impβ  with the RanBP2 complex. (A,B) In vitro 
sumoylation assays were performed in the presence of 69nM E1, 56nM E2, 15µM SUMO1 or 
SUMO2, 5mM ATP, and 72nM RanBP2 complex (in vitro reconstituted). Where indicated 435nM 
Crm1, 400nM Impβ or Impβ∗RanQ69L (GTP loaded) complex or 400nM Imp13*RanQ69L (GTP 
loaded) complex were added. The reactions were incubated at 30°C and stopped at indicated time 
points with 2X SDS sample buffer. The proteins were resolved on 5-20% gradient gels followed by 
immunoblot analysis with anti-Crm1, anti-Imp13, and anti-Impβ antibodies. Protein markers are 
indicated as kDa. Arrow and * indicate the sumoylated Impβ and unspecific band recognized by 
Impβ antibody, respectively. 
 
detected within the technical limits of the experiment (e.g. due to poor antibody 
sensitivity). Another explanation would be that sumoylation might require certain 
stimuli, such as a specific cell cycle stage or DNA damage, etc., which might be missing in 
the experimental set-up. In conclusion, we decided to take another approach to test the 
sumoylation of Ran, and we switched to semi-permeabilized cells. Here, cells are treated 
with low concentrations of digitonin which selectively permeabilizes the plasma 
membrane leaving nuclear envelope intact (Adam et al., 1990). This allows to specifically 
inhibit SUMO isopeptidases with the help of SUMO-Vme, which is a recombinant SUMO 
protein modified with vinylmethylester at its C-terminus (Hemelaar et al., 2004; Schulz et 
al., 2012). Due to this modification, which mimics the peptide bond, the attacking SUMO 
isopeptidases form a covalent bond with SUMO-Vme and thereby are inactivated. If 
reversible sumoylation of Ran takes place in semi-permeabilized cells that are fully 
competent to transport proteins into the nucleus, addition of the SUMO-Vme should 
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To ensure that my conditions of digitonin permeabilization retain enough SUMO E1 and 
E2 enzymes in the cells, I determined the levels of cell-associated SUMO E1 and E2 
enzymes after semi-permeabilization. For this, HeLa suspension cells were treated with 
0.007% digitonin and separated from the leaking cytosol by centrifugation (Fig. 9A). Both 
cellular and cytosolic fractions were lysed in sample buffer, resolved by SDS PAGE, and 
probed with Ran, Ubc9, Aos1, Uba2, SUMO1, and SUMO2 antibodies (Fig. 9B) The results 
showed that a large proportion of Ran was found in the cytosolic fraction as expected, 
which indicates that permeabilization of the cells worked properly (Fig. 9B). Concerning 
the SUMO enzymes, Ubc9 was found in both cellular and cytosolic fractions at significant 
levels, whereas Aos1 and Uba2 were mostly cellular. SUMO1 and SUMO2, on the other 
hand, seemed to remain in the cells although minor levels of free SUMO2 as well as 
several SUMO2-modified species were found in the cytosolic fraction (Fig. 9B, top panels). 
Taken together, the results  showed that HeLa cells permeabilized with digitonin still 
have significant amounts of E1 and E2 enzymes whereas free SUMO1 and SUMO2 levels 
could potentially be limiting. To adress the question whether this system is sufficient to 
sumoylate Ran, semi-permeabilized cells were incubated with recombinant Ran and YFP-
SUMO1 in the presence of ATP (Fig. 10A). Where indicated, cells were pretreated with 
SUMO-Vme in order to block isopeptidases. The samples were resolved by SDS PAGE 
and immunoblotted with antibodies against Ran, GFP (to detect YFP-SUMO), and SENP1. 
SENP1 was used as a positive control to test whether the SUMO-Vme was efficient to 
block isopeptidases. Active SUMO-Vme should form an adduct with SENP1, which can 
easily be visualized by immunoblotting. Analysis of these sumoylation experiments 
clearly showed that semi-permeabilized cells have sufficient sumoylation machinery to 
covalently link YFP-SUMO1 to unknown targets in the system in an ATP-dependent 
manner (Fig. 10B, left panel, lanes 1&2). Pre-treatment of cells with SUMO-Vme blocked 
the isopeptidases as can be clearly seen by the shift of SENP1 (Fig. 10B, right panel), and 
this was accompanied by a clear increase in the overall sumoylation levels (Fig. 10B, 
compare lane 3 and 4). Addition of 120nM E1 and 155nM E2 together or separately 
slightly boosted the sumoylation reaction. When the same samples were probed with Ran 
antibody, Ran sumoylation was clearly observed even under core reaction conditions 
(Cells + Ran, YFP-SUMO1, ATP) (Fig. 10C, lane 3). However, it was a very small 
proportion of the Ran population. Blocking isopeptidases with SUMO-Vme or adding E1 
and E2 enzymes clearly increased the sumoylation of Ran (Fig. 10C, compare lane 3 with 
lanes 4, 5, and 6). In summary, these  results not only demonstrated that recombinant Ran 
is sumoylated in semi-permeabilized cells in the presence of YFP-SUMO1 but also 
showed that endogenous isopeptidases contribute to the low steady state levels of Ran 
sumoylation.  
 





Fig. 9: Digitonin permeabilization of HeLa cells leads to rapid leakage of Ubc9 and Ran, 
whereas Aos1/Uba2 heterodimer mainly remains in the cells. (A) Experimental setup for  the 
permeabilization of HeLa cells. HeLa suspension cells were briefly centrifuged and washed with 
transport buffer followed by 0.007% digitonin treatment on ice for 5min. After permeabilization, 
cellular and cytosolic fractions were separated by centrifugation and lysed with 2X SDS sample 
buffer. (B) Lysed cells prior to permeabilization were separated by SDS PAGE together with 
permeabilized cells and the leaked cytosol. Approximately 200.000 intact and permeabilized cells 
were loaded whereas cytosol corresponded to ~100.000 cells. Following SDS PAGE, the samples 
were analyzed by western blot with αSUMO1, αSUMO2, αRan, αUbc9, αUba2, and αAos1 
antibodies as indicated. 
 
5. Analysis of Ran Sumoylation in vitro  
5.1. Ran sumoylation is inefficient with SUMO E1 and E2 For some SUMO targets such 
as RanGAP1, catalytic amounts of E1 and E2 are sufficient for efficient sumoylation 
whereas for most targets low amounts of E1 and E2 are not enough, and E3 ligase activity 
is required. In some cases, very high amounts of E1/E2 can compensate for the lack of E3. 










































































Fig 10: Ran is sumoylated with YFP-SUMO1 in semi-permeabilized cells supplemented with 
ATP. (A) General experimental setup for in vitro sumoylation with semi-permeabilized cells. Cells 
were treated with 0.007% digitonin on ice for 5min, and incubated with 5µM Ran and 35µM YFP-
SUMO1 at 30°C for 30min in the presence of an ATP-regenerating system (final concentrations 




























































































(B,C) In vitro sumoylation assays with semi-permeabilized cells were done as described in A, and 
modifications to the core reaction were shown above the gels. Where indicated, cells were 
preincubated with SUMO-Vme (Trap) for 30min on ice prior to the sumoylation assay in order to 
block isopeptidase activity. For lanes 5, 6, 7, and 8, the sumoylation reaction was stimulated with 
the addition of 120nM E1 and/or 155nM E2. The reactions were stopped by 2X SDS sample buffer, 
and the proteins were resolved by SDS PAGE. Western blot analysis was done with αGFP (for 
YFP-SUMO1), αRan, and αSENP1 antibodies.  
 
or not, in vitro sumoylation assays with recombinant Ran in the presence of E1 and E2 
were performed. The reactions were pushed with 400nM E1 and 500nM E2 at 37°C  for a 
time course of maximum 2 hours. The results showed that Ran can be sumoylated in the 
presence of high E1 and E2 concentrations, with both SUMO1 and SUMO2 (Fig. 11A and 
11B). However, this reaction is very inefficient, and a small fraction of sumoylated Ran 
could be observed only after 1h at 37°C. Of note, sumoylation assays with SUMO1 and 
YFP-SUMO1 seemed more efficient compared to SUMO2 and YFP-SUMO2, respectively 
(Fig. 11A and 11B), which might be a hint for paralog specificity. 
 
5.2. The RanBP2/ Ubc9/ RanGAP1-SUMO1 complex stimulates Ran sumoylation 
whereas PIAS proteins do not 
The low efficiency of in vitro sumoylation of Ran with E1 and E2 suggests that Ran 
sumoylation is E3 ligase-dependent. In order to test this idea, RanGDP and RanGTP were 
purified and incubated with different E3 ligases (RanBP2 fragment or PIAS E3 ligases) in 
an in vitro sumoylation assay. The results were striking. Ran was efficiently sumoylated 
with SUMO1 and SUMO2/3 in either conformation by RanBP2 fragment (Fig. 12A and 
12B). RanGDP sumoylation resulted in one distinct band, whereas RanGTP was heavily 
sumoylated resulting in a smear in addition to the monosumoylated Ran (Fig. 12). PIAS 
E3 ligases, on the other hand, did not stimulate RanGDP sumoylation in the presence of 
SUMO1 or SUMO2/3 although all of them except for PIASxβ stimulated p53 sumoylation 
(Fig. 13, lower panel). In the same reactions, RanBP2 fragment was sufficient to sumoylate 
Ran. For RanGTP, preliminary experiments suggested that it is not sumoylated by PIAS 
proteins neither with SUMO1 nor with SUMO2/3 although the experiments need to be 
repeated (data not shown). Overall, the results suggested that RanBP2 is likely to be the 
relevant E3 ligase. Therefore, I repeated the sumoylation reaction in the presence of the 
RanBP2 complex. Indeed, Ran could again be sumoylated. RanGDP and RanGTP 
sumoylation had identical patterns over 30min reaction time (Fig. 14, upper panel). This 
was surprising considering that Ran-binding domains of RanBP2 recognize RanGTP with 
a much higher affinity. One explanation for this observation was that all RanGTP was 
quickly hydrolyzed to RanGDP by RanGAP1 present in RanBP2 complex. In order to  
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Fig. 11: High concentrations of E1 and E2 are required for sumoylation of Ran in vitro (A,B) In 
vitro sumoylation assays were performed with 2µM Ran, 400nM E1, 500nM E2, and 5mM ATP at 
37°C. Where indicated 3µM SUMO1, SUMO2, YFP-SUMO1, or YFP-SUMO2 were added. The 
reactions were stopped at indicated time points with 2X sample buffer. The samples were resolved 















Fig. 12: RanBP2 fragment stimulates sumoylation of Ran in GDP- and GTP-bound 
conformations. In vitro sumoylation of Ran was performed with 400nM RanGDP or RanGTP, 
68nM E1, 56nM E2, 72nM RanBP2 fragment, 15µM SUMO1 or SUMO2/3, and 5mM ATP at 30°C. 
Reactions were stopped with 2X SDS sample buffer at indicated time points for SUMO1, and after 
one hour for SUMO2/3. The samples were resolved by SDS PAGE followed by immunoblotting 













































circumvent this problem, the RanBP2 complex was reconstituted using a truncated 
version of RanGAP1 (lacking the N-terminal catalytic domain), which can no longer 
catalyze the hydrolysis of RanGTP to RanGDP (provided by Dr. Andreas Werner). When 
in vitro sumoylation of RanGDP and RanGTP was performed with this RanBP2 complex 
variant, RanGTP sumoylation was more efficient compared to RanGDP sumoylation (Fig. 
14, lower panel). Interestingly, the sumoylation pattern was quite different compared to 
Ran sumoylation with the RanBP2 fragment: Rather than the high molecular weight 
smear, only one distinct band corresponding to the monosumoylated Ran was visible 
indicating different behaviour of the RanBP2 fragment and the RanBP2 complex. The 



















Fig. 13: Ran is not sumoylated by PIAS E3 ligases. In vitro sumoylation assays were performed in 
the presence of 400 nM RanGDP or 460nM GST-p53, 68nM E1, 56nM E2, 15µM SUMO1 or SUMO2, 
5mM ATP, and 72nM RanBP2 fragment or ~50nM PIAS proteins (GST-PIAS1, GST-PIASxα, PIAS-
xβ, PIAS3 and GST-PIASy). The reactions were incubated at 30°C for an hour and stopped with 2X 
SDS sample buffer. The proteins were resolved on 5-20% gradient gels followed by immunoblot 
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Fig. 14: In vitro reconstituted RanBP2 complex stimulates Ran sumoylation with a preference for 
RanGTP. In vitro sumoylation of Ran was performed at 30°C with 400nM RanGDP or RanGTP, 
68nM E1, 56nM E2, 15µM SUMO1, 5mM ATP, and 72nM of either RanBP2 complex (upper panel) 
or a variant containing a RanGAP1 that lacks the N-terminal catalytic domain (lower panel). The 
reactions were stopped at indicated time points with 2X SDS sample buffer. The samples were 
resolved by SDS PAGE followed by immunoblotting with Ran antibodies. Protein markers are 
indicated as kDa. 
 
5.3. Transport receptors prevent poly- or multi-mono-sumoylation of Ran but still 
allow mono- sumoylation 
During interphase, Ran shuttles continuously between nucleus and cytoplasm and 
interacts with RanBP2 complex largely in association with nuclear transport receptors 
(NTRs). There are 21 NTRs belonging to Impβ-superfamily members (Görlich and Kutay, 
1999) in humans, and all of them interact with RanGTP in order to release or recognize 
their respective cargos in the nucleoplasm. Therefore, at any given time, a significant 
portion of Ran is bound to transport receptors. In fact, it has been estimated that there is 
only a three fold excess of Gsp1 (Ran homologue in S.cerevisiae) over all Impβ family 
members in the nucleus (Hahn and Schlenstedt, 2011). Since a significant portion of Ran is 
in complex with NTRs, which then encounter RanBP2 complex, I wanted to test whether 
transport receptors have an influence on Ran sumoylation. For this, different 
concentrations of the main import and export receptor, Impβ and Crm1, respectively were 
added to in vitro sumoylation reactions of RanGTP with RanBP2 fragment. The 
concentrations of transport receptors varied from ~100nM to ~800nM whereas Ran 
concentrations were kept constant at ~200nM. The results clearly showed that in the 
presence of both transport receptors higher molecular weight species, which are either 




























Fig. 15: Ran can be sumoylated in the presence of nuclear transport receptors. (A,B) In vitro 
sumoylation reactions were performed at 30°C for 30min in the presence of 68nM E1, 56nM E2, 
15µM SUMO1, 148nM RanBP2 fragment, and 5mM ATP (except for the first lane, top panel). The 
reactions were stopped with 2X SDS sample buffer. The samples were resolved by SDS PAGE 
followed by immunoblotting with Ran antibodies. For (A), 210nM RanGTP was used. Where 
indicated, Crm1 or Impβ was titrated into the reaction at 836-418-209-104nM concentrations. For 
(B), either 205nM RanGTP*Imp13 complex (purified over gel filtration, right panel) or 205nM Ran 
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Ran was detected even with the highest concentrations of transport receptors (Fig. 15A). 
Importantly, the results are consistent with the crystal structures of Impβ*RanGTP (Vetter 
et al., 1999) or Crm1*RanGTP*Snurportin (Monecke et al., 2009) complexes in that some of 
the surface area of RanGTP is no longer accessible when it is in complex with either of the 
transport receptors. After testing one prototype for import and export receptors, I also 
wanted to test the effect of Imp13 since it is a unique, bidirectional transport receptor 
which can work both as an importin and exportin. Therefore, I compared sumoylation of 
RanGTP when Imp13 was added separately or allowed to form a proper complex run 
over gel filtration (Fig. 15B). Surprisingly, Imp13 did not have a dramatic effect on Ran 
sumoylation by RanBP2 fragment. Monosumoylated Ran as well as the higher molecular 
weight smear were visible (Fig. 15B). Interestingly Ran in Imp13*RanGTP preformed 
complex was sumoylated more efficiently compared to when Imp13 was added 
separately to the reaction. The depletion of unmodified Ran was discernible when Ran 
was in complex with Imp13 (Fig. 15B, lane 1), which was not the case when the 
components were pipetted separately. Imp13 seems to have a slight stimulatory effect on 
the reaction.  One explanation for the slight differences observed concerning Ran 
sumoylation in the presence of different transport receptors might be the different 
affinities between Ran and transport receptors. To give an example, the Kd value 
determined for Impβ and RanGTP is ~140pM with a very low dissociation rate (Villa 
Braslavsky et al., 2000), whereas it is likely to be much higher for Crm1 and Imp13, since 
export factors’ interactions with RanGTP is not very stable, and cargo associations 
increase the affinity. 
 
6. Identification of Ran sumoylation sites 
Next, I wanted to determine the target lysines for sumoylation in Ran. For this purpose, 
the in vitro sumoylation of RanGTP in the presence of RanBP2 fragment was upscaled, 
and the proteins were methanol-chloroform precipitated. Precipitated samples were 
separated on SDS PAGE followed by colloidal coomassie staining to visualize nanogram 
quantities of proteins. With this method, it was possible to visualize the sumoylated Ran 
in the presence of RanBP2 and SUMO1 (Fig. 16, Lanes 1 and 2). The regions shown with 
red boxes in Fig. 16 were cut and subjected to mass spectromety (In collaboration with 
Prof. Henning Urlaub, MPIbpc, Götingen), which in turn identified three consecutive 





















Fig. 16: Mass spectrometry analysis of Ran sumoylation identified three lysines: K130, K132, and 
K134. In vitro sumoylation reactions of 1µM RanGTP in the presence of 69nM E1, 83nM E2, 148nM 
RanBP2 fragment (except for last lane), 15µM SUMO1 (Lanes 1&2), and 5mM ATP were performed 
in 200µL reaction volumes. The whole reaction was precipitated by methanol-chloroform, and 
proteins were seperated by SDS PAGE. Subsequent staining with colloidal coomassie visualized 
distinct bands. Indicated areas with red boxes were cut, and sent for mass spectrometry. Protein 
markers are indicated as kDa. Of note, RanBP2 fragment undergoes massive autosumoylation. 
Therefore, it is not visible in the presence of ATP and SUMO1. 
 
In order to test whether these lysines are the main acceptor sites, all three lysine residues 
were mutated to arginine in a site-directed mutagenesis reaction followed by the 
purification of the mutant protein. The Ran K130,132,134R variant (Ran triple mutant) 
behaved exactly like the wild type in terms of elution volume from gel filtration and ion 
exchange columns during purification, which indicated that the mutant was folded 
properly. To confirm the sumoylation sites, I applied the Ran triple mutant (Ran tm) to 
sumoylation assays with semi-permeabilized cells. The core reaction and the 
modifications were carried out as described for Fig. 10. As already seen earlier, Ran wild 
type was sumoylated in the presence of semi-permeabilized cells, YFP-SUMO1, and ATP, 
and the sumoylation was stimulated in the presence of SUMO-Vme and/or E1 and E2 
(Fig. 17, lanes 1-4). Of note, E1 and E2 enzymes were not sufficient to sumoylate 
recombinant Ran in the absence of cells (Fig. 17, lane 5). Sumoylation of Ran triple mutant, 
on the other hand, was not detected at all with the core reaction components alone (Fig. 
17, lane 6). Upon stimulation of sumoylation by either blocking isopeptidases or by 
adding E1 and E2 enzymes, minor amounts of sumoylated Ran triple mutant could be 
observed, but much less compared to wild type (Fig. 17, compare lanes 3 and 8). As the 




































Fig. 17: Ran K130,132,134R sumoylation is strongly reduced compared to Ran wild type in semi-
permeabilized cells. Cells were semi-permeabilized with 0.007% digitonin on ice for 5min, and 
incubated with 5µM Ran (wild type or K130,132,134R mutant) and 35µM YFP-SUMO1 at 30°C for 
30min in the presence of ATP regenerating system (final concentrations 1.3mM ATP, 3.7mM 
creatine phosphate, and 13U/mL creatine phosphate kinase) (Core reaction) for sumoylation 
assays. Modifications to the core rx were shown above the gels. Where indicated, cells were 
preincubated with SUMO-Vme (Trap) for 30min on ice before sumoylation in order to block 
isopeptidase activity. For lanes 3-5 and 8-10, the sumoylation reaction was stimulated with the 
addition of 120nM E1 and 155nM E2. The reactions were stopped by 2X SDS sample buffer, and the 
proteins were resolved by SDS PAGE. Western blot analysis was done with αRan and αSENP1 
antibodies. Protein marker is shown in kDa. 
 
important to note that there is still residual endogenous Ran present in the system even 
though digitonin permeabilization causes a rapid loss of Ran from cells (Fig. 9B).  
 
Next, I wanted to test whether Ran triple mutant can be in vitro sumoylated with RanBP2 
or not. For this purpose, Ran variants were preloaded with GTP or GMP-PNP, a GTP 
analog which locks Ran in GTP bound conformation since it can not be hydrolyzed by 
RanGAP1 in the RanBP2 complex. Both RanGTP and RanGMP-PNP were then subjected 
to in vitro sumoylation assays with RanBP2 fragment and the RanBP2 complex, 
respectively. The sumoylation assays over a period of 30 min indicated that Ran triple 
mutant in GTP-bound conformation was sumoylated with equal efficiency compared to 
Ran wild type by both RanBP2 fragment and the RanBP2 complex (Fig. 18). Overall, the 

































































relevant sumoylation sites for Ran. However, whether RanBP2 complex is the relevant E3 




Fig. 18: Ran K130,132,134R and Ran wild type in GTP-bound conformation are equally well 
sumoylated by RanBP2 fragment and the RanBP2 complex. In vitro sumoylation of 200nM Ran 
wild type or 500nM Ran triple mutant (TM) was performed at 30°C in the presence of 69nM E1, 
56nM E2, 15µM SUMO1, 5mM ATP, and 148nM RanBP2 fragment or the RanBP2 complex. Ran 
variants were preloaded with GTP and GMP-PNP (a non-hydrolyzable analog of GTP) for in vitro 
sumoylation assays with RanBP2 fragment and the RanBP2 complex, respectively. The reactions 
were stopped at indicated time points with 2X SDS sample buffer. The proteins were resolved on 5-
20% gradient gels followed by immunoblot analysis with anti-Ran antibodies. Protein markers are 
indicated as kDa. 
 
7. Functional Analysis of Ran sumoylation 
Showing that Ran is sumoylated via K130, 132, and 134, we next wanted to investigate the 
functional outcomes of the sumoylation of Ran with a main focus on nucleocytoplasmic 
transport. 
 
7.1.Does sumoylation of Ran affect its nuclear localization? 
Considering Ran function in nucleocytoplasmic transport, an obvious question was 
whether sumoylation alters its intranuclear localization. To test whether sumoylation of 
Ran contributes to its correct nuclear localization, two different approaches were taken: In 
the first approach, Ran wild type and Ran triple mutant were cloned with an N-terminal 
GFP fusion in an eukaryotic expression vector. GFP-Ran fusion proteins were expressed 
for 48hours in HeLa cells seeded on cover slips followed by formaldehyde fixation. The 
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microscopy. As shown in Fig. 19A, both variants were observed to localize mainly to the 
nucleus. To ensure that both variants were expressed as full-length proteins, a fraction of 
the cells were lysed with 2X SDS sample buffer followed by immunoblotting with anti-
Ran antibodies. Importantly, both Ran wild type and the triple mutant were expressed at 
full length with comparable expression levels (Fig. 19B). These observations allowed to 
conclude that sumoylation is not essential for intranuclear localization of Ran. 
 
 
Fig. 19: GFP-Ran K130,132,134R localizes to nucleus as Ran wild type. (A) HeLa cells seeded on 
coverslips were transiently transfected with pEGFP-Ran wild type (WT) and pEGFP-
RanK130,132,134R (Triple mutant-TM). 48h post transfection, cells were fixed, and the nuclei were 
counterstained with Hoechst. The images were taken by confocal microscopy. Scale bar, 10µM. (B) 
48h post transfection, cells were lysed with 2X SDS sample buffer. The samples were resolved on 
SDS PAGE, and the expression of full length Ran wild type and the mutant was verified by 
immunoblotting using anti-Ran antibodies. Protein markers are indicated as kDa. 
 
In an alternative approach, the catalytic subunit of the E1 heterodimer, Uba2, was 
knocked down in HeLa cells, and the localization of endogenous Ran was analyzed by 
indirect immunofluorescence by using monoclonal Ran antibodies. HeLa cells were 
transfected with either non-targeting control siRNAs or siRNAs against Uba2 for 48 and 
72 hours at two different concentrations (20nM and 40nM). Post 48h and 72h 
transfections, the cells were lysed with 2X SDS sample buffer, and the efficiency of the 
knockdown was evaluated by immunoblotting with anti-Uba2, anti-α-tubulin, and anti-
SUMO1 antibodies. The results clearly showed that Uba2 knockdown was very efficient 
after 72hours, and the loss of Uba2 was accompanied by an overall decrease in 
sumoylation and a slight increase in free SUMO1 levels (Fig. 20A, top and bottom panels). 
Quantification of the Uba2 knockdown demonstrated that almost 90% knockdown 
























































Fig. 20: Endogenous Ran localization does not change upon knockdown of Uba2. (A) HeLa cells 
were either transfected with control siRNA (+: 20nM) or siRNA directed against Uba2 (+: 20nM 
and ++: 40nM) for 48h and 72h. The efficiency of the knockdown was monitored by 
immunoblotting using anti-Uba2, anti-α-tubulin, and anti-SUMO1 antibodies for indicated time 
points (left panel). Quantification and normalization of Uba2 levels with respect to α-tubulin is 
shown in the right panel. Y-axis represents the ratio of Uba2/α-tubulin, which is set to 100 for 
control samples (B) 72h post transfection, the localization of endogenous Ran and the knockdown 
were monitored by indirect immunofluorescence using anti-Ran and anti-Uba2 antibodies. The 
nuclei were counterstained with Hoechst, and the images were taken by confocal microscopy. Scale 
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more than 95% knockdown efficiency (Fig. 20A, right panel). Subsequently, the 
localization of endogenous Ran was determined by indirect immunofluorescence, and no 
difference could be observed between control and siRNA samples (Fig. 20B). Ran seemed 
to be mostly nuclear with a slight cytoplasmic signal in each case. This result strongly 
suggested that Ran localization to the nucleus is not linked to the sumoylation status of 
the protein. 
 
7.2. Does sumoylation of Ran play a role in regulation of nucleocytoplasmic transport? 
Since the primary function of the small GTPase Ran during interphase is to regulate the 
directionality of nucleocytoplasmic transport, I wanted to investigate Ran sumoylation in 
the context of transport. Ran can interact with all members of the Impβ superfamily, albeit 
with differing affinities, and it regulates their cargo release or association. Therefore, it 
could be envisioned that any transport event that is dependent on Ran could in principle 
be regulated by sumoylation of this small GTPase. In order to test the effects of Ran 
variants on transport, I turned to in vitro import assays with semi-permeabilized HeLa 
suspension cells (Melchior et al., 1995). A brief summary of the experimental setup is 
shown in Fig. 21. In this system, semi-permeabilization of cells leads to the leakage of 
cytosolic nuclear transport receptors as well as Ran. Therefore, the cells can no longer 
support import or export unless they are provided with exogenous transport receptors 
and Ran as well as an ATP-regenerating system. Ran is an indispensible component of the 
system and required for transport cycles. Therefore, I aimed to compare the effects of Ran 
wild type and the sumoylation-deficient mutant on transport cycles without saturating 
the system. Among different transport pathways, I decided to start with the canonical 
Impα/β-dependent import. 
7.2.1. Ran triple mutant can bind to its interactors NTF2 and RCC1 with comparable 
affinities to Ran wt 
Although in vitro import assays provide an easy way of testing import or export, the 
system is still complicated in that for one round of recycling of import receptors, series of 
biochemical reactions have to take place as described in detail in introduction. In such a 
complicated series of protein-protein interactions, any kinetic advantage that 
RanK130,132,134R gained for one of its interactors could lead to an increased import rate. 
In order to test whether the Ran mutant has altered affinity towards any of its interactors 
and to make sure that Ran variants behave similarly except for their sumoylation 
potential in import assays, I started to characterize the interaction between Ran variants 
and their known interactors before in vitro import assays. Although the list is not 
complete, the interactions of Ran wild type or mutant with NTF2 and RCC1 could be  






Fig. 21: In vitro transport assay 
experimental setup. HeLa cells were semi-
permeabilized with 0.007% digitonin for 
5min on ice. Semi-permeabilized cells were 
incubated with selected import receptor, 
recombinant Ran, and fluorescently labeled 
cargo in the presence of ATP-regenerating 
system at 30°C for 30min. The reactions 
were stopped with excess transport buffer, 
and the cells were spun down at 200g for 
5min. The supernatant was removed except 
for ~300µL buffer. The fluorescence was 
measured by flow cytometry and where 
indicated by microscopy. 
 
tested by pulldown assays, and other Ran effectors still require further investigation. The 
results of the pulldown experiments with immobilized NTF2 and GST-RCC1 indicated 
that Ran wt and the triple mutant bind to either NTF2 or GST-RCC1 comparably under 
the experimental conditions tested (Fig. 22A & 22B).  
7.2.2. RanK130,132,134R behaves as RanWT in Impα/β-dependent import  
Next, I wanted to adress the question whether Ran variants have any effect on Impα/β-
dependent import. For this purpose, I performed in vitro import assays in the presence of 
0.5µM Impα/β and 0.5µM transport cargo (FITC-BSA-NLS). The recycling of Imp β was 
stimulated with the addition of differing concentrations of Ran wt or Ran triple mutant 
(1µM-6µM). The reactions were allowed for a period of 30 min, stopped by the addition of 
excess buffer, and analyzed by flow cytometry for cell-associated fluorescence. The 
experiments showed that the stimulatory effects of Ran variants for Imp α/β-dependent 
import turned out to be very comparable (Fig. 23) at non-saturating Ran concentrations. 
The results also indicated that Ran mutant is fully functional and the mutations did not 





































Fig. 22: Comparable interaction of Ran wild type and sumoylation-deficient mutant with NTF2 
and RCC1. (A) NTF2 was coupled to CNBr-activated sepharose beads (20µL), which were 
equilibrated in transport buffer and incubated with ~12µg Ran wt or RanK130,132,134R at 4°C for 
1h. The beads were washed three times followed by elution with 2X SDS sample buffer. Samples 
were boiled at 95°C for 5min and resolved by SDS PAGE. The gel was stained with colloidal 
coomassie. For negative control, empty sepharose beads were used. Of note, NTF2 forms a dimer 
and therefore is detected in the eluate fraction. (B) GST-Pulldown assays. GST-RCC1 and GST 
(negative control) were immobilized to glutathione-sepharose beads prior to pulldowns. GST-
RCC1 and GST (170nM each) were incubated with either Ran wt or RanK130,132,134R (260nM, 
each) at 4°C for 1h. The beads were washed three times followed by elution with 2X SDS sample 
buffer. Samples were boiled at 95°C for 5min and resolved by SDS PAGE. The gel was stained with 









































































































Fig. 23: The RanK130,132,134R behaves like Ran wild type in Imp α/β-dependent import. 
Imp13-dependent import assays were carried out in duplicates with 1µM Imp13, 60nM GST-Ubc9-
Alexa488, and increasing concentrations of either RanWT or RanK130,132,134R (4µM-8µM) as 
indicated. Imp α/β-dependent import assays were perfomed with 0.5µM Impα and Impβ, 0.5µM 
FITC-BSA-NLS, and increasing concentrations of either RanWT or RanK130,132,134R (1µM-6µM) 
as indicated. For each type of tranport assays, Ran was omitted from the first sample as a control 
for background levels of import. Transport reactions were incubated at 30°C for 30min, and were 
stopped by the addition of excess transport buffer. The fluorescence was quantified by flow 
cytometry and represented as the mean value calculated from 10,000 cells. The two concentration 
values where the effect was observed were highlighted with dark blue. 
 
7.2.3. RanK130,132,134R is more efficient than wild type in in vitro import reactions 
involving GST-Ubc9-Alexa488 and Imp13  
Next, I turned to Imp13-dependent transport pathway due to mainly two reasons: First of 
all, Imp13-dependent import is intriguing since it is the import receptor for Ubc9 (Mingot 
et al., 2001) and therefore is required itself for nuclear sumoylation. Secondly, it is a 
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additional regulation. In order to compare the effects of Ran variants on Imp13-dependent 
import, we decided to use Ubc9 as a model substrate in in vitro transport assays. 
However, Ubc9 is a small protein which also leaks into the nucleus by diffusion. In order 
to circumvent this problem, previous studies used GST-tagged Ubc9 labeled with the 
fluorophore Alexa488 as a cargo in their in vitro transport assays, and it was efficiently 
imported by Imp13 (Mingot et al., 2001). Therefore, Ubc9 was cloned as a GST-fusion 
protein followed by purification. It was subsequently labeled with Alexa488 to have a 
read out for flow cytometry or microscopy. First, control experiments were performed to 
optimize the cargo/transport receptor ratio for maximal dependence on Ran, and it 
turned out that in the presence of 60nM cargo and 1µM Imp13, import was stimulated 
maximally when 10µM Ran wild type was used (data not shown). GST-Ubc9 was 
completely inactive in sumoylation assays (data not shown), and in order to prevent a 
dominant-negative effect of GST-Ubc9, the concentration was kept slightly lower than 
typical cargo concentrations in in vitro import assays. Next, the import assays were 
performed at constant cargo/Imp13 and increasing Ran concentrations (in a range where 
it is rate-limiting). Since the import levels are highly dependent on the amounts of Ran 
present in the system, recombinant Ran variants added to the cells were controlled 
tightly. This was done by directly comparing the concentrations of Ran preparations (Fig. 
24B, left panel) as well as the total amounts of Ran in the actual experiment (Fig 24B, right 
panel). Of note, recombinant Imp13 amounts added were very comparable as well 
between the two samples tested (Fig 24B, right panel). Intriguingly, the results of the 
experiment showed that Ran mutant seemed more efficient to stimulate import than wild 
type Ran (Fig. 24A, dark blue columns).  
7.2.4. The Ran triple mutant seems independent of NTF2 in Imp13-dependent import 
To understand if Ran import itself is the reason for the different effects observed, I 
decided to add NTF2, the import receptor of Ran, to the in vitro import assays. NTF2 
should accelerate the nuclear accumulation of Ran, which in turn increases the rates of 
recycling of import receptors leading to an increase in overall import levels. Therefore, it 
was interesting to see whether NTF2 would increase the import levels for both Ran wild 
type and the mutant. To answer this question, I performed in vitro import assays with 
Imp13, GST-Ubc9-Alexa, 12µM Ran variants in the presence and absence of 1.2µM NTF2 
over a period of 30min. At different time points (10, 20, 30min) the reactions were stopped 
and analyzed by flow cytometry. Interestingly, the results showed that NTF2 stimulated 
Imp13-dependent import in the presence of 12µM Ran wt but not in the presence of Ran 
triple mutant (Fig. 25). It seemed that the kinetic advantage that was observed with Ran 
mutant could be leveled out for Ran wt by adding NTF2. It is surprising to observe that t 
 












Fig. 24: The RanK130,132,134R is more efficient than wild type to stimulate Imp13-dependent 
import. In vitro import assays were carried out in duplicates with 1µM Imp13, 60nM GST-Ubc9-
Alexa488, and differing concentrations of either RanWT or RanK130,132,134R (2µM-10µM) as 
indicated. Ran was omitted from the first sample as a control for background import. Transport 
reactions were incubated at 30°C for 30min, and were stopped by addition of 4mL transport buffer. 
The fluorescence was quantified by flow cytometry and represented as the mean value calculated 
from 10,000 cells. The two concentrations where the effect was the most prominent are highlighted 
with dark blue, and one of them is indicated by arrows. (B) Recombinant Ran wt and 
RanK130,132,134R protein stocks were titrated (1ng-8ng), and the signal intensities were compared 
after immunoblotting with anti-Ran antibodies (left panel). Transport mixes with 6µM Ran wt or 
Ran K130,132,134R were analyzed by immunoblotting with anti-Imp13 and anti-Ran antibodies to 
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he import levels stimulated by Ran mutant were not further stimulated when NTF2 was 
present. The residues mutated (K130, 132, and 134) were not reported to be critical for 
RanGDP interaction with NTF2 as deduced from the crystal structure of the Ran*NTF2 
complex (Stewart et al., 1998), which makes it unlikely that the interaction of Ran with 
NTF2 is changed due to the mutations. Therefore, the lack of stimulation of the import for 
Ran mutant must be due to another rate limiting event. 
 
 
Fig. 25: NTF2 stimulates the in vitro import of GST-Ubc9-Alexa488 in the presence of RanWT 
but not RanK130,132,134R. Imp13-dependent import assays were carried out in duplicates with 
1µM Imp13, 60nM GST-Ubc9-Alexa488, 12µM either RanWT or RanK130,132,134R. Where 
indicated, 1.2µM NTF2 was added to the reaction mix. Ran was omitted from the first sample as a 
control for background levels of import. Transport reactions were incubated at 30°C, and were 
stopped at indicated time points by addition of excess transport buffer. The fluorescence was 















Chapter II: The mechanisms of intranuclear localization of SUMO E1 activating 
enzyme, Aos1/Uba2 heterodimer 
A former PhD student in our lab, Marie Christine Moutty, investigated the mechanisms 
that cause the intranuclear localization of SUMO E1 activating enzyme, Aos1/Uba2 
heterodimer. She discovered that both subunits of this enzyme have nuclear localization 
signals (NLSs), interact with Impα/β, and can be separately imported into the nucleus by 
the Impα/β heterodimer. By microinjecting the pre-assembled E1 complexes from the 
individual subunits (wild type or NLS-mutant) into HeLa cells, she also demonstrated 
that Impα/β can import the assembled E1 complex as well and recognizes the NLS of 
Uba2 in the context of the holo-enzyme. 
 
Although the basic mechanism underlying the transport of the E1 heterodimer was 
resolved by Marie, several questions remained unanswered that needed to be addressed 
for revision of her manuscript. The first question was related to the role of transportin and 
Imp13 in Aos1 import since she observed that they interact with the immobilized Aos1 in 
a RanGTP-sensitive manner. The second question was whether recombinant Impα/β 
heterodimer recognizes the NLS of Uba2 in the context of the recombinant preassembled 
holo-enzyme. In an attempt to answer these two questions, I was able to show that Imp13 
and transportin do not support the nuclear import of Aos1 alone. I was also able to show 
that recombinant Impα/β heterodimer interacts with the Aos1/Uba2 complex, and this 
interaction is mainly via the NLS of Uba2 rather than the NLS of Aos1 by gel filtration 
experiments. Together with my contribution, this study led to the publication 
“Impα/β mediates nuclear import of individual SUMO E1 subunits and of the holo-
enzyme” (Moutty M.C., Sakin V., Melchior F., 2011 MBoC). A short summary of the 
biochemical analysis performed by me will be given in the following sections. 
 
1. Generation of tools for in vitro import assays 
In order to carry out import assays with Impα/β, Imp13, and transportin, the nuclear 
transport receptors and their respective model cargos were purified. For Imp13-
dependent import assays, an expression plasmid for GST-Ubc9 was newly constructed 
followed by purification of the protein and labeling with Alexa488. For other import 
assays, Impα/β, Imp13, transportin, and YFP-M9 were purified and used in the following 
assays. 
 
2. Neither transportin nor Importin 13 support the import of Aos1 
In vitro transport assays clearly showed that neither transportin nor Imp13 was able to 
import CFP-Aos1 into the nucleus (Fig. 26 & Fig. 27A). However, it is known from the 
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literature that some transport receptors synergize to carry out the import of specific 
cargos. One example is the import of histone H1, which is carried out by the heterodimer 
of Imp β and Importin 7 (Jäkel et al., 1999). In line with this idea, I also tested whether 
Imp13 can synergize with Imp α/β for the import of CFP-Aos1. The results showed that 
Imp13 did not stimulate the import of CFP-Aos1 under rate-limiting concentrations of 




Fig. 26: Transportin does not mediate import of CFP-Aos1 in vitro. In 
vitro import of CFP-Aos1 (1µM) in semi-permeabilized HeLa cells was 
tested in the presence of Transportin (1µM) and 12 µM Ran with or 
without ATP. The transportin dependent cargo YFP-M9 (1µM) (Siomi 
and Dreyfuss, 1995; Nakielny et al., 1996) was included as a positive 
control. Nuclear accumulation of fluorescently labeled cargo proteins 
was analyzed by confocal microscopy. Bar, 10 µm. 
 
 
3. Importin α/β  binds to the Uba2 NLS of the SUMO E1 holo-enzyme 
After showing that both subunits of the E1 heterodimer can separately be imported by the 
Impα/β heterodimer, Marie wanted to know whether the assembled dimeric E1 complex 
can be imported by Importin α/β as well. Microinjection of pre-assembled E1 complexes 
from the individual subunits (wild type or NLS-mutant) into HeLa cells demonstrated 
that Impα/β recognizes the NLS of Uba2 in the context of the holo-enzyme (Moutty et al., 
2011). This finding suggested that in the assembled E1 heterodimer, the NLS of Aos1 is no 
longer accessible for complex formation with Imp α/β. In order to test this idea, I 
preformed E1 complexes with different variants of Aos1 and Uba2 (wt and NLS-mutants) 
and incubated them with 2-fold molar excess of Imp α/β. The formation of tetrameric 
complexes was then analyzed by analytical gel filtration. The results showed that when 
the NLS of Uba2 was intact, the tetrameric complex between E1 heterodimer and Imp α/β 
could form (Fig. 28B, compare panel 3 and 5). However, when the Uba2 NLS was 
mutated, complexes were no longer stable, although some residual interactions were still 
observed (Fig. 28B, compare panel 4 and 6). This is likely due to the high protein 
concentrations used in the experimental set-up. Overall, the results clearly demonstrated 
that in the stable E1 heterodimer, the Uba2 NLS is important and should be intact for the 
dimer to be recognized by Imp α/β. When the NLS is mutated, the interaction is mostly  
 


















Fig. 27: Importin 13 does not support the import of CFP-Aos1 in vitro. (A) CFP-Aos1 (5 µM) 
import was tested in semi-permeabilized HeLa cells in the presence of importin 13 (1 µM) and Ran 
(12 µM) with or without ATP. Alexa488 labeled GST-Ubc9 (Mingot et al., 2001) served as a positive 
control. Nuclear accumulation of CFP-Aos1 and GST-Ubc9-Alexa488 was analyzed by fluorescence 
microscopy. Bar, 10 µm. (B) Importin 13 does not synergize with importin α/β for the import of 
CFP-Aos1. In vitro import of CFP-Aos1 (1µM) using semipermeabilized HeLa cells was performed 
with the indicated concentrations of Importin α  and importin β in the presence of Ran (12µM), 
with or without addition of 2 µM importin13. Nuclear accumulation of CFP-Aos1 was analysed by 























Fig. 28: Importin α/β  binds to the Uba2 NLS of the SUMO E1 holo-enzyme. 
Wild-type and mutant CFP-Aos1/Uba2-YFP complexes (5 µM) were incubated with a twofold 
molar excess of importins α and β (10 µM each), and subjected to gel filtration. Aos1 mut, Aos1-
KR195,196A2; Uba2 mut, Uba2-KR623,624A2. (A) Elution profies from the Superose 6-HR10/30 
column were recorded by the Äkta purifier system (GE Healthcare), and processed with sigma plot 
8.02 (SystatSoftware). (B) Fractions were analyzed by SDS–PAGE and Coomassie staining.





The aim of this thesis was to test whether nuclear transport receptors and Ran are subject 
to sumoylation, to test whether RanBP2 is the responsible E3 ligase, and to further 
investigate the mechanisms as well as the functional consequences of this modification. In 
this work, I could confirm the endogenous sumoylation of several nuclear transport 
receptors and provide evidence that Ran can be sumoylated in the context of semi-
permeabilized cells. I went on to map the SUMO acceptor sites, and discovered that 
mutation of these sites results in stimulation of a specific transport pathway, which is 
Imp13-dependent. Intriguingly, the sumoylation deficient mutant loses dependency on 
the transport factor NTF2, suggesting that it may enrich in the nucleus by other means. 
 
In addition to the main course of my PhD work, I could also show that the import of the 
SUMO E1 enzyme subunit, Aos1, is not supported by transportin or Imp13, and could 
demostrate that Imp α/β interacts mainly via the NLS of Uba2 in the context of the E1 
heterodimer. These findings complemented the work by Dr. Marie Christine Moutty and 
were included in the publication “Imp α/β mediates nuclear import of individual SUMO 
E1 subunits and of the holo-enzyme” (Moutty M.C., Sakin V., Melchior F., 2011 MBoC).  
 
The findings presented in this work open up interesting aspects concerning the regulation 
of nucleocytoplasmic transport, some of which will be discussed in detail in the following 
sections. 
 
1. Heat shock and transport receptor sumoylation  
As mentioned earlier, heat shock increases globally the sumoylation of proteins especially 
with SUMO2/3 (Saitoh and Hinchey, 2000). A couple of proteomic screens utilized this 
fact to identify sumoylated proteins that are heat shock-dependent. In two of these 
screens, several nuclear transport receptors (Impβ, Imp5, Crm1, Impα, Imp4, CAS, and 
Imp7) were identified as putative SUMO substrates (Golebiowski et al., 2009; Bruderer et 
al., 2011). Here, endogenous sumoylation could be confirmed for three nuclear transport 
receptors: Impβ, Imp5, and Crm1. Impα, CAS, and Imp7 could not be confirmed whereas 
Imp4 could not be tested due to lack of good antibodies. There might be several 
explanations for this: First, these proteins may not be sumoylated in vivo. In this work, 
cells were lysed under denaturing conditions in the presence of 1% SDS, and the SUMO 
IPs were performed under RIPA buffer conditions. However, it was still possible to 
observe the unmodified nuclear transport receptors in the eluates although they were 
much less compared to the input samples (see Fig. 6D). Since the IP or the pulldown 
conditions in the above-mentioned studies were not more stringent than the conditions 
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used in this work, unmodified transport receptors could have been sticking to the bead 
materials as is the case in my own work. Another explanation might be that although it 
takes 1-2 hours for the cells to recover completely after heat shock as judged by the the 
general sumoylation pattern for SUMO2/3 (Golebiowski et al., 2009), the recovery period 
might differ among different proteins. It might be that for certain nuclear transport 
receptors the sumoylation period is very brief, and therefore the protein is rapidly 
desumoylated as soon as heat shock stress is removed, which makes sumoylated 
receptors difficult to capture. Last but not least, the antibodies used for Impα, CAS, and 
Imp7 might be not sensitive enough to detect the sumoylated transport receptors. 
Although I could confirm the sumoylation of Impβ, Imp5, and Crm1, none of the 
receptors seemed to be dependent on heat shock to be sumoylated. On the contrary, all 
three receptors were found to be better mono- or multi-sumoylated at 37°C. One 
explanation for the lack of signal for the sumoylated transport receptors might be 
SUMO2/3 chain formation on receptors, which may lead to high molecular weight 
species get stuck in the stacking gels. Since the stacking gels were not probed with the 
antibodies in this work, the signal was simply not detected.  
 
Although it is well-documented in the field that heat shock increases SUMO2/3 
conjugation globally, functional consequences of this modification remained elusive. One 
possible outcome of heat shock-dependent polysumoylation might be the degradation of 
proteins that are denatured due to heat shock. In this likely scenario, the dimeric RING 
ubiquitin E3 ligase RNF4, which recognizes polysumoylated targets and ubiquitinates 
them for proteasomal degradation (Tatham et al., 2008; Plechanovova et al., 2011), might 
play a role for the ubiquitination of proteins to be degraded. In order to adress the role of 
heat shock-dependent sumoylation, more careful analysis is needed. SUMO IPs from cells 
either treated with proteasome inhibitors such as MG132 or knocked down for RNF4 
might be useful to adress the question of whether several proteins are also ubiquitinated 
following heat shock. Simultaneous ubiquitination and sumoylation of transport receptors 
would result in very high molecular weight species, which should be taken into 
consideration during analysis. 
 
2. Functional consequences of nuclear transport receptor sumoylation 
In this work, three important transport receptors, Impβ, Imp5, and Crm1, are confirmed 
to be endogenously sumoylated in HeLa cells. However, the functional consequences of 
this modifications currently remain a mystery. Interestingly, towards the end of this work 
the first example of nuclear transport receptor regulation by sumoylation was shown in 
yeast (Rothenbusch et al., 2012). Rothenbusch and her colleagues discovered that Kap114p 
(Imp9 homolog in yeast), is sumoylated in Mms21-dependent manner in the nucleus. This 




modification synergizes with RanGTP to dislocate the cargo from Kap114p  (Pemberton et 
al., 1999; Greiner et al., 2004; Caesar et al., 2006) (see also the model in Fig. 29B). Another 
mechanism of regulation of cargo release was shown previously for TATA-binding 
protein (TBP), which is taken to the nucleus by Kap114p-mediated import. In this case, 
TATA-containing DNA, which is the target binding partner of TBP protein, stimulated the 
Gsp1-mediated dissociation of TBP from Kap114p (Pemberton et al., 1999). Such examples 
clearly showed that for some transport pathways, additional factors such as intranuclear 
interaction partners, or PTMs are required for efficient cargo release from import 
receptors. Rothenbusch and her colleagues also suggested that such a regulatory 
mechanism would serve to function as an intranuclear targeting of the cargos carried by 
Kap114p if sumoylation occurs at a distinct site in the nucleus where the cargo protein is 
spatially required. In this likely scenario, transport receptor Kap114p would function as a 
nuclear chaperone, which prevents the immediate unselective dissociation of the cargo 
protein upon nuclear entry. In fact, the idea that nuclear transport receptors might 
function as chaperones was previously suggested especially for the cargo proteins having 
exposed basic domains such as histone or ribosomal proteins which tend to aggregate or 
stick to other anionic proteins when not escorted by chaperones (Jäkel et al., 2002). In 
analogy to Kap114p regulation by sumoylation, it is intriguing to speculate that Impβ and 
Imp5 that were shown to be sumoylated in this work, are regulated in a similar manner. 
Interestingly, the two import receptors as well as Imp9 (Kap114p homolog in mammals) 
function in the nuclear import of core histones during the S-phase of the cell cycle, when 
the cell produces and imports vast amounts of histone proteins for the replicating DNA 
(Mühlhäusser et al., 2001). Therefore, it is very tempting to speculate that sumoylation of 
nuclear import receptors might be a general mechanism that is required for the controlled 
release of cargo proteins, which otherwise tend to interact with the proteins of the nuclear 
compartment in an unspecific manner, or with each other leading to aggregation. If this is 
the case, it is  likely that Impβ and Imp 5 are sumoylated during S-phase, when their 
import activity is required most. Given that very low steady state sumoylation can be 
observed for Impβ and Imp5, it would be interesting to test whether sumoylation of 
transport receptors is stimulated during S-phase. This idea can be tested by synchronizing 
HeLa cells e.g., by double thymidine block and 2 hour release in S-phase followed by 
SUMO IPs. If sumoylation is S-phase dependent, the sumoylated import receptors should 
be readily captured. Overall, it seems to be a likely mechanism to sumoylate certain 
import receptors to have a controlled release of some cargos depending on the needs of 























Fig. 29: Possible molecular consequences of sumoylation of nuclear transport receptors and the 
small GTPase Ran. (A) Sumoylation of transport receptors or Ran might be a mechanism to 
promote the assembly of import or export complexes by selecting certain cargos with SUMO-
interaction motifs (SIMs) for transport. (B) Sumoylation of import receptors in concert with 
RanGTP might be a mechanism to distrupt the import complexes. The first example for such 
mechanism was documented by Rothenbusch and her colleagues (Rothenbusch U. et al., 2012).  
 
Another possible function for import receptor sumoylation would be to promote the 
assembly of certain cargos with SUMO interactions motifs (SIMs) into import complexes 
(see Fig. 29A). In this scenario, the cargo NLS-import receptor interaction is not sufficient 
to form stable import complex, and sumoylation of the import receptor increases the 
stability by introducing another interaction surface via SUMO-SIM interactions. This 
mechanism would provide a reversible way of controlling the import of SIM-bearing 
cargos if the import is required only under certain circumstances. 
 
Crm1, on the other hand, is an export receptor, and the proposed model for the regulation 
of Impβ and Imp5 by sumoylation would not directly apply for it since RanGTP 
stimulates the interaction of Crm1 with its NES substrates. However, mechanistically, it 
would be possible to imagine that the dissociation of certain Crm1 substrates in the 
cytoplasmic compartment is regulated by Crm1 sumoylation. In order for such a scenario 
to happen, RanGTP hydrolysis by itself should not suffice for the trimeric export complex 

































RanGTP. However, most NES-cargos have relatively weak affinities towards Crm1, and in 
the absence of RanGTP they do not bind stably. So far, only two cargos with an unusual 
strong affinity towards Crm1 were identified: Snurportin and Nmd3. Both proteins bind 
to Crm1 with affinities that are 100-fold higher than the typical cargo such as the Rev 
protein (Paraskeva et al., 1999; Thomas and Kutay, 2003). However, they can still be 
dissociated from Crm1 by RanGTP hydrolysis. A cargo with even stronger affinity 
towards Crm1 was described in an artificial NES peptide. This peptide was named 
„supraphysiological NES“ since it did not require RanGTP for Crm1 association 
(Engelsma et al., 2004). However, this peptide accumulated at nuclear envelopes in vivo, 
arguing that such a strong interaction between NES cargoes and Crm1 would be 
physiologically irrelevant. Interestingly, the first example of a protein that has a very 
strong affinity towards Crm1 was recently identified in parvovirus minute virus of mice 
(MVM) (Engelsma et al., 2008), which proved the existence of supraphysiological NESs in 
nature. In line with this finding, it is possible to imagine that sumoylation of Crm1 by the 
RanBP2 complex at NPCs might act in concert with RanGTP hydrolysis to stimulate the 
dissociation of certain cargo proteins having a higher affinity for the receptor. Moreover, 
there is an usually strong affinity between Crm1 and RanBP2, and the two proteins co-IP 
from mitotic HeLa cell extracts (personal communication, Dr. Annette Flotho). However, 
whether RanBP2 complex is the relevant E3 ligase for Crm1 and whether the strong 
interaction between these two proteins contribute to the sumoylation of Crm1 by the 
RanBP2 complex requires further investigations. 
 
Crm1 is responsible for the export of a great variety of proteins and ribonucleoprotein 
particles (Hutten and Kehlenbach, 2007). Considering the relatively simple nature of the 
NESs that can be recognized by Crm1, it is difficult to explain the wide plethora of cargos 
that Crm1 can interact with. It has been shown that modifications of several cargo 
proteins regulate the Crm1-dependent export events. For example, phosphorylation of 
cyclin D1 stimulates Crm1-dependent export, whereas phosphorylaton of c-Fos inhibits 
the export of this transcription factor (Benzeno et al., 2006; Sasaki et al., 2006). Besides the 
regulation at cargo level, there are also examples for the regulation at the transport 
receptor level. For example, Impα is known to be phosphorylated and acetylated, which 
might regulate the interactions with its respective cargos (Azuma et al., 1997; Zou et al., 
2008). In a similar manner, sumoylation of Crm1 might be yet another regulation that is 
important for cargo selection. One intriguing idea is that cargo proteins with SUMO 
interaction motifs (SIMs), which are short stretches of hydrophobic amino acids, might be 
selected specifically by sumoylation of Crm1 (see the Fig. 29A, middle panel). This way, 
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upon specific stimuli, the export of certain cargoes can be selected for Crm1-dependent 
export via the sumoylation of Crm1 itself. 
 
3. Mechanistic aspects of Ran sumoylation 
3.1. Where does Ran sumoylation occur? Is it dependent on the RanBP2 complex? 
In this work, we showed that Ran is sumoylated in semi-permeabilized cells on one or 
several of the three lysine residues that could be mapped. However, where modification 
happens and the physiologically relevant E3 ligase still remain unknown. Recombinant 
Ran in semi-permeabilized cells can diffuse or be actively imported into the nucleus by 
residual NTF2, which makes both the cytoplasm and the nucleus likely locations where 
sumoylation might occur. Moreover, E3 ligases are known in both compartments. Given 
the fact that stimulation of the active import of Ran by adding NTF2 in semi-
permeabilized cells did not result in any increased levels of Ran sumoylation (data not 
shown), both locations remain equally likely. Ran is either sumoylated in the cytoplasm or 
it goes through the nuclear pores and get sumoylated in the nucleus, more likely in GTP-
bound conformation. In vitro sumoylation reactions with semi-permeabilized cells in the 
presence of fusion proteins of Ran, which can no longer passively diffuse through the 
nuclear pores in combination with wheat germ agglutinin (WGA) treatment of cells to 
block the active import, would be helpful to adress this question. 
 
Current evidence obtained in this work strongly suggests that sumoylation of Ran in 
semi-permeabilized cells is an E3-ligase dependent reaction due to the inefficient 
sumoylation of Ran with E1 and E2 only. There are mainly two possible candidates for 
SUMO E3 ligase activity: RanBP2 complex and PIAS E3 ligases. The RanBP2 complex as 
well as an isolated fragment of it stimulated the in vitro sumoylation of Ran very 
efficiently. Since RanBP2 protein is cytoplasmic, there are two possible scenarios how Ran 
can interact with it: Either on its way to the nucleus when it is in complex with NTF2 or 
on its way to cytoplasm in complex with different transport receptors. Neither complex 
formation with NTF2 (data not shown) nor with transport receptors prevent the 
sumoylation of Ran, which makes both scenarios equally likely. PIAS proteins, on the 
other hand, are mostly nuclear (Liu et al., 2001; Sachdev et al., 2001; Kotaja et al., 2002; 
Miyauchi et al., 2002), and several of them tested did not stimulate the sumoylation of 
Ran in vitro. Taken together, although we can not formally exclude the PIAS proteins, the 
RanBP2 complex seems to be the most likely E3 ligase for the sumoylation of Ran. For the 
clarification of this issue, it would be helpful to identify the localization of Ran 
sumoylation in semi-permeabilized cells which would provide indirect evidence 
concerning the relevant E3 ligase. Ultimate proof would require in vitro sumoylation 
assays with semi-permeabilized cells knocked down for RanBP2. 




3.2. Sumoylation sites in Ran: K130,132, and 134 
For the identification of sumoylation sites in Ran, the in vitro sumoylation of RanGTP 
with RanBP2 fragment was carried out at large scale and subjected to mass spectrometry, 
which revealed three critical lysine residues as SUMO target sites. Mutation of all three 
sites resulted in clear reduction in sumoylation of Ran in semi-permeabilized cells. 
However, it is currently not clear whether all three lysines contribute equally to the 
sumoylation of Ran since single mutants were not tested in this system. In vitro 
sumoylation of Ran triple mutant in GTP-bound conformation with RanBP2 fragment and 
the RanBP2 complex, on the other hand, did not abolish or diminish sumoylation (Fig. 18). 
This observation can be explained by the presence of many surrounding lysines in Ran 
and the strong interaction between RanGTP and Ran-binding domains of RanBP2 
fragment. In cells, the residence time of RanGTP on RanBP2 complex is limited by 
RanGAP1, which hydrolyzes RanGTP. Our in vitro sumoylation system with recombinant 
proteins, however, lacked RanGAP1. This, in turn, increases the residence time of Ran on 
RanBP2 dramatically, and under such circumstances it seems that RanBP2 starts 
unspecifically sumoylating surrounding lysine residues available.  
 
Recently, another member of our lab Tobias Winter in collaboration with Dr. Thomas 
Ruppert could repeat the identification of sumoylation sites in Ran by mass spectrometry 
following in vitro sumoylation of RanQ69L by the physiologically relevant RanBP2 
complex. Interestingly, the analysis revealed two lysine residues this time: K134 and 
K159. K134 had a higher peptide score in the mass spectrometric analysis compared to 
K159 and was also found in the previous analysis. Therefore, it is very likely that the 
major sumoylation site in Ran is K134. In light of the current findings, it would be now 
interesting to test the single and double mutants for K134/K159 in semi-permeabilized 
cells for sumoylation. 
 
4. Functional Aspects of Ran sumoylation 
4.1. Ran sumoylation in mammals 
In this work, we showed that the sumoylation-deficient Ran triple mutant stimulated 
Imp13-dependent import more efficiently compared to wild type, and the effect was not 
observed with Imp α/β-dependent import. Currently, it is unclear why the Ran triple 
mutant is more efficient to stimulate Imp13-dependent import. Is it the lack of 
sumoylation of Ran, or is it the K-to-R mutations per se which can change the interactions 
of Ran or other PTMs that might be involved? There are several  effectors of Ran, which 
are critical for the nucleocytoplasmic transport cycle. Although not fully covered, 
pulldown assays suggested that there is no change in the interaction of Ran and NTF2 or 
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RCC1 due to three mutations introduced (Fig. 21). Concerning other interactors of Ran, 
even though the experimental data is currently missing, a rational guess can be made 
from all the crystal structures available such as Ran in complex with Ran-binding 
proteins, nuclear transport receptors, or nucleoporins. None of the three lysines identified 
belong to the switch I, switch II, or the C-terminal acidic tail region or were reported to 
play a significant role in the interaction of Ran with NTF2, Imp13 or RanBD (Stewart et 
al., 1998; Seewald et al., 2002; Grünwald and Bono, 2010). On the other hand, RCC1 and 
RanGAP1 seem to interact with one of the three lysines identified by mass spectrometry: 
the Ran-RCC1 interaction is mediated via several aminoacid contacts (24 aa.), among 
which is K134 of Ran (Renault et al., 2001). This residue may contribute to the interaction 
by salt bridges, which should not be abolished with the arginine mutations if the atomic 
distances are comparable. Interestingly, one of the lysine residues identified, K130, seems 
to be clashing with RCC1 in the complex. Upon RCC1 binding, due to this steric clash, the 
residues between 129-142 are repositioned resulting in the release of the acidic tail of Ran 
from the G domain (Renault et al., 2001). The very same residue, on the other hand, was 
reported to be involved in ionic interactions with Asp225 of RanGAP1, which was shown 
to contribute to the overall reactivity of RanGAP1 (Seewald et al., 2002). Overall, although 
it seems unlikely that the affinities between Ran and its effectors including RCC1 and 
RanGAP1 are affected dramatically by three arginine mutations considering the 
experiments with Impα/β and the structural information available, it would still be very 
useful to determine the Kd values of the interaction of the Ran mutant with RCC1 and 
RanGAP1. Moreover, determination of the rate of nucleotide-exchange by RCC1 and GTP 
hydrolysis by RanGAP1 in the presence of Ran mutant would be extremely helpful to 
understand the contribution of the three lysines to Ran biology. Although the structural 
data suggested that the three lysines do not play a major role in Ran-Imp13 interaction, it 
is still worthwhile to determine the affinities between Ran variants and Imp13 
quantitatively, since this is the major difference between two transport pathways tested. 
 
In order to test whether it is the lack of sumoylation that results in the stimulation of 
Imp13-dependent pathway, I tried to manipulate in vitro import assays by adding the 
components of sumoylation machinery or by blocking isopeptidases. However, import 
levels were not affected by such modifications to the system (data not shown), which 
argues against the role of sumoylation in this particular pathway. If sumoylation plays a 
role, it must slow down the recycling of Imp13 by any means. Although we have no 
evidence, one explanation might be related to the unique feature of Imp13. As mentioned 
previously, it works as a bidirectional transport receptor. While it imports Ubc9, as an 
export receptor, it carries the translation initiation factor, eIF1A, to the cytoplasm (Mingot 
et al., 2001). Currently it is not known whether Imp13 exits the nucleus as a dimeric 




complex with RanGTP or as a trimeric complex with eIF1A in addition. Of note, it would 
be extremely useful to determine the association/dissociation constants for the interaction 
of RanGTP with Imp13 in the presence and absence of an export cargo, eIF1A, to adress 
the question. Although unlikely, if trimeric complex formation is an absolute requirement 
for Imp13 to leave the nucleus, sumoylation of Ran might interfere with it whereas 
sumoylation-deficient Ran would stimulate it. Since for nuclear export, formation of the 
export compex is the rate limiting step (Kehlenbach et al., 2001), sumoylation of Ran 
would decelerate the recycling of Imp13. This scenario might be a way of keeping Imp13 
nuclear and blocking its export pathway by Ran sumoylation. Overall, how and why 
should Ran sumoylation slow down or block Imp13-dependent export remains as a 
challenge to explain.  
 
Another interesting observation in this work was that Ran triple mutant was not 
responsive to the presence of NTF2 in terms of stimulating the Imp13-dependent import 
whereas Ran wild type-dependent stimulation was increased in the presence of NTF2 
(Fig. 25). One possible explanation could be that nuclear accumulation of Ran triple 
mutant by simple or facilitated diffusion is faster or more effective than the Ran wild type. 
The Ran triple mutant would thus reach nuclear concentrations required to stimulate the 
Imp13-dependent in the absence of NTF2. Why Ran mutant may diffuse more effectively 
than the wild type remains elusive. One reason might be that the mutant is more effective 
due to the lack of PTMs such as sumoylation or acetylation via one of the three lysines 
mutated if these PTMs play a role in slowing down the diffusion of Ran wild type. It is 
possible that post-translationally modified Ran has different affinities towards its 
interactors, which might slow down its diffusion. Although theoretically it is possible, it is 
not known whether the semi-permeabilized cell system supplemented only with ATP is 
able to provide acetylation or sumoylation. Another possibility is that due to the three 
mutations introduced to Ran, the mutant might be kept in nucleus more efficiently. This 
can be achieved by increased interactions between Ran mutant and Imp13 or Rcc1 or any 
other Ran interactors in the nucleus, which in turn help Ran mutant accumulate in the 
nucleus faster. In order to shed some light to this issue, Ran import by NTF2 should be 
analyzed by in vitro import assays with fluorescently-labeled Ran to see if NTF2 can 
import both proteins comparably. The effect of NTF2 also needs to be tested in another 
import pathway such as Imp α/β- or transportin-dependent import to see if the effect is 
similar. As mentioned previously, quantitative data concerning the interaction between 
Ran and certain transport receptors including Imp13 and Impβ would also be  very 
helpful to figure out the underlying mechanism for the differential effects of Ran wild 




Another intriguing idea concerning the function of Ran sumoylation would be that 
sumoylation of Ran might be used as a mechanism to promote the export complex 
assembly in a model similar to transport receptors sumoylation (see Fig. 29A) . In this 
model (Fig. 29A, right scheme), the interaction between export receptor and cargo is too 
low to stimulate stable export complex formation, and Ran sumoylation is used to select 
cargos with SIMs, which in turn contributes to the stability via SUMO-SIM interactions. 
As suggested for transport receptor sumoylation, this mechanism would provide a 
reversible way of controlling the export of SIM-bearing cargos if the export is required 
only under certain circumstances. 
 
Although not investigated during the course of this work, Ran sumoylation might be 
involved in regulating mitosis-specific interactions since RanGTP is a key player of 
mitotic spindle formation as well as nuclear envelope reassembly (Kalab and Heald, 
2008). Spindle formation is regulated in a mechanistically similar way to 
nucleocytoplasmic transport. RanGTP releases microtubule regulators such as TPX2 and 
NuMA from the inhibitory effect of Impβ by interacting with the transport receptor in the 
vicinity of chromosomes, thereby leading to the formation of microtubules in a spatially-
regulated manner (Kalab and Heald, 2008). Ran sumoylation can be envisioned to play a 
role for certain cargo release or assembly processes, which might be otherwise inefficient. 
Although the molecular mechanisms how Ran is involved in nuclear envelope reassembly 
is not well-understood, since sumoylation changes molecular interactions, it would not be 
so surprising to see if such a regulation is involved for the fusion of nuclear membranes to 
reform the nuclear envelopes. 
 
4.2. Ran sumoylation in A.nidulans 
Ran as well as all three lysines are conserved throughout evolution from yeast to 
mammals. In order to understand the importance of these lysines, we turned to a lower 
organism, namely A.nidulans, where the wild type protein can be replaced with the triple 
mutant to see the effects on cell growth. For this purpose, a collaboration with Prof. 
Gerhard Braus (Institute of Microbiology & Genetics, University of Göttingen), who is 
working with the model organism A.nidulans, has been initiated. The preliminary 
experiments with A.nidulans strains which are replaced with the mutant variant of Ran, 
showed a drastic phenotype with respect to asexual development, whereas sexual 
development was not effected (personal communication, Rebekka Harting/Prof.Gerhard 
Braus’s lab). In short, the number of asexual spores formed with the mutant strain was 
significantly lower compared to the wild type strain, and interestingly, similar results 
were observed with SUMO-knock-out strains. The preliminary results suggest that the 




identified lysines are important for the biology of Ran, although not essential since all the 
strains with the mutant variant were viable. Whether the observed phenotype is linked to 




The results of the present work opened up two interesting research areas: The 
sumoylation of nuclear transport receptors and the small GTPase Ran in mammals & 
A.nidulans. Endogenous sumoylation of nuclear transport receptors shown in this work 
provides the first clear demonstration of nuclear transport receptor sumoylation in 
mammals. It was previously shown in yeast that Kap114p (yeast homolog of Imp9) is 
regulated by sumoylation (Rothenbusch et al., 2012). However, it remains an open 
question whether sumoylation of nuclear transport receptors serve a similar function in 
higher organisms or whether it has different functional consequences. Therefore, 
additional work is required to pinpoint the E3 ligase(s) responsible for this modification 
as well as to understand the mechanisms, localization, and the outcome of nuclear 
transport receptor sumoylation. 
 
Similarly, Ran sumoylation presented in this work is at its infancy. Despite the fact that 
the SUMO sites in Ran were mapped and an interesting transport-related phenotype was 
observed with the triple mutant of Ran that can no longer be sumoylated, detailed 
analysis is still required to understand why the mutant Ran is more active  than the wild 
type for Imp13-dependent import. Whether the differential behaviour of Ran is due to the 
lack of sumoylation or due to the K-to-R mutations remains elusive. Together, these 
investigations will help us gain important insights concerning the novel regulation of the 
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~ thioster bond in context of sumoylation 
aa  amino acids 
A.nidulans Aspergillus nidulans 
APS  Ammonium persulfate 
A.thaliana  Arabidopsis thaliana 
ATP  Adenosine-5’-triphosphate 
BSA  Bovine serum albumin 
C-  Carboxyl- 
C.elegans  Caenorhabditis elegans 
CNBr  Cyanogenbromide 
cNLS  classical nuclear localization signal 
Da  Dalton 
DeSI1  DeSumoylating isopeptidase 1 
D.melanogaster  Drosophila melanogaster 
DMEM  Dulbecco’s modified eagle medium 
DMP  Dimethyl pimelimidate 
DMSO  Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid 
dNTP  2’-deoxynucleoside-5’-triphosphate 
ddNTP  2’,3’-deoxynucleoside-5’-triphosphate 
DTT  Dithiothreitol 
E-  Enzyme- 
ECL  Enhanced chemical luminescence 
E.coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
FBS  Fetal bovine serum 
GDP  Guanosine-5’-diphosphate 
GMP-PNP  5'-Guanylyl imidodiphosphate 
GST  Glutathione S-transferase  
GTP  Guanosine-5’-triphosphate 
H2A and H2B  Histone 2A and 2B 
HCI  Hydrochloric acid 
HDAC4  Histone deacetylase 4 
HEAT   Huntingtin, elongation factor 3, protein phosphatase 2A, 
   and the yeast kinase TOR1  
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HeLa  Henrietta Lacks 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HF  High fidelity 
HIV  Human immunodeficiency virus 
IDCR  Ionic detergent compatibility reagent 
IF  Immunofluorescence 
IgG  Immunoglobulin G 
Imp  Importin 
IP  Immunoprecipitation 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
ISG15  IFN-stimulated gene 15 
kDa  Kilodalton 
LB  Luria-Bertani 
MAPL  Mitochondrial-anchored protein ligase 
Mg   Magnesium 
mRNA  Messenger ribonucleic acid 
N-  Amino- in context of protein 
NaOH  Sodium hydroxide 
NCS  Newborn calf serum 
Nedd8  Neural precursor cell expressed developmentally 
   down-regulated protein 8 
NEM  N-Ethylmaleimide 
NES  Nuclear export signal 
NLS  Nuclear localization signal 
NPC   Nuclear pore complex 
Nt  nucleotide 
NTF2  Nuclear transport factor 2 
NTRs  Nuclear transport receptors 
NuMa  Nuclear mitotic apparatus protein 1 
Nups  Nucleoporins 
OH  Hydroxyl 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline tween 
Pc2  Polycomb 2  
PCR  Polymerase chain reaction 
PIAS  Protein inhibitors of activated STATs 
PKI  Protein kinase inhibitor 
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PML  Promyelocytic leukemia 
PMSF  Phenylmethylsulfonyl fluoride 
PTMs Posttranslational Modifications 
Ran  Ras-related nuclear protein 
RanBP1 and 2  Ran-binding protein 1 and 2 
RanGAP1  Ran GTPase-activating protein 1 
Ras  Rat sarcoma 
RCC1  Regulator of chromosome condensation 1 
Rev  Regulator of virion expression 
RHES  Ras Homolog Enriched in Striatum 
RNA  Ribonucleic acid 
SAB  Sumoylation assay buffer 
SAE1 and 2  SUMO-activating enzyme subunit 1 and 2 
SDS  sodium dodecyl sulfate 
SENP  SUMO/Sentrin specific protease 
S.cerevisiae  Saccharomyces cerevisiae 
S.pombe  Schizosaccharomyces pombe 
SIM  SUMO-interaction motif 
SMT3  Suppressor of Mif2 3 
SOC  Super Optimal broth with Catabolite repression 
SUMO  Small Ubiquitin-like Modifier 
TAE  Tris/acetate/EDTA 
TB  Transport buffer 
TCA  Trichloroacetic acid 
TE Tris/EDTA 
TEMED  Tetramethylethylenediamine  
TLS  Translocation in liposarcoma 
TOPORS  Topoisomerase I Binding, arginine/serine-Rich 
Tpx2  Targeting protein for Xklp2 
Tris  Tris (hydroxymethyl) aminomethane 
Ub  Ubiquitin 
Ubc9  Ubiquitin-conjugating enzyme 9 
Ubls  Ubiquitin-like modifiers 
Ulp1 and 2  Ubiquitin-like protease 1 and 2 
Urm1  Ubiquitin-related modifier 1 
Uspl1  Ubiquitin-specific protease-like 1 
Usp25  Ubiquitin-specific protease 25 
UV  Ultraviolet 
 ABBREVIATIONS 
 129 
v/v  volume/volume 
w/v  weight/volume 
 
Physical units 
A  ampere 
°C  degree Celsius 
g  gram 
x g  acceleration of gravity on earth 
h  hour 
L  liter 
M  molar (mol/L) 
min  minute 
OD  optical density 
pH  negative common logarithm of the proton concentration 
rpm  rotations per minute 
sec  second 
V  volt 
 
Prefixes 
k  kilo 103 
c  centi 10-2 
m  milli 10-3 
µ  micro 10-6 
n  nano 10-9 
p  pico 10-12 
 
Code for amino acids 
A Ala alanine 
C Cys cysteine 
D Asp aspartate 
E Glu glutamate 
F Phe phenylalanine 
G Gly glycine 
H His histidine 
I Iso isoleucine 
K Lys lysine 
L Leu leucine 
M Met methionine 
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N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp tryptophane 
Y Tyr tyrosine 
X  any amino acid 
ψ  bulky hydrophobic residue 
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